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ABSTRACT
Mixed lineage leukemias have a relatively poor prognosis and arise as a result of
translocations between the MLL gene and one of multiple partner genes. Downstream
targets of MLL are aberrantly upregulated and include the developmentally important
HOX genes and MEIS1, as well as multiple miRNAs, including the miR-17-92 cluster and
miR-196b. Here I utilize custom anti-miRNA oligonucleotides to examine the
contribution of specific miRNAs to MLL leukemias both as individual miRNAs and in
cooperation with other miRNAs. Combinatorial treatment with antagomirs against miR17 and miR-19a of the miR-17-92 cluster dramatically reduces colony forming ability of
MLL-fusion containing cell lines but not non-MLL AML controls.
Further, I validated PKNOX1 as a target of both miR-17 and miR-19a. MEIS1 and
PKNOX1 are TALE domain proteins that participate in ternary complexes with HOX and
PBX proteins. Here I examine the competitive relationship between PKNOX1 and
MEIS1 in PBX-containing complex formation and determine the antagonistic role of
PKNOX1 to leukemia in a murine MLL-AF9 model. Collectively, these data implicate the
miR-17-92 cluster as part of a regulatory mechanism necessary to maintain
MEIS1/HOXA9 -mediated transformation in MLL leukemia. This approach represents a
paradigm where targeting multiple non-homologous miRNAs may be utilized as a novel
therapeutic regimen.
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CHAPTER 1
INTRODUCTION
MLL leukemias develop as the result of a balanced translocation involving the
MLL gene located at the 11q23 locus and one of over 70 fusion partners [1]. The
resulting leukemias develop as either acute myeloid leukemia, acute lymphocytic
leukemia, or a mixed lineage leukemia and have a poorer prognosis than many non-MLL
leukemias [2, 3]. MLL leukemias possess a chimeric fusion protein which aberrantly
upregulates expression of target genes, including HOXA9 and MEIS1 [4, 5]. HOXA9 and
MEIS1 are essential for MLL leukemia [5-7]. The poorer prognosis associated with
MLL leukemia gives reason to better understand it, and undertake studies to clarify the
mechanisms by which it operates.
MiRNAs are small noncoding RNAs of approximately 22 nucleotides which
function through repression of target mRNAs [8, 9]. Currently, over 2500 miRNAs have
been identified in humans and are thought to contribute to the regulation of up to half of
all transcribed genes [10]. Previous studies by our lab and others found that multiple
miRNAs, including miR-196b, and the miRNAs of the miR-17-92 cluster, are
overexpressed in MLL leukemias relative to other acute myeloid leukemias [11, 12].
These miRNAs present an attractive target for therapeutic intervention in MLL leukemias
due to their critical roles in regulation of important target genes. Recent work has been
1
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undertaken to develop modified nucleic acids for the inhibition of miRNAs [8, 13, 14].
Antagomirs and other anti-miRNA technologies have been tested in vitro and in vivo to
this effect [8, 13, 14].
This dissertation examines the role of miRNAs disregulated in MLL leukemias
through two aims. My first aim is to determine the necessity of miRNAs to the
development of leukemia, both individually and in combination. I hypothesized that one
or more miRNA upregulated in MLL leukemia are essential to leukemia function. To
examine the contribution of miRNAs to leukemia, I have inhibited miRNA function
using custom oligonucleotides termed ‘antagomirs.’ I examined the changes in colony
forming ability as a surrogate for leukemogenesis in human cell lines with MLL
translocations and in MLL-AF9 transduced murine bone marrow utilizing individual
antagomir treatments. Further, I have performed colony assays in human cell lines
(MOLM-13 MV4-11, RS4;11) accompanied by analysis of cell cycle and cell growth in
liquid culture.
My second aim is to determine the potential downstream targets of miRNAs
disregulated in MLL leukemia. I have hypothesized that miRNAs contribute to MLL
leukemia through downregulation of PKNOX1 (a.k.a. PREP1), a TALE domain protein
closely related to the essential MLL target gene MEIS1. I have additionally hypothesized
that miRNA mediated disruption of the balance between PKNOX1 and MEIS1
contributes to MLL leukemia. To examine the relationship between miRNA levels and
PKNOX1, I have performed luciferase assays and have further examined the change in
PKNOX1 protein levels upon antagomir treatment in human cell lines. To determine the
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competitive role between PKNOX1 and MEIS1, I have further examined the role of
PKNOX1 in MLL leukemia through both colony assays and liquid culture experiments.

CHAPTER 2
LITERATURE REVIEW
MLL leukemia background
The Mixed Lineage Leukemia (MLL, a.k.a. ALL-1, HRX, KMT2A) gene is located
at the chromosomal position of 11q23 and has been identified as recurrent site of
chromosomal translocations in leukemia [15]. Leukemias arising from MLL
translocations may result in either Acute Lymphoid Leukemia (ALL) or Acute Myeloid
Leukemia (AML) (reviewed in [2, 3]). These leukemias may additionally be biphenotypic or mixed lineage leukemias, as defined by the presence of mixed surface
markers (reviewed in [2, 3]).
Both ALL and AML are relatively heterogeneous as characterized by cytogenetic
abnormalities, and possess numerous cytogenetic abnormalities of which MLL related
leukemias represent a significant fraction. ALLs possess cytogenetic abnormalities,
including t(12;21) encoding TEL-AML1; t(8;14), t(2;8) and t(8;22) encoding MYCrelated translocations; t(1;19) encoding E2A-PBX; t(9;22) translocations encoding BCRABL; and 11q23 translocations encoding MLL rearrangements [16]. AMLs also display
numerous cytogenetic abnormalities, as well as cytogenetically normal karyotypes, which
account for half of all AMLs. Several commonly occurring cytogenetic abnormalities
within AML produce fusion genes involving members of the core binding factor
heterodimeric transcription factor complex which is comprised of AML1 (RUNX1) and
4
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CBFB [17]. The balanced translocation t(8;21)(q22;q22) generates a chimeric protein
AML1-ETO (RUNX1-RUNX1T1), while abnormalities of chromosome 16, including
inv(16) (p13;q22) and t(16;16)(p13;q22) affect the core binding factor beta subunit
(CBFB) [17]. The balanced translocation of t(15;17)(q22;q12) is another commonly
observed cytogenetic abnormality associated with AML, encoding a fusion proteins
known as PML-RARα and resulting specifically in Acute Promyelocytic Leukemia
(APL) [17].
AMLs are classified according to the French-American-British (FAB)
classification system, with MLL translocation leukemias predominantly resulting in M5a
(Monoblastic, poorly differentiated) and M5b (Monoblastic, differentiated) leukemias,
with 38.5% and 21.2%, respectively [18]. MLL leukemias further result in M4
(Myelomonocytic) leukemias (21.2%) [18]. ALL leukemias may be classified by FAB
classification system (L1-L3), but are more commonly classified by immunophenotype
under the World Health Organization guidelines. Within these guidelines, MLL
rearrangements are present in both T-cell ALLs and B-cell ALLs [19].
MLL leukemias are responsible for 7-10% of all ALLs and 5-8% of all AMLs [2].
Within infant leukemias, affecting children <1 year old, MLL leukemias account for 70%
of infant ALLs and 35-50% of infant AMLs [3]. Additionally, MLL translocations are
often observed in therapy associated leukemia, which presents almost exclusively as
AML, representing approximately 10% of all leukemias, often developing after treatment
with Topoisomerase 2 inhibitors [3]. MLL rearrangements also represent approximately
3% of de novo leukemias [18]. Prognosis for MLL rearranged leukemias is poor, with 5
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year overall survival rates of ~10 %, and a median survival of 9 months after diagnosis
[18].
Wild-type MLL
Human MLL is an ortholog the Drosophila gene Trithorax (Trx) which acts in
opposition the polycomb group by maintaining the expression of target genes (reviewed
in [20]). The MLL gene encodes a 3969 amino acid (~430 kDa) multi-domain regulator
of transcription encoded on chromosome band 11q23 (reviewed in [20]). Located toward
the N-terminus of MLL, between amino acids 170-310, the AT-Hooks of MLL recognize
cruciform DNA and facilitate the binding of the MLL complex to DNA [21]. MLL
possesses a repression domain located between amino acids 1101-1400 [21]. The MLL
repression domain recruits factors associated with repression of target genes, including:
BMI-1 and HPC2 of the Polycomb group, the histone deacetylases HDAC1 and HDAC2,
and CtBP [22]. Within the repression domain, the MLL CXXC domain is defined by
eight cysteine residues which coordinate 2 zinc ions to mediate interaction with
unmethylated cytosine-containing CG dinucleotides within CpG islands [23]. Previous
studies by our lab have shown that the MLL CXXC domain protects unmethylated CpG
islands from DNA methylation through direct binding to DNA in the promoter regions of
target genes and subsequently maintains the target gene expression [24]. The MLL
CXXC-DNA relationship is essential to the leukemogenic capacity of MLL fusions.
Disruption of this relationship by mutations in the CXXC domain decreases colony
forming ability of an MLL-AF9 construct when transduced into murine bone marrow
progenitor cells [23]. MLL additionally possesses 4 PHD (plant homeodomain) fingers
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that mediate protein-protein interactions, as well as an atypical bromodomain, located
between PHD fingers 3 and 4. Of the 4 PHD fingers, PHD finger 3 has been shown to
bind to bind to H3K4 modified by di- and tri- methylation [25] and also the cyclophylin
Cyp33 [26]. However, PHD finger 3 binding of methylated H3K4 and Cyp33 are
mutually exclusive, suggesting that PHD finger 3 may function as a key regulatory
domain of MLL [27]. MLL possesses an H3K4 histone methyltransferase SET
(Su(var)3-9,ehanancer of zeste, trithorax) domain located at the C-terminal end [4, 28].
H3K4 methylation is associated with transcriptional activation [29]. The MLL protein
domain schematic is illustrated in Figure 1.
Upon transcription and translation, the full length MLL protein is cleaved in two
places by TASPASE1, a threonine aspartase protease; at amino acids 2719 and 2730, to
excise a 12 amino acid polypeptide and form a 320 kDa N-terminal fragment (MLL-N)
and 180 kDa C-terminal fragment (MLL-C) [30, 31]. The cleaved MLL proteins
associate together in MLL-containing complexes involved in the regulation of
transcription [31]. Association between MLL-N and MLL-C occurs through noncovalent
binding between the FYRN and FYRC domains (FY-Rich C-terminal) and (FY-Rich Nterminal) of MLL-N and MLL-C, respectively [31].
In addition to self-association between the N- and C-terminal proteins, MLL
recruits >29 additional complex components [28]. Menin (Multiple endocrine neoplasia
type 1) is a DNA binding protein, originally characterized as a tumor suppressor [32].
Menin associates with the N-terminus of MLL-N, where an RXRFP interaction domain
located at the amino-terminal end of MLL binds to Menin (MEN1) [33, 34]. LEDGF
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(lens epithelium derived growth factor), in turn, associates with Menin [35]. C-Myb has
also been shown to associate with MLL through interaction with Menin [36].
Collectively, these proteins interact with DNA in cooperation with the AT-Hooks and
CXXC domain of MLL [2]. Interaction with both Menin and LEDGF are required for
MLL regulation of target genes [33, 35] and loss of the N-terminal domain of MLL
abrogates the leukemogenic activity of the MLL fusion protein [34].
MLL-C facilitates numerous protein-protein interactions with several additional
factors to the complex, including: WDR5 [37], ASH2L [38], RBBP5 [39], and CBP [40].
ASH2L and RBBP5 dimerize and bind to the C-terminus of MLL, stabilizing the active
conformation of the MLL SET domain [39]. CBP is a histone acetyltransferase that
acetylates histones, among other substrates [41]. WDR5 recognizes H3K4 without
discriminating between unmethylated, mono-, di-, or tri- methylation and positions the
H3K4 residue for methylation by the MLL SET domain [37, 42]. WDR5 has additionally
been implicated in the binding of non-coding RNA HOTTIP [43] in the regulation of the
HOXA cluster (schematic of MLL complex illustrated in Figure 1).
Previous studies have characterized Mll function through the development of a
murine hypomorphic model, which is commonly referred to as an Mll knockout model.
Mll (-/-) mice are embryonic lethal and embryos display developmental defects including
brachial arch dysplasia and aberrations in segmental boundaries [44, 45]. Examination of
the expression of known target genes, including Hoxa7 and Hoxc9, in Mll (-/-) embryos,
implicate MLL in the maintenance, but not initiation of expression of genes. Mll (-/-)
embryos were able to initiate expression of these target genes, but were unable to
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maintain expression past 8.5-9 dpc [44]. Knockout studies additionally showed a
hematopoietic phenotype, with Mll (-/-) embryos displaying a defect in yolk sac
hematopoiesis [46].
MLL fusions
MLL fusions arise as the result of chromosome translocations which result in an
in-frame joining of the MLL gene to a partner gene. MLL fusions most often occur as a
result of incorrect non-homologous end joining from double stranded DNA break repair
[47]. Chromosomal breakage occurs within a defined 8.3 kb region of the MLL gene
called the Breakpoint Cluster Region (BCR). Currently, 79 partner genes have been
identified as fusion partners in MLL translocations [1]. Despite the myriad of MLL
fusion partners, >85 % of MLL fusions occur with only 6 partners [1]. These most
common fusion partners are AF4 (38%), AF9 (18%), ENL (13%), AF10 (8%), ELL
(4%), AF6 (4%) [1]. The occurrence of fusion partners is distinctly different between
MLL AMLs and MLL ALLs, with AF4 being the most common fusion partner in MLL
ALL (60%) and AF9 being the most common fusion within MLL AML (29%)[1].
MLL fusion proteins are functionally distinct from wild type MLL. In MLLfusions proteins, the AT-Hooks and the MLL CXXC domain is retained within the fusion
protein. However, while wild type MLL-C recruits additional factors involved in the
maintenance of expression of target genes, loss of the MLL-C and replacement with a
fusion partner alters the recruitment of cofactors. Many of the resulting fusions enable
the recruitment of factors including DOT1L and the super elongation complex (SEC).
DOT1L is a histone methyltransferase that targets H3K79 for methylation as an
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activating chromatin mark occurring along transcriptionally active genes (reviewed in
[48]). H3K79 methylation usually corresponds to transcription of associated genes [49].
MLL leukemias display aberrant H3K79 methylation along known MLL-targeted genetic
regions, including the HOXA loci [50, 51]. DOT1L has been shown to be necessary for
transformation of murine bone marrow by MLL fusions, with Dot1l deletion resulting in
a loss of colony forming ability and an increase in apoptosis [52]. Subsequent studies
have shown that selective inhibition of DOT1L catalytic function effectively blocks
H3K79 methylation and inhibits proliferation and promotes apoptosis and differentiation
of MLL rearranged cell lines [53].
Both MLL and MLL fusions recruit the RNA Polymerase 2- interacting
Polymerase Associated Factor complex (PAFc) through interaction between MLL
repression domain and the PAFc subunit PAF1 [54]. Interaction with the PAF complex
is required for proper recruitment of MLL to the Hoxa9 locus and the transformation by
MLL fusions [54]. Several common fusion partners are components the super elongating
complex (SEC) that enables transcriptional elongation by releasing RNA Polymerase 2
from transcriptional pausing at the transcriptional elongation control checkpoint (TECC).
(Function of SEC extensively reviewed in [55-57]). The SEC is comprised of several
subunits, including: AF9 (ALL1 fused gene from chromosome 9) or its homolog ENL
(eleven nineteen leukemia), ELL (eleven nineteen Lys-rich leukemia) family protein,
AFF1/4, EAF1/2, and the kinase P-TEFb (Pol 2 transcription elongation factor comprised
of cyclin T1 or T2 and Cdk9) [57]. Of these complex components, several are MLL
fusion partners, including: AF4, AF9, AF10, ENL, and ELL [1, 3]. Functionally, P-TEFb
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Figure 1. MLL domains and complexes

A) Schematic depiction of MLL protein domains for both wild-type MLL (top) and MLL
fusion (bottom) proteins. Adapted from Krivstov et al. [58]. B) Cartoon depiction of
MLL interaction with proteins and chromatin for wild-type MLL (top) and MLL fusion
(bottom). Adapted from Krivstov et al.[58] and Slany et al. [3].
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phosphorylates RNA Polymerase 2 at serine 2, which allows release of RNA Pol 2 from a
pause site [55] (schematic illustrated in Figure 1).
Additional, but less frequent fusions have been documented which include fusion
partners that facilitate dimerization of MLL fusion proteins, including AF1p and GAS7
[59]. These fusion partners are cytoplasmic proteins that possess homo-oligomerizing
coiled-coiled domains which are sufficient to allow for leukemic transformation by these
MLL fusion proteins [59]. Examination of a pharmacologically dimerizable MLL, MLLFKBP, indicates that MLL amino-terminal dimers bind to the CpG islands of the Hoxa9
locus and upregulate critical MLL target genes including Hoxa7, Hoxa9, and Mies1 [60].
In addition to chromosomal translocations, MLL also undergoes partial tandem
duplications (MLL PTD) accounting for 4% of MLL leukemias [1]. MLL PTDs contain
duplication of exons 5-11, allowing for MLL to dimerize and subsequently misregulate
target genes [58].
MLL target genes
Several studies have sought to define the genes targeted by MLL and MLL
fusions by examining the global disregulation of genes in MLL fusion leukemias [61-65].
Examination of MLL occupancy sites indicates that MLL associates with RNA
Polymerase 2 across the entire gene for a subset of transcriptionally active target genes,
and dissociates upon downregulation, consistent with MLL's function in transcriptional
maintenance [61]. Armstrong et al. examined the gene expression signature of MLL
leukemia patients compared to non-MLL ALL and AML leukemias [62]. They found
that MLL leukemias regulated a gene set distinct from either ALL or AML that was rich
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with highly expressed HOX genes [62]. Examination of the binding of MLL-ENL and
comparison of MLL-ENL binding with MLL wild-type binding, indicates that MLL
fusions bind to a subset genes regulated by wild type MLL [63]. MLL-ENL bound to
223 genes with significant increase in mRNA expression of 12 genes, including Hoxa9
and Meis1 [63]. A separate study performed by Li et al. examined the deregulation of
genes in leukemias possessing MLL-ENL and MLL-ELL translocation [64]. 88 genes were
found to be disregulated in both human and murine leukemia models, including Hox
genes and the miR-17-92 cluster [64]. Critically, changes in gene expression were
conserved between human and mouse [64]. Collectively, these studies corroborate earlier
findings that MLL functions to maintain gene expression, particularly at Hox genes.
However, they also implicate MLL in the maintenance of expression of other target genes
including the miR-17-92 cluster.
HOX genes
HOX genes are the most well studied downstream targets of MLL. MLL and MLL
fusions directly regulate posterior HOX genes, as well as the HOX partner MEIS1,
resulting in an aberrant maintenance of the expression in MLL leukemias [4, 5]. Both
HOXA9 and MEIS1 and direct downstream targets of MLL [4, 5]. Previous studies have
shown that HOXA9 is essential to the development of MLL leukemias [5-7]. Hoxa9
deficient murine bone marrow cells cannot be transformed with MLL fusions in vitro [6],
while depletion of HOXA9 in human cell lines harboring MLL translocations blocks
proliferation and induces apoptosis [7].
HOX genes encode transcription factors critical to body patterning, development,
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and hematopoiesis [66]. Mammals possess 39 HOX genes organized in 4 paralogous
clusters (HOXA – HOXD) at 4 different genetic loci, with HOXA, HOXB, HOXC, and
HOXD located on 7p15, 12q21, 12q13, and 2q31, respectively (reviewed in [67]). Each
cluster is similarly organized with the lower numbered HOX genes located towards the 3'
end of the cluster and higher numbered HOX genes located at the 5' end. HOX genes are
illustrated in Figure 2. HOX gene expression is important for determining the spatial
identity and segmentation in development, with HOX genes expressed collinearly from
lower to higher number along the anterior-posterior axis, with the lower numbered HOX
genes expressed toward the anterior and the higher numbered HOX genes expressed
towards the posterior (reviewed in [67, 68]). Temporal control of HOX gene expression
is also controlled collinearly with lower numbered HOX genes being expressed earlier in
development than their higher numbered counterparts (reviewed in [67, 68]).
Disregulation and mutation of HOX genes results in limb malformations and
developmental diseases, including cancers (reviewed in [67]). Critical to understanding
the development of AML, the NUP98-HOXA9 fusion drives AML development [69].
Further, a study of 6817 genes in acute leukemia identified HOXA9 expression as a
negative prognostic indicator for AML [70].
HOX proteins contain a 60 amino acid homeodomain consisting of 3 alpha
helices, with DNA helix 3 contacting DNA [67]. The homeodomain interacts with target
DNA sequences through the DNA helix 3. HOX proteins additionally possess a short
amino acid sequence (YPWM) which interacts with the homeodomain of a PBX partner
gene [71].
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Figure 2. HOX gene clusters

Schematic depiction of HOX gene clusters in human. HOX genes are organized into 4
paralogous clusters lettered A-D. HOX gene expression occurs in a co-linear fashion with
Anterior expression occurring from HOX genes located towards the 3' end of the HOX
clusters and posterior expression occurring from HOX genes located towards the 5' end of
the HOX clusters. Adapted from Argiropoulos and Humphries [66].
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HOX-TALE complexes
HOX proteins function in complexes formed with TALE domain containing partner
proteins, primarily MEIS proteins, PBX proteins, PKNOX (PREP) proteins. The TALE
(Three Amino acid Loop Extension) family of proteins were identified and characterized
as having an atypical homeodomain with 3 amino acids positioned between the first and
second helices of the homeodomain [72, 73]. This TALE possessing homeodomain is
highly conserved and present in all family members and subfamilies of the larger TALE
family [72, 73]. The TALE family is subdivided into the several families, including:
PBC, MEINOX, IRO, TGIF, and MKX families [72, 73]. MEINOX and PBC family
members are critical cofactors of HOX genes in leukemia.
The PBC family consists of the 4 PBX homologs (PBX1, PBX2, PBX3, PBX4) in
both mouse and human [72]. Additional functional forms of PBX are formed by splice
variants of PBX1 (PBX1A, PBX1B) and PBX3 (PBX3A, PBX3B) (reviewed in [74]).
Common to all members of the TALE family of proteins, the PBC family possesses and
homeodomain with a three amino acid loop extension. PBC family members additionally
possess a "bipartite" PBC domain divided into PBC-A and PBC-B, N-terminal to the
homeodomain, which function in protein-protein interactions (reviewed in [74]). High
conservation is observed in both the homeodomain and the PBC domains.
The MEINOX family (originally categorized as the MEIS family) consists of 3
MEIS proteins (MEIS1, MEIS2, MEIS3) and 2 PKNOX proteins (PKNOX1, PKNOX2)
in both human and mouse [72, 73]. Members of the MEINOX family possess the TALE
domain containing homeodomain which is highly conserved between MEIS and PKNOX
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subfamilies [72, 73]. Additionally, both MEIS and PKNOX families share high
homology in the bipartite MEIS domain, consisting of a MEIS-A and MEIS-B and
utilized for protein-protein interactions (reviewed in [74]). However, there is divergence
in the presence or absence of nuclear localization signals, as well as the C-terminal region
[74].
While HOXA9 and MEIS1 are often discussed as the critical downstream effectors
of MLL leukemias and are used to generate AML independently of MLL involvement,
these proteins are able to participate in a diverse combination of protein complexes.
MEINOX proteins are capable of forming binary MEINOX-PBX complexes through
interaction of the MEIS-A and MEIS-B domains of MEIS1/PKNOX1 with the PBC-A
and PBC-B of PBX partners [75, 76]. MEINOX-PBX complexes form in the presence or
absence of DNA, indicating that interaction is not DNA dependent [75]. This interaction
does not occlude or otherwise interfere with the PBX component's homeodomain. In
addition to interactions with MEINOX family proteins, PBX proteins are capable of
forming stable HOX-PBX dimers with HOX protein partners (reviewed in [71]). HOXPBX interactions are mediated by the Tryptophan of the HOX protein's YPWM motif
binding to the homeodomain of the PBX partner (reviewed in [71]). Notably, HOX-PBX
interactions do not utilized the PBC-A or PBC-B domains required in PBX-MEINOX
interactions.
Numerous studies document the formation of ternary complexes containing a
HOX component, a MEINOX component, and a PBC component [77-81]. HOX-PBXMEIS protein complexes may contain PKNOX1 (also known as PREP1) as an alternative
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to MEIS1 as protein-protein interactions within the ternary complexes are mediated
through MEINOX-PBX interaction [82]. PKNOX1 and MEIS1 are highly homologous
in the domains required for both PBX interaction and DNA binding and interact with the
same surface on PBX1 [76].
AbdB-like HOX proteins, encoding HOX9-13, are uniquely capable of directly
interacting with MEIS1 [83-85]. This interaction is not conserved across the MEINOX
family as it requires residues located within the C-terminal domain of MEIS1 that are not
conserved in PKONX1 [84]. Thus, only MEIS1, and not PKNOX proteins, directly bind
to with HOX partners. TALE domain complexes are illustrated in Figure 3.
Functional roles of TALE proteins
While numerous studies have utilized PBX1 to study the protein-protein
interactions of the PBX family of proteins, an increasing body of evidence has implicated
PBX3 as the critical PBX protein in MLL leukemia. Recently, PBX3 upregulation has
been identified as part of a 4 gene signature associated with poorer prognosis in MLL
leukemias [86]. Though PBX3 is highly upregulated, its homologs, PBX1 and PBX2, are
down regulated [87]. Functionally, inhibition of the PBX-HOX interaction through an
18-mer peptide in cell lines harboring MLL-related translocations results in decreased
proliferation and apoptosis [87].
Meis1 was initially identified as a viral insertion site in BHX2 mice in the
development of leukemia [88]. The gene for human MEIS1 was cloned and identified as
a homoebox-containing gene located at chromosome 2p13-p14 [89]. Along with HOXA7
and HOXA9, MEIS1 overexpression was implicated in the development of AML [90].
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Figure 3. TALE domain proteins and complexes

A) Schematic depiction of HOX protein families. HOX family members are depicted in green. PBX
family members are depicted in purple. MEIS1 is depicted in blue. PKNOX1 is depicted in orange.
Homeodomains are shown in black, while TALE domains are shown with a red stripe located
within the Homeodomain. PBC domains are shown in dark purple, while MEIS domains are
shown in gray. Adapted from Ladam, et al. [71] Longobardi, et al. [74] B) Cartoon depiction of
different HOX-TALE complexes and their DNA interactions. Coloring of proteins and protein
domains are matched to schematics in panel A.
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Numerous studies have indicated that Meis1 is essential to the development of
MLL leukemia. In fetal liver cells, Meis1 (-/-) cells are incapable of serial replating
ability after transformation with MLL fusion-expressing retrovirus [91]. Moreover, the
level of Meis1 expression correlates to the latency of leukemia development in murine
models [91]. Knockdown of Meis1 using a lentiviral shRNA results in a decrease in
proliferation and an increase in survival in vivo [92].
The leukemogenic capacity of Meis1 requires several domains to generate
leukemia when infected into murine bone marrow along with Hoxa9. Meis1 oncogenic
activity requires both the Pbx interacting motif and the C-terminal region [93]. Specific
deletion of the C-terminal domain in Meis1 ablates transforming capacity of Meis1, while
replacement with a strongly activating VP16 activation domain allows Meis1 to retain
leukemogenic capabilities [94]. The retention of leukemogenic capability in a chimeric
Meis1-VP16 mutant indicates that Meis1 generates leukemia through activation of target
genes. The oncogenic activity of Meis1 is located in the C-terminal domain which differs
from that of Pknox1 [93-95]. Meis1 cooperates with Hoxa9 in transformation; whereas
co-expression of Pknox1 with Hoxa9 lacks this effect [94]. However, chimeric Pknox1
proteins which replace the Pknox1 C-terminal domain with the Meis1 C-terminus can
restore acceleration of leukemia development [94].
The MEIS1 C-terminal domain is responsible for numerous protein-protein
interactions including interaction with HOX proteins in binary complexes. Several lines
of evidence, however, implicate ternary complexes as the critical leukemogenic
complexes. Deletion of the Pbx-interacting domains of Meis1 abrogated its leukemogenic
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potential when co-infected with a Hoxa9-expressing virus [93]. PBX3 is upregulated in
MLL leukemia and disruption of the HOX-PBX interaction through a small peptide
inhibitor promoted apoptosis and decreased expression of known HOX-MEIS targets in
an MLL leukemia cell line [87]. Collectively, these findings suggest that HOX-MEIS
activity requires PBX participation in a ternary complex.
Numerous HOXA9-MEIS1 target genes have been identified. Most prominently,
MEIS1 regulates FMS-like tyrosine kinase 3 (FLT3) in AML [93]. FLT3 encodes a
receptor tyrosine kinase expressed in hematopoietic stem and progenitor cells whose
signaling pathway regulates proliferation, apoptosis, and differentiation (FLT3 function
reviewed in [96]. Activating mutations, such as FLT3 internal tandem duplications have
been identified as a causative genetic lesion in cytogenetically normal AML. Within
infant MLL leukemias FLT3 expression is often elevated and corresponds to a worse
prognosis. However, transduction of murine bone marrow with Meis1 and Hoxa9
generates leukemia in both Flt3 (+/+) and Flt3 (-/-) cells, indicating that Flt3 is
dispensable for the Meis1-Hoxa9 viral overexpression-generated leukemia [97].
c-Myb was additionally identified as a target for upregulation by Hoxa9-Meis
leukemogenesis after being identified in an array analyzing genetic disregulation of
Hoxa9-Meis1 transformed murine bone marrow [98]. Inhibition of c-Myb through either
a dominant negative mutant or siRNA ablated the leukemogenic capability of MLL-ENL,
indicating that c-Myb function is essential for MLL transformation [98]. Subsequent
studies showed c-Myb directly interacts with MLL complexes through binding to Menin,
suggesting a regulatory feedback mechanism whereby Hoxa9-Meis1 activity influences
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MLL complex composition.
Additional documented HoxA9-Meis1 targets include: gata1 [99], Trib2 [100],
Ccl [100], and cyclin D3 [101]. An Illumina-based ChIP-Seq examination of Hoxa9 and
Meis1 binding sites indicated that Hoxa9 and/or Meis1 bind to 825 genomic regions, with
approximately 200 genomic regions bound by both [102]. Hoxa9 binding is enriched at
enhancers, and coincides with binding by additional lineage restricted transcription
factors including PU.1, C/EBP, CREB, STAT, and RUNX1 [102].
PKNOX1 (also known as PREP1) was identified as a homeodomain containing
protein and the gene subsequently localized to the human chromosome 21q22.3 and
mouse chromosome 17B/C [103, 104]. Pknox1 was initially characterized as a Pbx
binding partner [105]. Functional characterization of Pknox1 indicated that it is a binding
partner of Pbx1 in both the presence and absence of DNA [106, 107]. Upon binding to
DNA, Pknox1 contributes to the specificity of complex binding through recognition of a
TGACAG motif [107]. Pknox1 expression correlates inversely with Meis1 expression
during mouse hematopoiesis, as indicated in publicly available datasets (Figure 4).
Pknox1 is expressed at low levels in more immature cells and increases in expression
during differentiation, while Meis1 expression is highest in immature cells and decreases
during differentiation.
Deletion of Pknox1 in a mouse is embryonic lethal early in development (day 7.5)
(Blasi lab, unpublished, discussed in [108]). A hypomorphic Pknox1 mutation, generated
by an insertion into the 5’ UTR of the Pknox1 transcript results in decreases in Pknox1
mRNA and protein levels, with Pknox1 (i/i) mutants expressing <10% relative to wt.
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Hypomorphic Pknox1 mutants display high rates of embryonic lethality with deaths
occurring between 17.5 dpc and birth. Embryos exhibited multiple developmental
defects, including reduced angiogenesis, eye development abnormalities, and severe
anemia [108]. Mice which survive to birth exhibit T-cell developmental defects and
develop lymphomas [109]. Further, a decrease in Pbx1 and Meis1 levels were observed
in a Pknox1 hypomorph, attributed to a loss of stabilizing effect that derived from
interaction with Pknox1 [108]. The stabilization effect of Pknox1 on partner proteins may
be governed with the nuclear import [110] .
Further characterization of Pknox1 hypomorphic mutants in an Eµ-myc model of
lymphomagenesis implicate Pknox1 as a tumor suppressor [109]. Loss of Pknox1 in cells
homozygous for a hypomorphic mutation Pknox1 (i/i) or heterozygous for a knockout
Pknox1(+/-) result in an increase in tumor volume, an acceleration of lymphoma
development, and decreased survival [109].
Pknox1 and Meis1 are highly homologous in their homeodomains and their Pbx
interacting motifs, but do not share much homology in the C-terminus [94]. Chimeric
Pknox1 proteins with the Meis1 C-terminus appended to the C-terminus of Pknox1 are
able to generate leukemia when transfected into murine bone marrow, along with Hoxa9
[94]. Further, chimeric Pknox1-VP16 mutants are similarly able to generate leukemia
[94]. These studies suggest that the C-terminus of Pknox1 lacks the gene activating
capabilities of Meis1. Recent ChIP-seq analysis of Meis1, Pknox1, and Pbx1/2/3
occupancies performed during murine embryo development in conjunction with analysis
of gene expression have further suggested that Pknox1- and Meis1-containing complexes
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Figure 4. Pknox1 and Meis1 expression during hematopoiesis

A) mRNA expression patterns from compiled microarray studies in mouse hematopoiesis
for Pknox1 (left) and Meis1 (right) as depicted by GEXC database indicating mRNA
upregulation (red) or downregulation (blue). B) Normalized values for Pknox1 and
Meis1 expression levels from panel A in mouse hematopoiesis. All stages in
differentiation indicated with blue dots. Arrows indicate HSC (red), GMP (purple),
Granulocyte (black), and Monocyte (green).
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often have antagonistic roles in the regulation of common target genes [111]. Both
Pknox1 and Meis1 are capable of interacting with Pbx proteins or in Hox-Meinox-Pbx
ternary complexes. ChIP-seq data characterizing the occupancies of Meis, Pbx1/2/3, and
Pknox1 in murine embryonic development indicate the diversity of co-occupancies of
TALE domain proteins in vitro [111]. Intriguingly, these studies have found that while
both Meis1 and Pknox1 can participate in ternary complexes in vitro, co-occupancies of
Meis1 and Pknox1 do not equally coincide with other complex components (e.g. Hoxc9
and/or Pbx1/2/3). Meis1 peaks often coincide with Hox peaks in the absence of Pbx1,
while Pknox1 peaks coincide with Pbx1 in the absence of Meis1 [111]. Consistent with
previous biochemical studies, this indicates that Meis1 may interact directly with Hox
partners. However, Meinox-Pbx dimers were primarily comprised of Pknox1 bound to a
Pbx component.
Recently, additional studies performed by the Blasi group published 2 papers
clarifying the competitive role of Pknox1 and Meis1 in Hox-Meinox-Pbx complexes in a
mouse model. In examining the colony forming ability of mouse embryonic fibroblasts
(MEFs), they found that Meis1 transforms in a Pknox1 (i/i) background, while exogenous
expression of Pknox1 ablates Meis1-mediated transformation [112]. Further, Pknox1
indirectly regulates the stability of Meis1 through binding to Pbx1, as unbound Meis1 is
degraded [112]. Examination of the Pknox1 - Meis1 relationship in bone marrow cells
indicates that Pknox1 functions as a tumor suppressor in hematopoietic cells [113].
Exogenous over expression of Pknox1 inhibits the capability of Hoxa9 and Meis1 to
transform hematopoietic stem cells; Hoxa9 and Meis1 transformation is accelerated in a
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Pknox1 (i/i) background [113]. These studies, however, do not address the competitive
relationship of PKNOX1 and MEIS1 in an MLL leukemia model.
miRNA Biogenesis and function
MiRNAs are small non-coding RNAs (~22 nt) that post-transcriptionally
downregulate the expression of mRNA targets and are among the many genes regulated
by MLL (reviewed in [8, 9]). miRNAs were initially identified and characterized in C.
elegans with the discovery of lin-4 [114]. While lin-4 has no homologs in human or
mouse, subsequent studies identified let-7, a gene regulating the developmental timing of
the C.elegans L4/Adult switch by down-regulating the developmental timing switch lin41 [115]. Let-7 is conserved in human and mouse [116]. According to the most recent
catalog of miRNAs, miRBase 21, as predicted by deep sequencing, 2588 miRNAs are
known to exist in human and 1915 are known in mouse [10].
miRNAs are located in genomically fragile hot-spots that are often subject to
DNA damage [117]. More than 50% of miRNAs are located in polycistronic clusters
where a single transcript gives rise to more than one mature miRNA [117]. miRNAs
arise from a diverse array of primary-miRNA transcripts. Most miRNAs arise from
capped and poly-adenylated primary-miRNA transcripts transcribed by RNA Polymerase
2 [118]. However, several studies have shown the production of miRNAs from
transcripts transcribed by RNA Polymerase 3 [119]. MiRNAs may arise from either
exonic or intronic sequences of both coding and non-coding RNAs, as well as 3' UTRs
[120, 121].
Mature miRNAs are generated through sequential processing events. Within the
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primary-miRNA transcript, the miRNAs form thermodynamically stable hairpins of ~70
nt that are cleaved within the nucleus by DROSHA, a type III RNAse, with assistance
from the RNA binding protein DGCR8/PASHA, which guides the positioning of the
RNAse onto the pri-miRNA [122-124]. The resulting hairpin, designated as a premiRNA, is subsequently exported to the cytoplasm by Exportin-5, a RAN-GTPase
nuclear exporting protein [125]. The pre-miRNA is loaded onto Dicer, which cleaves the
hairpin into 2 strands of ~22 nt, leaving 2 nucleotide overhangs at the ends of each strand
to produce a mature miRNA duplex [126].
The mature miRNA duplex is loaded into an Argonaute containing complex,
consisting of Dicer, TRBP, and an Argonaute component [127]. Humans possess four
argonaute genes (AGO1/2/3/4), which are defined by common domains including a PAZ
and PIWI domains [128]. Together, these domains form a "bilobal" structure engaged in
binding to both the miRNA and the target mRNA. For each mature miRNA duplex, only
one strand is incorporated as a miRNA into the RISC complex while the opposite strand
is rapidly degraded, with strand selection being determined by the stability of the cleaved
5' end of each strand of the miRNA duplex [129, 130]. The Argonaute component
additionally associates with GW182 to form the core of the RISC complex.
The most critical nucleotides of the mature miRNA are nucleotides 2-7, which are
termed the "seed region" of the miRNA [131]. These nucleotides must be
complementary to the target mRNA, with some exceptions allowing for G:U wobble, in
order for the RISC-miRNA complex to effectively downregulate the target mRNA [132,
133]. Within the RISC complex, the miRNA is situated within the complex so that the
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miRNA seed region is projected outward toward the targeted mRNA [134]. The RISC
complex then scans target mRNAs for complementarity, with miRNA targeting focused
on the 3’ UTR of the target mRNA. Perfectly matched miRNA:mRNA pairing results in
a cleavage event in Argonaute 2-containing complexes whereby the target mRNA is
cleaved opposite the miRNA by the "slicer" activity present in Ago2 [135]. In both
perfectly matched and imperfectly matched pairings, the RISC complex recruits
additional factors to the mRNA to de-cap and degrade the mRNA transcript [136]. In this
manner, all targeted mRNAs are reduced upon recognition and binding by miRNA
containing RISC complexes. miRNA mediated degradation of target mRNAs occurs in
the cytoplasm within subcellular structures known as P-Bodies (aka GW bodies) which
consist of miRISC complexes and decapping and deadenylation factors [137].
Recognition of the target mRNA is primarily mediated by the 'seed' region of the
miRNA [131], and may be predicted using computer matching algorithms that seek to
identify complementarities between the miRNA and target mRNA (review of target
prediction algorithms in [132, 133, 138]). Numerous publicly available algorithms have
been developed, including (but not limited to): TargetScan [131], MiRanda [139], DianamicroT [140], RNA22 [141], and miRWalk [142]. While most miRNA target prediction
algorithms require a match between the seed region and the putative target mRNA [138],
targeting models require different spans of matching complementarity within the seed
region and several allow for a less stringent matching with a G:U wobble in the seed
region [132]. miRNA biogenesis is illustrated in Figure 5.
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Figure 5. miRNA biogenesis

Canonical miRNA biogenesis pathway. miRNAs are generated as a result of transcription
by RNA Polymerase and sequential cleavage steps. Mature miRNAs are incorporated
into a RISC complex. Adapted from Mian and Zeleznik-Le [8].
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Further advances in the understanding of miRNA will likely change the targeting
prediction for miRNAs, and our understanding of miRNA function. It has been accepted
that miRNAs may target the 5'UTR of mRNA target transcripts as well as the 3'UTR for
downregulation by the RISC complex [143]. Meanwhile several groups have explored
alternate novel mechanisms of miRNA activity such as miRNA upregulation of target
transcripts, whereby miRNA binding to the target mRNA may occlude a binding site
targeted by a repressive factor and thereby protect the transcript from downregulation.
The primary example of this form of regulation is the relationship between miR-10 and
TOP motifs [144]. Additionally, a bioinformatic analysis of miRNA binding has
suggested that miRNA may simultaneously bind to both the 5'UTR and 3'UTR of a target
mRNA [145]. However, this phenomenon has yet to be functionally demonstrated, and
may be impeded by steric hindrance. Examination of miRNA:mRNA through RISCcomplex pulldowns, coupled with target mRNA sequencing (HITS-CLIP) has been used
to document the interactions of miRNAs in neuronal cells. Strikingly, this study found
many instances of miRNA:mRNA interaction in the absence of matched seed
region[146]. Further study is required to fully examine the functional interaction of
miRNAs with targeted transcripts.
In addition to dysregulation of specific miRNAs, the miRNA biogenesis pathway
has been implicated as a potential target of dysregulation in various cancer models.
Schmittgen et al. found that downregulation of Dicer occurred in a several cancer
models, resulting in global miRNA downregulation [147].
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miRNA disregulation in leukemia
MiRNA dysregulation has been implicated in numerous forms of cancer,
including leukemia. Considerable effort has been applied toward discerning the
disregulation of miRNAs within leukemias to determine how miRNA disregulation
corresponds to lineage, cytogenetic abnormality, and clinical prognosis (reviewed in [8]).
Further effort has been applied to discerning the signature of miRNA disregulation within
leukemias (illustrated Table 1).
Acute leukemias are divided into lymphoid and myeloid lineages, with different
gene expression patterns. To examine the potential difference in miRNA expression
between lineages, a study by the Chen group examined the miRNA expression between
ALL and AML leukemias with common cytogenetic abnormalities including MLL
related translocations in both the AML and ALL subsets, and identified 27 miRNAs
differentially expressed between AML and ALL [148]. The 4 most discriminatory were:
miR-128a and miR-128b upregulated in ALL and let-7 and miR-223 downregulated in
ALL. Interestingly, MLL related leukemias clustered with their lymphoid or myeloid
counterparts, and not together. Several AMLs and ALLs with the same MLL-ENL
translocation clustered with their lymphoid and myeloid counterparts, suggesting that
these miRNAs are regulated by factors other than MLL.
Further examination of the miRNA expression differences between ALL and
AML, were performed using 85 leukemia patient samples with either ALL or AML and
identified a signature of 16 miRNAs differentially expressed between ALL and AML
[149]. This signature identified 9 miRNAs upregulated (miR-128a, miR-128b, miR-155,
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miR-146a, miR-150, miR-17, miR-20a, miR-29a/c, and miR-29b) and 7 miRNAs
downregulated (miR-223, miR-196b, miR-221, miR-222, miR-23a, miR-27a/b, and let-7)
in ALL relative to AML. This study also identified miRNAs whose expression positively
or negatively correlated with overall survival for ALL (miR-221 was associated with
improved survival, while miR-146a, miR-181a/c were associated with poorer survival)
and AML patients (miR-25 was associated with improved survival, while miR-26, miR29b, miR-146a, and miR-196b were associated with poorer survival).
Numerous studies have examined the expression of miRNAs in both ALL and
AML, looking for patterns of miRNA dysregulation corresponding to molecular subtype
and prognosis. Studies of miRNA dysregulation in ALL have examined the differential
expression of miRNAs within ALL, including those harboring MLL translocations. One
study performed by Zanette et al. examined the miRNA expression profiles of
lymphocytic leukemias utilizing a Taqman system designed to asses miRNA levels for
164 commonly expressed miRNAs [150]. ALL samples were pooled and compared to
both B-CLL and CD19+ B-Cells. Pooled ALL samples identified a miRNA signature
differentiating ALL from CD19+ B-Cells. The 5 most highly upregulated miRNAs were
miR-128b, miR-204, miR-218, miR-331, and miR-181; while the 5 most downregulated
miRNAs were miR-135b, miR-132, miR-199, miR-139, and miR-150 [150]. In addition to
the most highly upregulated miRNAs, the authors also detected elevated expression of
miRNAs of the miR-17-92 cluster, as well as the miR-17 family member miR-106a [150].
Schotte et al. examined miRNA expression in MLL and non-MLL precursor B-ALLs
(including TEL-AML1, BCR-ABL, E2A-PBX1, hyperdiploid leukemias, and B-ALLs
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lacking known genetic abnormalities) [151]. ALLs had a genetic signature or 19
miRNAs differentially expressed between ALL and CD34+ cells, with 14 upregulated
miRNAs (miR-128a, -142-3p, 142-5p, -150, -151-5p, -181a, -181b, -181c, -193, -30e-5p,
-34b, -365, -582, -708) and 5 downregulated miRNAs (miR-100, -125b, -99a, -196b, let7e). MLL ALLs had a miRNA expression pattern that was distinct from non-MLL
precursor B-ALLs with 1 miRNA upregulated (miR-196b) and 7 miRNAs downregulated
(miR-193, -151-5p, -30e-5p, -34b, -582, -708, let-7e) (Table 1). Strikingly, miR-196b was
expressed 560-fold higher than in B-ALLs lacking known genetic abnormalities [151].
Numerous studies have examined miRNA dysregulation of AML through high
throughput methodologies, attempting to characterize differential miRNA expression
between different cytogenetic abnormalities [152-156] and among cytogenetically normal
AML [155, 157-159]. Jongen-Lavrencic et al. utilized a multiplex qRT-PCR assay
system to characterize miRNA dysregulation of AMLs with common cytogenetic
abnormalities and molecular abnormalities [153]. Unsupervised clustering analysis
indicated 22 clusters of similar miRNA expression, which in turn corresponded to
cytogentic subgroups (i.e. cytogenetic abnormalities) and molecular subgroups (i.e.
commonly observed mutations observed within cytogenetically normal AMLs). MLL
leukemias showed upregulation of miR-9 and miR-429 and downregulation of miR-213
and miR-146a relative to all non-MLL AMLs. Dixon-McIver, et al. analyzed 157
miRNAs from 100 AML patients via a multiplex qRT-PCR platform [154]. Normal bone
marrow vs. AML showed a signature of 17 upregulated miRNAs (miR-27a, miR-30d,
miR-142-5p, miR-155, miR-181a/b/c, miR-195, miR-221, miR-222, miR-324-5p, miR-326,
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miR-328, miR-331, miR-340, miR-374, and let-7) and 16 downregulated miRNAs (miR9*, miR-15b, miR-26a, miR-30a-3p, miR-34c, miR-103, miR-147, miR-151, miR-182,
miR-184, miR-199a, miR-302b*, miR-302d, miR-325, miR-367, miR-372). MLL
leukemias clustered together with monocytic leukemias. Garzon et al. examined the
differential miRNA expression patterns by microarray and qPCR validation with respect
to both cytogenetic abnormality and prognosis [155]. Examination of miRNA levels in
AML samples revealed a signature of 26 miRNAs downregulated and none upregulated
relative to miRNA expression in CD34+ cells from normal bone marrow donors. Further,
elevated miR-191 or miR-199 expression were negatively correlated to event-free and
overall survival. Within AML samples, MLL leukemias were identified by a signature of
8 upregulated miRNAs and 14 downregulated miRNAs relative to non-MLL patients.
Variance within the MLL translocated samples was further present with 16 miRNAs
upregulated in MLL-AF6 relative to MLL-AF9, indicating an increased level of
complexity governing MLL miRNA regulation. A high throughput bead based study by
Jianjun Chen's group examined the differential miRNA expression between several
common cytogentically abnormal AMLs, including Core Binding Factor translocations,
PML-RARα translocations, and MLL translocations [152]. The miR-17-92 cluster was
strongly upregulated in MLL leukemias relative to non-MLL AMLs. Several miRNAs
from within the HOX cluster, miR-196b, miR-10a, and miR-10b are upregulated in MLL
leukemias. MiR-124a and j-miR-2 were also upregulated. Several miRNAs were down
regulated in MLL leukemias relative to non MLL leukemias including the miR-181
family (miR-181a/b/c/d), miR-126/miR-126*, miR-130a, miR-146a, miR-224, miR-368,
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TABLE 1. miRNAs differentially expressed in acute leukemias
Subject

Compared

Upregulated

Downregulated

Reference

t(11q23) ALL

AML

miR-128a, - 128b,-130, -151, 210, j-miR-1

miR-223, -125a, -221, -222, -23a,
-23b, -24, -27a, -27b, -199b, -26a,
-335, -21, -22, -424, -451, let-7a,
let-7b, let-7c, let-7e

Mi, et
al.[148]

ALL

AML

miR-128a, miR-128b, miR-155,
miR-146a, miR-150, miR-17, miR20a, miR-29a/c, and miR-29b

miR-223, miR-196b, miR-221,
miR-222, miR-23a, miR-27a/b,
and let-7

Wang, et al.
[149]

inv(16)

other AMLs

miR-424, -199b, -365, -335, -511,
-193a

miR-192, -296, -155, -148a, -218,
-135b, -196b, -196a, -432, -135a,
-10a, -10b, -127, -let-7b

JongenLavrencic, et
al. [153]

other AMLs

miR-126*

miR -19a, -221, -107, -188, -338, 342, -20b, -187, -501, -339, -210,
-502, -182, -500, -152, -135a, 148a, -125b, -100, -99a, -1, -133a,
-133b, -224, -9, -10a, - 10b, 196a, -196b, let-7b, let-7c

JongenLavrencic, et
al. [153]

t(15;17)
AML

other AMLs

miR-130a, -130b, -335, -148a, 222, -146a, -181d, -193a, -450, 213, -199, -409-5p, -181b, -496, 181a, -424, -497, -154, -125b, 365, -369-5p, -99a, -203, -433, 323, -494, -100, -370, -432, -224,
-127, -452, -299-5p, -376a, -134, 485-5p, -382, -379, -193b

miR-196a, -196b, -151,-10b, let7c

JongenLavrencic, et
al. [153]

t(11q23)
AML

other AMLs

miR-9, -429

miR-213, -146a

JongenLavrencic, et
al. [153]

JongenLavrencic, et
al. [153]

t(8;21) AML

NPM1
mutated AML

other AMLs

miR-10a, -10b, -135a, -196b, 196a, -152, let-7b

miR-99b, 323, -143, -146a, -497, 320 -511, -450, -151, -494, -193b,
-365, -203, -335, -130a, -485-5p, 126*, -299-5p, -433, -451, -134, 370, -379, -432, -224, -382, -376a,
-424, -127

FLT3
mutated AML

other AMLs

miR-511, -155, -10b, -135a

miR-30a-3p, -203, -130a, -214, 338, -143, -145, -182

JongenLavrencic, et
al. [153]

ALL

CD19+
normal

miR-128b, -204, -218, -331, 181b, -204, -148, -210, -218, 296, -381, 17-3p, -17-5p, -19a, 20, -92

miR-135b, -132, -199, -139, -150

Zanette, et
al. [150]

36

ALL

normal
CD34+

miR-128a, -142-3p, 142-5p, -150,
-151-5p, -181a, -181b, -181c, 193, -30e-5p, -34b, -365, -582, 708

miR-100, -125b, -99a, -196b, let7e

Schotte, et
al. [151]

t(11q23) ALL

other ALL

miR-196b

miR-193, -151-5p, -30e-5p, -34b, 582, -708, let-7e

Schotte, et
al. [151]

AML

normal
CD34+

NA

miR-126, -130a, -135, -93, -146, 106b, -224, 125a, -92, -106a, -95,
-155, -25, -96, -124a, -18, -20, 7d, -26a, -222, -101, -338, -371, 199b, -29b, -301

Garzon, et
al.[155]

t(11q23)
AML

other AMLs

miR-326, -219, -194, -301, -324, 339, -99b, 328

miR-34b, -15a, -29c, -372, -30a, 29b, -30e, -196a, let-7f, -102, 331, -229, -193

Garzon, et
al.[155]

FLT3
mutated AML

FLT3 wt

miR-155, -10a, -10b

NA

Garzon, et
al.[155]

NPM1
mutated AML

NPM1
unmutated
AML

miR-10a, -10b, -100, -21, -16a, 16b, -19b, -18a, -29c, -29a, -16-1,
-29b, -24, -20, -17, -369, - 19a, 106, -16-2, -195, -102, -152, -9, 142, -378, -98, -374, -15a, 155,
let-7a-3, let-7f, let-7c, let-7a-2,
let-7a-1, let-7g, let-7d

miR-22, -192, -128a, -383, -373, 324, -127, -373, -324, -127, -373*,
-139, -193b, -145, -498, -135a, 299, -429, -493, -326, -204, -198,
486

Garzon, et
al. [159]

FLT3
mutated AML

FLT3 wt

miR-155, -302a, -133a

NA

Garzon, et
al. [159]

t(11q23)
AML

Other AMLs

miR-27a, miR-30d, miR-142-5p,
miR-155, miR-181a/b/c, miR-195,
miR-221, miR-222, miR-324-5p,
miR-326, miR-328, miR-331, miR340, miR-374, and let-7

miR-9*, miR-15b, miR-26a, miR30a-3p, miR-34c, miR-103, miR147, miR-151, miR-182, miR-184,
miR-199a, miR-302b*, miR-302d,
miR-325, miR-367, miR-372

DixonMcIver, et
al. [154]

t(8;21),
inv(16),
t(16;16)
AML

other AMLs

miR-126/126*, -130a

miR-196b, -17-5p, -17-3p, -18a, 19a, 19b, 20a, 92

Li, et al.
[152]

t(15;17)
AML

other AMLs

miR-181a, -181b, -181c, -181d, 100, -125b, -224, -368, -382, -424

miR-126/126*, -422b, -10a, -150,
-124a, -17-5p, -20a, j-miR-2

Li, et al.
[152]

t(11q23)
AML

other AMLs

miR-10a, -10b, -124a, -196b, -175p, -17-3p, -18a, -19a, -19b, -20a,
-92, j-miR-2

miR-126/126*, -130a, -146a, 181a, -181b, -181c, -181d, -224, 368, -382, -424

Li, et al.
[152]

miR-21

miR-26a, miR-30c, miR-30d, miR100, miR-125b, miR-126-3p, miR143, miR-146a, miR-146b-5p,
miR-181a, miR-181b, miR-181d,
miR-221, miR-222, and let-7

Dashkey, et
al. [156]

t(11q23)
AML

Other AMLs

miRNA dysregulation was cataloged for miRNAs dysregulated in acute
leukemias. Adapted from Mian and Zeleznik-Le [8].
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miR-424. Dashkey et al. examined 102 samples from childhood and adolescent AMLs
by microarray across multiple cytogenetic abnormalities, including: CBF translocations,
PML-RARα translocations, and MLL rearrangements [156]. MLL leukemias showed a
unique signature relative to non MLL leukemias of 15 downregulated miRNAs (miR-26a,
miR-30c, miR-30d, miR-100, miR-125b, miR-126-3p, miR-143, miR-146a, miR-146b-5p,
miR-181a, miR-181b, miR-181d, miR-221, miR-222, and let-7) and a single upregulated
miRNA (miR-21).
Collectively, these studies of miRNA signatures of AMLs with different
cytogenetic abnormalities present very different pictures, with some overlap in results.
These differences can be attributed to different comparison groups and different
platforms. However, the role of several miRNAs were verified by detailed functional
studies verifying dysregulation of miRNAs.
HOX associated miRNAs
5 miRNAs are located within the HOX clusters in mammals, including miR-10a,
miR-10b, and miR-196a-1, miR-196a-2, and miR-196b [160]. Several of these miRNAs
have been shown to be upregulated in MLL AML relative to non-MLL AMLs [152].
miR-196b has several homologs located at other loci within the HOX clusters. Mir-196a1 and miR-196a-2 are located upstream from HOXB9 and HOXC9, respectively (Figure
6). Within the miR-196 family, miR-196a and miR-196b differ only at nucleotide 12 with
miR-196a encoding an adenine and miR-196b encoding a uracil [161]. Both miR-196a-1
and miR-196a-2 are identical in their mature miRNA sequence (Figure 6).
MiR-196b is located within the HOXA9 locus and is evolutionarily conserved
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throughout mammals [11]. The pri-miR-196 transcript is a non-coding transcript that is
expressed from an alternate AB exon of HOXA9 that is directly regulated by MLL and is
highly upregulated in MLL AMLs relative to other non-MLL AMLs [11, 152]. Previous
work from our lab has shown that inhibition of miR-196b through 'antagomir' inhibitors
abrogates the leukemogenic capacity of MLL-AF9 transduced bone marrow, while
transduction of miR-196b enhances colony forming ability of murine bone marrow
progenitor cells [11]. Studies of miR-196b in ALL have revealed that miR-196 expression
levels correlate with HOXA9 expression and miR-196b is upregulated in ALLs where the
HOXA cluster is often highly expressed [162]. miR-196b was implicated in the
downregulation of HOXA9 and MEIS1 in MLL leukemia [163]. Overexpression of miR196b in a murine model transformed with MLL-AF9 results in a delay in onset of AML,
implicating miR-196b can function as a tumor suppressor. Secondary transplantation,
however, result in an accelerated onset of leukemia, indicating the dualistic role of miR196b in targeting both oncogenes and tumor suppressors [163].
miR-196 was initially characterized as regulator of HOXB8 despite a G:U wobble
mismatch located within the seed region matching site of the HOXB8 MRE [161]. In
addition to regulating HOXB8, miR-196a and miR-196b are predicted to regulate several
additional HOX genes, including HOXC8, HOXD8, and HOXA7 (Figure 6).
Numerous studies have implicated miR-196 in development and hematopoiesis.
During embryonic development, miR-196 downregulates Hoxb8, which induces
expression of Sonic hedgehog (Shh) to promote the development of nascent limb buds
[164]. In embryonic chicken development, miR-196b regulation of Hoxb8 governs
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Figure 6. HOX associated miRNAs

A) Schematic depiction of HOX associated miRNAs in human. miRNAs are indicated by
stem loop structures drawn onto HOX clusters. miRNA regulatory relationships with
HOX genes are indicated on chart. Adapted from Yekta et. al. [160]. B) miRNA sequences
from the miR-10 and miR-196 families grouped by family and color coded with the miR196 family indicated in green and the miR-10 family in orange. Seed region indicated in
red. Underlined sequences indicate non conserved bases.
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vertebrate segmental identity, with specific knockdown of miR-196 resulting in skeletal
abnormalities in the last cervical vertebra [165].
miR-196b is dysregulated in a number of additional cancer models, as both an
oncogene and tumor suppressor; including glioblastoma multiforme [166], cervical
cancer [167], and chronic myeloid leukemias [168]. In glioblastoma, high miR-196b
expression levels are correlated to lower overall survival with increased cellular
proliferation, implicating miR-196b as a potential oncogene [166]. However, in cervical
cancer and chronic myeloid leukemia, miR-196b has been shown to function as a tumor
suppressor, regulating HOXB7 in cervical cancer [167], and BCR-ABL and HOXA9 in
CML [168].
In addition to miR-196b, miR-10a also arises from within the HOX gene clusters
and has been found to be upregulated in MLL leukemias [152]. The miR-10 family is
comprised of two HOX cluster located miRNAs. miR-10a is located downstream of
HOXB4, while miR-10b is located downstream of HOXD4 [169]. miR-10a and miR-10b
differ only in nucleotide 12, with miR-10a encoding a uracil and miR-10b encoding an
adenine [169]. miR-10 family members have been implicated in both canonical miRNA
function through RISC-mediated mRNA downregulation as well as non-canonical
function. For example, miR-10b downregulates HOXD10 in breast cancer through the
canonical miRNA:RISC mechanism, leading to a decrease in HOXD10 mRNA stability
and an increase in tumor metastasis [170]. However, miR-10a has been shown to bind to
TOP motif containing mRNA transcripts, immediately downstream of the TOP motif,
resulting in increased expression of these target mRNAs [144]. TOP (terminal
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oligopyrimidine tract) sequences consist of a short tract of 4-15 pyrimidine residues
located adjacent to the 5' cap within the 5'UTR of an mRNA, and have a regulatory
function as a binding site for translational repressors [171]. The role of miR-10a in
regulating the translation of these mRNAs is unusual in that: 1) it does not entail perfect
seed matching between miR-10a and the target, and 2) binding of miR-10a results in an
increase in translation rather than a decrease [144].
miR-17-92 cluster
The miR-17-92 cluster (also known as oncomir-1) consists of 6 miRNAs coexpressed from a single transcript (miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1, and
miR-92 located on band q31 of chromosome 13 in humans [172, 173] . The miR-17-92
cluster has several homologous miRNA clusters including the miR-106a cluster and the
miR-106b cluster located on chromosome X band q26 and chromosome 7 band q22,
respectively (Figure 7). The miR-17-92 cluster arises from an intron of a pri-miRNA
transcript that is non-coding. However, the homologous miR-106a primary miRNA
transcript has not been identified [174]. The miR-106b cluster arises from an intron of
the MCM7 mRNA transcript, which encodes a protein, mini chromosome maintenance 7,
and includes only 3 different miRNA encoding hairpins [174].
Numerous studies have implicated the miR-17-92 cluster in cancers, cell cycle
control, and development (extensively reviewed in [173, 175]). Knockout of the miR-1792 cluster and its homologous clusters in mouse models produced several distinct
phenotypes. miR-17-92 (-/-) embryos are smaller than their wild type counterparts, and
miR-17-92 knockout mice die shortly after birth, with lung hypoplasia [176]. In these
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studies, bone marrow transplantation experiments implicated the miR-17-92 cluster in B
cell development [176].
The miR-17-92 cluster was initially identified as a target of Myc regulation [177].
However, recent studies have indicated that additional regulatory factors also control
miR-17-92 expression. Examination of endogenous E2F binding indicates that E2F1,
E2F2, and E2F3 bind to the miR-17-92 promoter and increase transcription of the miR17-92 host gene [178]. Further studies, indicate that p53 suppresses miR-17-92
expression through direct transcriptional regulation under hypoxic conditions [179].
Examination of the miR-17-92 cluster in MLL leukemia has identified a direct regulatory
relationship by both wild-type MLL and MLL fusion proteins [12]. Both wild type and
fusion MLL proteins localize to the promoter of the miR-17-92 host gene, as indicated by
chromatin immunoprecipitation assays [12]. Cell lines with MLL translocations showed
an increase in MLL binding to the miR-17-92 promoter, increased H3 acetylation, and
H3K4 trimethylation as compared to those without MLL translocations [12]. Further,
examination of miRNA expression profiles in AML with common translocations indicate
that the miR-17-92 cluster is upregulated in MLL AMLs relative to non-MLL AMLs
[152]. The miR-17-92 cluster and its homologous miRNA clusters, encode four families
of miRNA categorized by homology in the seed region (miRNA sequences are reviewed
in [172, 173]). Homologous miRNAs are generally accepted to have overlapping
functions and target sequences, as a result of commonalities within the seed region. For
example, miR-17 and -20a share the same seed sequence which is critical for target
recognition (reviewed in [174]).
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Figure 7. miR-17-92 cluster and related miRNAs

A) Organization of the miRNAs within the miR-17-92 cluster (top), miR-106a-363 cluster
(middle), and miR-106b-25 cluster (bottom). Light colored box indicates the arm (5p or
3p) which produces the predominant mature miRNA. miRNA families are grouped by
color with the miR-17 family indicated in blue, miR-19 family in orange, miR-18a family
in red, and the miR-92 family in green. B) miRNA sequences from the miR-17-92 cluster
and paralogous clusters. miRNAs organized by family. Seed region indicated in red.
Underlined sequences indicate non conserved bases.
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The miR-17 family is comprised of miR-17 and miR-20a of the miR-17-92 cluster;
miR-106a and miR-20b of the miR-106a-363 cluster, and miR-106b and miR-93 of the
miR-106b-25 cluster. MiRNAs of the miR-17 family have a common seed sequence of
AAAGUG, and share a great deal of homology throughout non-seed nucleotides as well,
often differing at only one or two nucleotides (Figure 7). Within the miR-17-92 cluster,
miR-17 and miR-20a differ at nucleotides 1 and 12, with miR-17 possessing cytosines in
these positions, and miR-20a possessing uracils. The miR-17 family, which is comprised
of miR-17 and miR-20a, is one of the most studied miRNA families, with numerous
defined targets, including (but not limited to): AIB1 [180], HSP27 [181], and TGFβ
[182]. Critically, the miR-17 family has been implicated in cell cycle progression,
through regulation of several components the G1/S checkpoint. MiR-17 downregulates
the negative checkpoint regulator CDKN1A (p21) [183]. Further examination of the miR17 homolog miR-106a, indicated that miR-106 also directly targets CDKN1A (p21)
[184].Conversely, miR-17 also downregulates the expression of E2F1, and in doing so
prevents the cell from dying due to double strand breaks that would otherwise occur as a
result of unrestricted growth [177, 185]. In addition to E2F1, miR-20a regulates several
other E2F family members, including E2F2 and E2F3 [178]. Recent work has identified
a feedback loop whereby the miR-17-92 cluster downregulates E2Fs which regulate the
miR-17-92 cluster. Within hematopoiesis, miR-17, 20a, and106a have been implicated as
regulators of monocytopoiesis through downregulation of AML1, which functions to
positively regulate the M-CSF receptor and negatively regulate the miR-17-92 and miR106a-363 clusters [186]. Introduction of exogenous miRNAs from the miR-17 family
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into cord blood CD34+ progenitor cells cultured under a monocytic differentiation
protocol resulted in an increase in blast cells and inhibition of monocytic differentiation
while inhibition of miRNAs from the miR-17 family results in decreased proliferation and
increased differentiation [186].
The miR-19 family is comprised of 2 separate 23 nucleotide miRNAs, miR-19a
and miR-19b-1, and have a common seed sequence of GUGCAA (Figure 7). MiR-19a
and miR- 19b differ in only a single nucleotide at position 11; miR-19a has an uracil,
while miR-19b has a cytosine. Located outside of the seed region, these nucleotides are
involved in stabilization of the miRNA:mRNA interaction, but are not essential for
targeting the miRNA to the transcript. Numerous miR-19 targets have been identified,
including (but not limited to): TNFα [187, 188], BCL2L11 [189], and PTEN [190]. Of
these targets, PTEN is often cited as a critical downstream target of the miR-19 family.
The regulatory relationship between miR-19 and PTEN was initially described using an
Eµ-myc model of lymphoma, where overexpression of miR-19b resulted in decreased
PTEN levels and increased cell survival [190].
miR-18a is additionally located within the miR-17-92 cluster, while its homolog
miR-18b is within the miR-106a-363 cluster. MiR-18a differs from miR-18b at a single
nucleotide with a uracil instead of a cytosine, and both share a common seed sequence of
AAGGUG (Figure 7). MiR-18a is one of the least well studied miRNAs of the miR-1792 cluster. However, several mRNAs have been identified as miR-18a targets, including
(but not limited to): PIAS3 [191], CTGF [192], and SMAD4 [182].. Intriguingly, miR18a was found to inhibit the global function of miRNAs through targeting of the Dicer
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mRNA [193]. In a cardiovascular model, miR-18, along with miR-19, has been
implicated in the regulation of angiogenesis via downregulation of the pro-angiogenic
factors CTGF and Tsp1 [192]. MiR-18a regulates function of the TGF-β signaling
pathway through downregulation of the downstream effector SMAD4 [182].
The miR-92 family is represented by miR-92a-1 within the miR-17-92 cluster;
miR-92a-2 and miR-363 within the miR-106a-363 cluster; and miR-25 within the miR106b-25 cluster (Figure 7). Numerous miR-92 targets have been identified including (but
not limited to): Integrin-5a [194], VHL [195], and PHLPP2 [196]. Critically, miR-92 has
been implicated in regulating apoptosis through regulation of BCL2L11 (Bim) [197].
Several mRNAs have been validated as targets of multiple non-family miRNAs
from the miR-17-92 cluster, suggesting that miRNAs may act cooperatively to regulate
targets. For example, PTEN is downregulated by miR-17, miR-19, and miR-18a through
miRNA binding to unrelated MREs within the 3'UTR [190, 198, 199]. The pro-apoptotic
BCL2 family member BCL2L11 (Bim) is an additional target of cooperation for miRNAs
of the miR-17-92 cluster, regulated by both miR-19 [189] and miR-92 [197]. Despite the
extensive work published on validating targets of the miR-17-92 cluster, few studies have
examined the contributions of this cluster to MLL leukemia or validated the potential
mechanism by which the miR-17-92 cluster acts in MLL leukemia. Enforced
overexpression of miR-17-19b increases the colony forming ability of MLL-ELL
transformed bone marrow [12]. Further, overexpression of the miR-17-92 cluster results
in downregulation of 363 potential target genes, indicating that dysregulation of the miR17-92 cluster has broad implications in target mRNA regulation [12]. Within MLL
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leukemia, miR-17 regulates CDKN1A (p21) expression [183]. Overexpression of miR-1719b accelerated the onset of MLL-AF10 leukemia in a murine model, which was
phenocopied by shRNA knockdown of CDKN1A (p21). The growing number of
validated targets for each miRNA suggests that miRNAs are not limited to single targets,
and that other, as yet non-validated targets, likely contribute to the disease process.
Antisense oligonucleotide technologies
Findings highlighting the importance of miRNAs in cancer, as well as other
diseases, have drawn attention to the potential therapeutic value of modulating miRNA
function, either by replacing lost/downregulated miRNAs or inhibiting
amplified/overexpressed miRNAs. To this end, multiple different technologies have
emerged to modulate miRNA levels utilizing synthetically manufactured oligos (history
of oligonucleotide therapeutics reviewed in [8, 13, 14]).
As miRNAs function to post-transcriptionally regulate transcription, replacement
of lost miRNA function may be achieved using anti-sense oligonucleotides (ASOs)
complementary to sequences found in target mRNAs and function in both RISCdependent and RISC-independent functions. RISC-independent mechanisms of ASO
function target specific mRNAs with perfectly matched complementary oligonucleotides
(oligos), and recruit the endogenously expressed RNAse H to cleave the mRNA:ASO
duplex (reviewed in [8, 200]). Alternatively, RISC-dependent replacements of miRNA
function can be attained through introducing either a shRNA, siRNA, or miRNA
analogue (reviewed in [201]).
Numerous chemical modifications have been developed for use in oligos (Figure
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8). The chemical modifications utilized for anti-miRNA oligonucleotides (AMOs) were
developed from those used for synthetic siRNAs and mRNA targeting ASOs, and utilize
the same modifications. AMOs directed against miRNAs function through stable binding
to miRNAs. AMO downregulation of miRNAs occurs through irreversible binding and
sequestration of target miRNAs [202]. Thus their most valuable attributes are a high
thermodynamic stability, compatibility with binding to RISC associated miRNAs, and
resistance to nuclease degradation (discussed in [13, 203]). Inhibition of miRNA
function is dependent on chemically modified anti-sense oligonucleotides (ASOs) that are
complementary to the target miRNAs and inhibit miRNA activity through
thermodynamically stable Watson-Crick base pairing to target miRNAs (reviewed in
[13]). The simplest ASOs may employ either unmodified RNA or DNA nucleotides
complementary to the target miRNA. However, unmodified oligos are poor candidates
for therapeutic use due to immune response activation, rapid oligo degradation, poor
cellular uptake, and limited bioavailability of ASOs (reviewed in [13, 200, 203]). To
improve bioavailability, nuclease resistance, and miRNA:AMO duplex stability;
numerous chemical modifications have been developed for ASOs, including modification
of the phosphodiester backbone and modification of the ribose sugars.
Modifications of the non-bridging oxygen of the phosphate group linking the
ribose sugars of the backbone, include methylphosphonates, phosphorothioates, and
boranophosphonates (reviewed in [14, 201, 203]). Modification of the non-bridging
oxygen introduces chirality to the phosphate, and each modification results in a racemic
mixture of both stereoisoforms of the of the phosphodiester linkage [203], increasing
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levels of nuclease incorporation result in increasing nuclease resistance.
Phosphorothioate modifications consist of the addition of a sulfur in place of one
of the non-bridging oxygen molecules of a phosphate within the oligo backbone. A
phosphorothioate modification confers resistance against RNAse degradation, at a slight
cost of binding affinity (~0.25° C/modification)[13], and thus may require additional
modifications to offset decrease in binding affinity. Further, in vivo examination of
siRNAs indicates that inclusion of phosphorothioate modifications modestly improved
serum stability of siRNAs, and produces similar biodistribution of siRNAs among organs
[204]. Phosphorothioate modifications are nuclease resistant, thus conferring a level of
resistance to degradation [205], but are compatible with RNAse H, and thus suitable for
use in ASO designs [14, 205].
Numerous modifications alter the ribose sugar at the 2' position, directly binding
either the 2' carbon or modifying the attached hydroxyl group, including: 2'- O-Methyl
(2'-O-Me), 2'-O-methoxyethyl (2'-O-MOE), 2'-Flouro (2'-F), 2'-Deoxy-2'-fluoro-β-Darabino (FANA), N3'-P5' phosphoramidates (NPs), and locked nucleic acids (LNA)
(reviewed in [13, 200, 201]). The sugars of nucleotides exist in multiple different
"pucker" conformations, which are described by the angles of the C2 and C3 tetrahedral
bonds of the furanose ring [203]. The principle stable sugar conformations employ either
a C3-endo, C2-exo conformation (a.k.a. North conformation, N-type conformation) or a
C3-exo, C2'-endo conformation (a.k.a. South conformation, S-type conformation) [206].
Pucker conformation, in turn, alters the bond lengths of the sugar and phosphate bonds
of nucleic acids, altering the thermodynamic stability of base pairing [207].
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2'- O-Methyl (2'-O-Me) modifications have been widely utilized in ASO
development. As with other modifications to the 2' position of the ribose sugars, 2'-O-Me
modifications improve the binding affinity of the oligo by forcing the ribose sugars into a
C3-endo conformation, resulting in an increase in thermodynamic binding stability of 2-3
°C/nucleotide [203]. Examination of chemically modified siRNAs has indicated that
incorporation of 2'-O-Me modifications confers resistance to immune activation [208].
2'-O-Me modified oligos were applied to AMOs targeting miRNAs incorporated in a
RISC complex in 2004. Two independent studies examined the use of uniformly
modified 2'-O-Me oligonucleotides to block the function of siRNAs associated with the
RISC complex in C. elegans [209] and human cell lines [210], and found the modified
oligonucleotides to be capable of inhibiting the function of siRNAs and miRNAs within
RNA-protein complexes. The 2'-O-methoxyethyl (2'-O-MOE) modification is another
commonly used 2'-alkyl ribose modification, altering ribose sugar conformation to result
in an increase in thermodynamic binding stability of 2 °C/nucleotide [203].
Locked Nucleic Acids (LNAs) are a 2'-O, 4'-C-methylene-β-D-ribofuranosyl
modified version of a ribose (consisting of a methylene bridge between the 2'-hydroxyl
group and 4' carbon of the ribose sugar), and were initially synthesized in 1998 [211,
212]. As with other 2' ribose modifications, LNA modifications lock the ribose sugar
into a C3 endo conformation and thermodynamically stabilizes binding to target
nucleotides [213, 214]. Incorporation of locked nucleic acids additionally affects the
pucker conformation of adjacent nucleotides [215]. LNAs increase the binding affinity of
nucleotides in a sequence dependent manner with an increase in thermodynamic stability
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that is partially dependent on adjacent nucleotides [216, 217], and results in a change in
binding affinity of 1.5-6 °C/nucleotide [13]. In addition to improving the thermodynamic
stability of binding with a target, incorporation of LNA modifications increase resistance
to nuclease mediated degradation [218]. Further, LNAs are incompatible with RNAse H
function but compatible with RISC activity function [219]. However, LNA
simultaneously increase hepatic toxicity [220]. Several additional modifications are
currently under development based on this chemistry, including amino-LNAs, thioLNAs, α-L-ribo-LNAs, and β-D-xylo-LNAs [213].
Chemical modifications appended to the ends of the oligo have been used to alter
the distribution and serum half-life of antisense oligos. Addition of a cholesterol to the 3'
end of an oligonucleotide was initially described in the context of a siRNA targeting the
ApoB mRNA transcript [221]. Cholesterol transport within the serum is mediated by
binding to albumin, high density lipoprotein (HDL), and low density lipoprotein (LDL)
[222, 223]. In addition to the cholesterol tag, several modified lipids (of varying lengths)
have been employed as tags conjugated to the 3' end of siRNAs, including: myristoyl,
lithocolic-oleyl, docosanyl, lauroyl, stearoyl, palmitoyl, oleoyl, and linoleoyl tags [224].
Modification of siRNAs by different lipophilic conjugates altered the biodistribution of
siRNAs in vivo [224]. Uptake method in vivo relies on the human homolog to the C
elegans transmembrane receptor Sid1 as well as the SR-B1 receptor [224].
Oligonucleotide chemical modifications are modular and may be applied across
the oligo or only at specific residues, resulting in 'mixmers," consisting of combinations
of multiple different chemical modifications and variation in the length of antisense
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oligonucleotides suited to different functions. Numerous chimeric mixtures of
oligonucleotide modifications have been employed for specifically targeting miRNAs,
including: 2'-O-MOE/PS [225], 2'-O-MOE/LNA/PS [226], 2'-O-Me/LNA/PS [227],
LNA/2'-O-Me [228], 2'-O-MOE/2'-F [229]. While numerous studies have utilized AMOs
of the same length as the target miRNA, additional studies have utilized AMOs shorter
than the target, focusing on developing the minimally required oligos so as to minimize
toxicity and non-specific binding while maintaining target affinity. For example, an 8mer oligonucleotide, comprised of LNAs with a complete phosphorothioate backbone,
targeting the seed region of miR-33, provided efficient knockdown of both miR-33a and
miR-33b in vivo in mouse and primate [230, 231].
Among the different ASO patterns of modifications, ‘antagomirs’ were
empirically developed as a specific pattern of multiple modifications consisting of: 2'-OMe modifications across all ribose sugars of the oligo, phosphorothioate bonds at the first
two and the last four phosphodiester linkages, and a cholesterol tag at the 3' end of the
oligo [232, 233]. These ASOs were initially characterized as a potential therapeutic
intervention to inhibit miRNAs in vivo [232, 233]. Krutzfeldt, et al. tested several
potential antagomir designs with different modification patterns. They observed a
decrease in knockdown efficiency for oligos containing phosphorothioate modifications
of all phosphodiester bonds, relative to oligos with phosphorothioate modifications at the
first 2 and last 4 phosphodiester bonds [232], and thus limited use to these specific
residues to block RNAse function while minimizing negative effects.
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Figure 8. Antisense oligonucleotide modifications and patterns

Canonical miRNA biogenesis pathway. A) Selected modifications for anti-sense
oligonucleotides. Adapted from DeLeavey, et al. [203]. B) Depiction of an unaltered
oligo nucleotide (top) and a modified oligonucleotide with ‘antagomir’ modifications
(bottom). Phosphorothioate modifications depicted with red circles, 2’-O-Me
modifications depicted in green, and cholesterol in yellow.
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Further, in examining the specificity of antagomirs and the potential effects of
single or multiple mismatches between the antagomir and the targeted miRNA,
Krutzfeldt, et. al. observed that a single mismatch at key residues abrogated miRNA
knockdown [232]. Examination of the subcellular location of fluorescently labeled
antagomirs indicated that antagomir modified oligonucleotides localized within punctate
structures located in the cytoplasm, but did not co-localize alongside the P-body marker
GW182 [232]. Examination of target miRNAs upon antagomir treatment indicate
consistent knockdown of target miRNAs throughout examined tissues [233].
Several groups have utilized the antagomir pattern of modifications to inhibit
miRNA function in vitro and in vivo. Previous work from our group, performed in
collaboration with the Grimes lab, utilized an anti-miR-196b antagomir in vitro colony
assay, to test the necessity of miR-196b to the clonogenic capacity of MLL-AF9
transduced bone marrow progenitor cells [11]. Studies by the Grimes lab have utilized
antagomir oligonucleotides against miR-21 and miR-196b to examine the contribution of
miRNAs in AML in vivo [234, 235].
In my dissertation research, I examine targeting miRNAs upregulated in MLL
leukemia both individually and in combinations as a potential therapeutic approach. I
find that combinatorial antagomirs function as a potent anti-leukemia treatment in vitro. I
further examine the regulatory role of miRNAs in modulating the expression of PKNOX1
and its availability for inclusion in HOX-PBX complexes. This establishes one potential
mechanism by which miRNA inhibition disrupts the leukemogenic potential of MLL
fusion proteins in leukemia.

CHAPTER 3
MATERIALS AND METHODS
Cell lines and culture conditions
Human leukemia cell lines were obtained from DSMZ and cultured according to
manufacturer’s instructions. MOLM-13 was derived from the peripheral blood of a
patient undergoing a relapse of M5 AML leukemia and harbors t(9;11) translocation
resulting in an MLL-AF9 fusion [236]. The THP1 cell line also harbors an t(9;11)
translocation, and is derived from a patient with a monocytic AML [237]. In addition to
cell lines with MLL-AF9 gene fusions, I also examined several cell lines with t(4;11)
translocations resulting in MLL-AF4 gene fusions. RS4;11 is an MLL-AF4 expressing
cell line derived from the bone marrow of a patient with a biphenotypic leukemia,
expressing characteristics of both B-cells and monocytes [238]. The MV4-11 cell line
also possesses an MLL-AF4 gene fusion, and was derived from the bone marrow of a
patient with a childhood leukemia [239]. I additionally utilized U937 and HL60 as nonMLL cell line controls. U937 cells were derived from a patient with histiocytic
lymphoma [240], while HL60 cells were derived from a patient with Acute myeloid
leukemia and harbors a c-Myc amplification [241]. Experiments performed in adherent
cell lines utilized HEK293T cells, originally derived from human embryonic kidney and
transformed with the SV40 T antigen [242].
MOLM-13 (MLL-AF9), and RS4;11 (MLL-AF4) were maintained at
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concentrations between 1X105 cells/mL and 1X106 cells/mL in RPMI with 10% Fetal
Bovine Serum and 1% Penicillin/Streptomycin (Pen/Strep). MV4-11 (MLL-AF9) and
K562 (BCR-ABL) was maintained at concentrations between 1X105 cells/mL and 1X106
cells/mL in IMDM with 10% FBS and 1% Pen/Strep. Adherent cell lines were cultured
HEK293T, Rat1A, NIH-3T3 cells were cultured in DMEM with 10% FBS and 1%
Pen/Strep. MLL-AF9 transformed bone marrow was cultured in liquid culture at
concentrations between 3X105 cells/mL and 1X106 cells/mLin RPMI with 10% fetal
bovine serum and 1% Pen/Strep. Cells were supplemented with IL-3 (10 ng/mL), IL-6
(10 ng/mL), and SCF (100 ng/mL) cytokines. All cells were kept at 37˚ C with 5% CO2.
HEK293T cells were transfected using CalPhos Mammalian transfection system
(ClonTech, Mountain View, CA, Cat #631312) per manufacturer’s instructions.
Constructs
MSCV-MLL-AF9 [23] MIGR1 [23], MSCV-Meis1-pgk-EGFP [94], and pKOF2Prep1-GFP [94] retroviral constructs were described previously. Briefly, the MSCVMLL-AF9 retroviral construct contains a human MLL-AF9 fusion gene within the Murine
Stem Cell Virus system and can be utilized to introduce and express genes of interest in
hematopoietic stem cells. The MSCV-Meis1-pgk-EGFP expresses a murine Meis1 within
the MSCV retrovirus with a gene encoding a fluorescent protein, EGFP, expressed from a
separate promoter [94]. The pKOF2-Prep1-GFP encodes the full length of Pknox1 (also
known as Prep1) cloned into a modified MSCV vector, with GFP expressed from a
separate promoter [94, 243].
Bone marrow isolation, enrichment, and infection for generation of MLL-AF9

57

transformed bone marrow was performed as previously described [244]. Additional
infection with MIGR1 or pKOF2-Prep1-GFP was performed on MLL-AF9 bone marrow
cell that had been cultured in methylcellulose for 4 weeks.
pRL-TK (Promega, Madison, WI, Cat# E2241), MSCV-PIG [190], and MSCVPIG- miR-17-19b [190] have been described previously. The pRL-TK construct encodes
Renilla luciferase driven by the HSV-1 Thymodine Kinase promoter, and serves as a
commonly used experimental control in luciferase due to: 1) the ability to readily
distinguish between Renilla and Firefly luminescence, and 2) the constancy of expression
of the luciferase enzyme under the TK promoter. Exogenous miRNA expression was
attained through transfection with the MSCV-PIG- miR-17-19b plasmid (received as a
generous gift from Dr. Jianjun Chen, University of Cincinnati). MSCV-PIG- miR-17-19b
was constructed by cloning a fragment of the miR-17-92 cluster containing the miRNA
hairpins from miR-17 to miR-19b-1, within the MSCV (Mouse Stem Cell Virus) retroviral
backbone [190]. The construct additionally contains a PIG cassette, encoding PuroIRES-GFP for use in selection [190]. MSCV-PIG, which lacks any fragment o the miR17-92 cluster was used as a control.
Luciferase constructs were generated by cloning the 3’ UTR from Pknox1 in the
pmiR-Report system (ThermoFisher Scientific, Cat#AM5795). The pmiR-Report system
encodes a firefly luciferase gene driven by CMV promoter within the pmiR backbone. A
multiple cloning site is located downstream of the luciferase to allow cloning of a 3'UTR.
Mutations to the miRNA binding sites were generated using the Stratagene Multi-site
directed mutagenesis kit (Stratagene, La Jolla, Cat# 200514). Details of cloning
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techniques and strategies described elsewhere in the Materials and Methods section.
Antagomir modifications and treatment
Antagomirs were synthesized by the Dharmacon division of Thermo (Lafayette,
CO) following the pattern of modifications outlined previously [232, 233]. Antagomirs
were designed as small oligonucleotides (oligos) complementary to the targeted miRNA.
All nucleotides contained 2’-O-methyl modifications on the ribose sugar. For all oligos,
the first 2 and last 4 phosphodiester linkages were replaced with a phosphorothioate
linkage. The 3’ ends of all oligos possess a cholesterol group. Fluorescent antagomirs
possess an additional DY547 fluorescent label at the 5’ end.
Antagomir treatments were performed according to 3 different protocols
(specified in text). For superficial treatment with antagomirs, cells were counted and
resuspended in fresh culture medium at 2X treatment concentrations (100k cells/mL).
Cells were then added to an equal volume containing antagomirs and 10X PBS in media
at 2X the concentration of the final solution. Superficial antagomir treatment with preincubation has been previously utilized by our lab and others [11, 234, 235]. For preincubation, cells were incubated in 100 µL of culture media, with antagomir at 10X the
final treatment concentration, along with 10X PBS to compensate for antagomir volume,
on ice for 30 mins and followed by at room temperature for 5 mins. The cell-antagomir
mixture was then diluted tenfold with culture media (for liquid culture experiments) or
with . Herein, I refer to this treatment as the "superficial treatment with pre-incubation" to
distinguish it from simple superficial treatments that do not require any pre-incubations.
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Table 2. Sequences and modifications of antagomirs
antagomir
anti-Ce-mir-67
anti-Ce-mir-67DY547
anti-mir-196b
anti-mir-10a
anti-mir-191
anti-mir-93*
anti-mir-17
anti-mir-18a
anti-mir-19a
anti-mir-19b-1
anti-mir-20a
anti-mir-92a-1

antagomir sequence (5'→3')
mU*mC*mUmAmCmUmCmUmUmUmCmUmAmGmGmAmGm
GmUmU*mG*mU*mG*mA-Chl
DY547*mU*mCmUmAmCmUmCmUmUmUmCmUmAmGmGm
AmGmGmUmU*mG*mU*mG*mA-Chl
mC*mC*mCmAmAmCmAmAmCmAmGmGmAmAmAmCmUm
A*mC*mC*mU*mA-Chl
mC*mA*mCmAmAmAmUmUmCmGmGmAmUmCmUmAmCm
AmG*mG*mG*mU*mA-Chl
mC*mA*mGmCmUmGmCmUmUmUmUmGmGmGmAmUmUm
CmC*mG*mU*mU*mG-Chl
mC*mG*mGmGmAmAmGmUmGmCmUmAmGmCmUmCmAm
G*mC*mA*mG*mU-Chl
mC*mU*mAmCmCmUmGmCmAmCmUmGmUmAmAmGmCm
AmC*mU*mU*mU*mG-Chl
mC*mU*mAmUmCmUmGmCmAmCmUmAmGmAmUmGmCm
AmC*mC*mU*mU*mA-Chl
mU*mC*mAmGmUmUmUmUmGmCmAmUmAmGmAmUmUm
UmG*mC*mA*mC*mA-Chl
mU*mC*mAmGmUmUmUmUmGmCmAmUmGmGmAmUmUm
UmG*mC*mA*mC*mA-Chl
mC*mU*mAmCmCmUmGmCmAmCmUmAmUmAmAmGmCm
AmC*mU*mU*mU*mA-Chl
mA*mC*mAmGmGmCmCmGmGmGmAmCmAmAmGmUmGm
C*mA*mA*mU*mA-Chl

Antagomir sequences are depicted above. Stars (*) indicate phosphorothioate
modifications to phosphodiester linkages. Lower-case m preceding nucleotide letter
indicates 2'-O-Me modifications to the furanose ring.
For Lipofectamine 2000TM treatment with antagomirs, cells were counted and
resuspended in serum-free media. Lipofectamine complexes were generated under sterile
conditions according to the manufacturer's protocol maximal dosage for RNAi/RNA
delivery (20 pmol or antagomiR). Cells were subsequently treated for 48 hrs with
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lipofectamine-antagomir complexes per the manufacturer's instructions.
Preparation of retrovirus
Virus was generated from relevant retroviral constructs using Phoenix Eco
packaging cells supplemented with packaging vector. Plasmids were generated by
maxiprep according to manufacturer’s instructions. DNA was quantified with a
Nanodrop 2000™ and transfected into Phoenix Eco cells by Calcium Phosphate
transfection (ClonTech, Mountain View, CA, Cat# 631312) according to manufacturer’s
protocol. Briefly, five 10 cm dishes were plated at 3x106 cells/ plate. Twenty four hours
later, media was changed. Transfection mix was prepared by adding DNA to H20 to
CaPO4. DNA was added in the following amounts: 22.5 µg of ecotropic viral plasmid
(MSCV-MLL-AF9, MIGR1, or pKOF2-Prep1-GFP )/plate and 2.5 µg packaging vector
(pCL-Eco)/plate. The mixture was briefly vortexed to mix and added dropwise to 2X
HBS while gently vortexing the HBS. Complexes were left to form for 20 minutes in the
sterile hood, after which the DNA complex solution was added dropwise to PhoenixEco
cells across the plates. Cells were incubated at 32˚C for 2 days. Supernatant was
collected each day and fresh media was added. Supernatant was stored at 4 degrees until
viral concentration.
To improve infection efficiency, MSCV-MLL-AF9 virus was concentrated using
Centricon Plus-70 Centrifugal Filters (Millipore, Billerica, MA, Cat# UFC710008).
Briefly, concentration columns were primed by centrifugation of sterile H2O at 3000 rpm.
70 mL of viral supernatant was added to the filter unit and centrifuged at 1645 rpm for 3
hours. To elute viral particles, filter units were inverted and spun at 1645 rpm for an
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additional 10 minutes. Eluant was collected and total volume was adjusted to 7 mL using
RPMI. Virus was aliquoted to 750 µl/tube and snap frozen on dry ice. Aliquots of virus
were stored at -80˚ C for later use.
Efficacy of MLL-AF9 virus generation was tested by infection in Rat1A cells.
Infectivity of viral aliquots was confirmed through infection titer of Rat1A cells. 8.5x104
Rat1A cells were plated in 6-well plates and cultured overnight at 37C in DMEM + 10%
FBS + 1% P/S. The following day, cells were infected with virus diluted at multiple
concentrations between 1:103 to 1:106 in DMEM+10% FBS + 16 µg/mL Polybrene.
Media was aspirated from cells and virus dilutions were added to plates for 4 hours at
37°C. After 4 hours of treatment, 1 mL of additional media was added to each well and
plates were reincubated for an additional 20 hrs. Cells were cultured in fresh media for
48 hrs and then continuously cultured in the presence of G418 for 12days. Colony
formation was visualized by removing media and briefly staining plates with methylene
blue. Colonies were counted and multiplied by dilution factor to determine the cfu/mL
virus.
pKOF2-Prep1-GFP and MIGR1 do not have a G418 resistance cassette and are
thus unable to be subjected to viral titrations by this methodology. To measure quality
viral particle generation, I infected Rat1A cells with 1:10 and 1:100 dilutions of virus and
tested for GFP positivity using FACS analysis on a LSR-FORTESSA (BD BioSciences,
Franklin Lakes, NJ).
Isolation and purification of bone marrow stem/progenitor cells
Analysis of MLL-AF9 in a murine model was performed using murine bone
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marrow stem and progenitor cells transformed with MLL-AF9-expressing retrovirus.
Murine bone marrow was collected and transformed consistent with previous
experiments performed by our lab. Briefly, C57BL/6 mice were euthanized with gaseous
CO2 and immediately dissected under sterile conditions to remove legs. Tibia and Femur
bones from both hind legs were isolated and epiphyses were removed. Bone marrow was
collected in 2% FBS supplemented media by flushing diaphyses with 1 mL media
through a 25G needle. Cell aggregates were dispersed and a single cell suspension was
generated by additional passing through a 1 mL syringe and 25G needle. Collected cells
were washed in chilled PBS supplemented with 2% FBS. To obtain a population of
white blood cells, red blood cells were lysed by incubating in red blood cell lysis buffer
(155 mM NH4Cl, 11.9 mM NaHCO3, 100 nM EDTA) for 5 mins on ice.
Bone marrow was enriched for c-Kit+ (CD117) stem and progenitor cells using
EasySep Positive selection kit (Stemcell Technologies, Vancouver, BC, Cat# 18056)
according to the manufacturer’s protocol. EasySep purification utilizes antibodies
directed against surface markers used to characterize sub-populations of cells.
Briefly, bone marrow was suspended in PBS+2%FBS at a concentration of (1x107
cells/mL). 70 µL of CD117-PE labeling reagent was added and incubated in the hood for
15 mins. 70 µL of PE selection cocktail was added and solution was incubated for an
additional 10 mins. 50 µL of magnetic nanoparticles were added and mixture was
incubated for 10 mins. Cells were purified by washing 3 times in PBS+5%FBS. To wash
cells, tubes containing magnetically labeled cells were placed into magnet for 5 mins.
After 5 mins, tubes were gently inverted to decant supernatant. Tubes were then removed
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from magnet and an additional 500 µL of PBS was added to each tube. After c-kit
positive selection, cells were counted and were activated overnight in RPMI+10%FBS
supplemented with cytokines.
Infection of bone marrow cells
Retroviral infection was performed to introduce a human MLL-AF9 fusion to
murine c-kit+ progenitor cells for AML transformation. After c-kit+ selection, cells were
activated overnight in a 96 well plate in RPMI+10%FBS supplemented with cytokines
(10 ng/mL each of IL-6, IL-3, and 100 ng/mL SCF).
Spinoculations were prepared in 1 mL volumes as follows: one 750 µL aliquot of
virus, 7.5 µL HEPES, 1 µL polybrene (4 µg/ul), 30 µL cells (at 1x106 cells/mL). For viral
infection, cells were centrifuged at 3000 rpm for 4 hrs at 33° C on 2 successive days.
Between spinoculations, each sample was rested overnight in 100 µL of RPMI + 10%
FBS supplemented with cytokines (10 ng/mL each of IL-6, IL-3, and 100 ng/mL SCF) in
96 well plates. Cells were put into methylcellulose colony assays immediately after the
second day of infection.
Murine methylcellulose colony assay
Murine cells were plated in H3234 Methocult supplemented with IL-3 (10
ng/mL), IL-6 (10 ng/mL), and SCF (100 ng/mL) cytokines. Murine cells were plated at
concentrations between 10k cells/plate and 500 cells/plate, depending on growth the
previous week and on anticipated colony number.
Cells were put into methylcellulose colony assays immediately after the second
day of infection. For antagomir treatments, appropriate cell volumes were added to a 5
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mL FACS tube containing a antagomirs, 10X PBS to compensate for antagomir volume,
and RPMI+10% FBS totaling 100 µL. Cells were incubated on ice for 30 mins and at
room temperature for 5 mins as specified by the Grimes lab protocol. After incubation,
cells were immediately transferred to a 1.5 mL microcentrifuge tube containing
antagomirs (2.3 µL for 100 nM treatment and 4.6 µL for 200 nM treatments), cytokines
(IL-3, IL-6, and SCF totaling 9.9 µL), G418 (82.5 µL for the first week) and media to
600 µL. This mixture was added to thawed methylcellulose aliquots (2.7 µL each), and
mixed via vortexing. 1.1 mL of the resulting mixture was added to culture dishes using a
3 mL syringe with a blunt end needle.
The initial round of plating for colony assay additionally included G418 at 10
ng/mL to select for successfully infected cells. All platings were set up in duplicate.
Colonies were counted at day 7 on a Leica DMIL inverted microscope and photographed
using a Cannon PowerShot SD1000, at 7.1 MP. Cells were collected under sterile
conditions by washing each plate with 2 mL PBS 3 times and collecting into a 50 mL
Falcon tube containing 30 mL of PBS. Cells were centrifuged for 10 minutes at 1500
rpm in a floor centrifuge. PBS was aspirated, and cells were resuspended in 0 .5 – 5 mL
of fresh PBS. Cells were counted by hemocytometer and total cell number was calculated
for each colony assay. For weeks 1-3, cells were re-treated with antagomir according to
the protocol described above. At week 4, all remaining cells were collected for RNA.
Slides were prepared for inspection of cellular morphology. 2.5x104 cells were
centrifuged onto positively charged slides at 1000 rpm for 4 minutes on a Thermo
Cytospin 4 (Thermo Scientific, Cat# 3120110). Slides were air dried and stained with
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Hema 3 Wright Giemsa stain (Fisher Scientific, Waltham, MA, Cat# 23-122-929, 23122-937, 23-122-952) for 15 seconds with each stain. Slides were visualized on an Evos
imagecore microscope (Life Technologies, Carlsbad, CA).
Cloning and screening strategy
Luciferase reporter constructs were generated by cloning the 3’UTR of PKNOX1
into the pmiR-Report system (obtained from Dr. Jianjun Chen, University of Cincinnati).
Wild-type reporter construct was cloned from human genomic DNA as described below.
PKNOX1 3’UTR was amplified using forward and reverse primers (Integrated
DNA Technologies, Skokie, IL) indicated in Table 3. The 3’UTR for PKNOX1 is
transcribed from within a single exon of PKNOX1. Thus, PCR amplification could be
performed on genomic DNA without potential inclusion of intronic sequence. PCR was
performed utilizing a high-fidelity recombinant polymerase, Phusion Taq (NEB, Ipswich,
MA, Cat# M0530) according to manufacturer’s guidelines. Amplification reactions were
set up as follows: 1 µL (100 ng) human genomic DNA template, 2.5 µL (0.25 µM)
Forward Primer, 2.5 µL (0.25 µM) Reverse primer, 5 µL 10X PCR Buffer, 1 µL dNTPs,
0.5 µL Taq, and 32.5 µL water to volume. Amplification reactions were performed in a
ThermoHybaid PCRExpress PCR block. Cycling parameters were set as follows: 5 mins
at 95˚ C, and 35 cycles at 95˚C for 30 sec, 65˚C for 30 sec, and 68˚C for 5 mins, and
68˚C for 5 mins.
The amplification product was electrophoresed on 1 % agarose gels and the
appropriately sized band (3.5 kb) was excised and purified by Qiaex II gel extraction kit
(Qiagen, Hilden, Germany, Cat# 20021). The resulting PCR amplicon was sequentially
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digested with MluI and SpeI in parallel with the pmiR-Report vector. Ligations were set
up at a 1:3 vector:insert ratio using the NEB ligation kit (NEB, Ipswich, MA, Cat#
M0202). Ligation was set up as follows: 1 µL vector ( 25 ng), 12.1 µL insert (75 ng), 1
µL T4 DNA Ligase, 2 µL ligation buffer, water to 20 ul. Ligations were incubated
overnight at 16˚C.
Ligation mix was transformed into chemically competent DH5a E. coli. Briefly,
chemically competent bacterial cells were thawed on ice for 10 mins and added to a prechilled 14 mL round bottom polypropylene tube with 1 µL of ligation mix. Mixture was
sequentially incubated on ice for 30 mins, at 42˚C for 45 seconds, and ice for 5 mins. 900
µL of pre-warmed SOC media was added and cultures were incubated with rotation (225
rpm) at 37˚C for 1 hour. Bacterial cells were plated on Ampicillin-LB plates. Potential
positive transformants were picked and grown in 2 mL LB-AMP. 1.5 mL was used for a
column free miniprep. Plasmid was digested with cloning enzymes (MluI and SpeI) to
test for the presence of insert. If insert is present, it will be apparent on a gel after
digestion.

Table 3. Primers for cloning luciferase constructs
Amplicon
PKNOX1

Primer sequence (5'→3')
Forward: GGACTAGTCCTGGTCTTGGAGAACAGTGACT
Reverse: CGACGCGTCGCTTTGATAAATCAATTGCTTCAC

Primers for cloning the 3'UTR of PKNOX1
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Site directed mutagenesis and screening strategy
Specific mutations were generated to remove the individual miRNA binding sites
from the PKNOX1 3’UTR. To make multiple mutations simultaneously, I used the
Stratagene Multi-Site Directed mutagenesis kit (Stratagene, La Jolla, CA, Cat #200514).
Multiple primers directed against the same strand of DNA may be added to the reaction
simultaneously. As the extended strand meets the next downstream primer, a ligase
present in the enzyme mix seals the nick in the DNA, allowing for multiple primermediated mutations to be incorporated simultaneously. The resulting single stranded
product is suitable for transformation. The PKNOX1 3’UTR possesses 6 putative binding
sites for miRNAs from the miR-17-92 cluster. Because of proximity of the sites to be
mutated and the decreased efficiency of introducing too many mutations simultaneously,
site directed mutagenesis was pursued in two separate multi-site directed mutagenesis
rounds. pmiR-Report-Pknox1 3’UTR (wt) was used as a template for initial mutagenesis,
with primers designed to mutate either MRE1, MRE5, MRE6 or MRE2, MRE3, MRE4.
Compound mutation of the miR-17 family MREs was generated by subjecting a plasmid
with only MRE1 to additional mutagenesis using the primer for MRE4. Compound
mutation of all putative MREs was achieved by subjecting a compound mutant (MRE1,
MRE5, and MRE6) to additional mutagenesis (for MRE2, MRE3, and MRE4). Primers
and mutations are depicted in Table 4.
Mutations to ablate miRNA binding were made by changing multiple nucleotides
within the seed match of the mRNA. To facilitate a screening strategy of restriction
mapping, seed match sites were converted to restriction enzyme sites recognized by
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enzymes that would only cut once in the wild type plasmid.
Site directed mutagenesis reactions were set up according to the manufacturer’s
instructions. Both rounds of mutations utilized the same reaction mix proportions.
Reactions were set as follows: 1 µL template (100 ng), 1 µL of primer 1 (100 ng), 1 µL
of primer 1 (100 ng), X µL of primer 3 (100 ng), 1 µL of enzyme, 2.5 µL of 10X reaction
mix, 1 µL dNTPs mix, 1 µL multi-enzyme mix, and ddH20 to 25 µl. Amplification
reactions were performed in a ThermoHybaid PCRExpress PCR block. Cycling
parameters were set as follows: 5 mins at 95˚ C, and 40 cycles at 95˚C for 30 sec, 55˚C
for 30 sec, and 65˚C for 10 mins. Resulting PCR products were cleared of template
plasmid by DpnI digestion. DpnI only digests methylated DNA. DNA methylation
occurs in bacteria, but not in PCR amplification. Restriction digestion of DNA with DpnI
would eliminate only the template bacteria, but not the resulting mutants, which were
generated via PCR. 1 µL of DpnI was added to each reaction mix and incubated for 15
minutes at 37˚C. 1 µL of resulting mix was transformed into XL-10 Gold competent
cells, per manufacturer's instructions (Competent cells provided with kit).
To screen for positive mutants, transformant colonies were picked and grown in 2
mL LB with ampicillin. 1.5 mL was subsequently purified by column-less miniprep.
Plasmids were digested using HindIII or MluI. Incorporation of any mutations by site
directed mutagenesis would result in an increasingly fragmented digestion pattern, with
compound mutants incorporating all mutations producing a very fragmented product.
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Table 4. Primers for mutagenesis of PKNOX1 3'UTR
Target
PKNOX1
MRE1
(∆19ab)
PKNOX1
MRE2
(∆17,20)
PKNOX1
MRE3
(∆18)
PKNOX1
MRE4
(∆17,20)
PKNOX1
MRE5
(∆92)
PKNOX1
MRE6
(∆92)
vector
internal

Primer sequence (5'→3')
GCAGGAGCAGAACCGCACCTGACTTTTTGGAGAAGCTTCAGCA
AACATTTTACACAGTTTTATTTCTAA
TTTCTAATATGTTTTATATGTAGATATAGAAGAGTGACGCGTTG
TATTTCATAGTAAGCTTAAAGCGCGTCTTTGCC
CAGCATGTTTGAGGTCAGTTGGACGCGTAAAACACCTGTTCTCC
AGCCC
GCCTGTGTGAGGTAGCAGTGGGACGCGTTCATTGAGACAAACT
CCAGGG '
CCCAGGCTGGAGGGCAATGGAAGCTTCTCAGCTCACTGCAACC
TC
CCCAGGCTGGAGGGCAATGGAAGCTTCTCAGCTCACTGCAACC
TC
GCACCCCAGGCTTTACACTTTATGCTTCCGGCT

The above table depicts the primers utilized for mutagenesis. All primers from the same
strand. miRNA Response element in red. Unaltered nucleotides within the seed region
in blue. Restriction sites in Orange or Green. Purine to pyrimidine changes (and vise
versa in bold. Nucleotide changes italicized.

Putative positives were regrown and plasmids were prepared with miniprep kit to provide
a cleaner plasmid prep suitable for sequencing. Plasmids were then sent to ATCC for
sequencing using both pmiR Forward and pmiR Reverse plasmids. Internal sequence of
the PKNOX1 3'UTR was out of range of end primers and was sequenced utilizing internal
primers specific to the PKNOX1 3'UTR: PKNOX1 seq1 and PKNOX1 seq2 (Table 5).
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Table 5. Primers for sequencing PKNOX1 luciferase construct
Target
pmiR Forward
pmiR Reverse
PKNOX1 seq1
PKNOX1 seq2

Primer sequence (5'→3')
CCCTTGAACCTCCTCGTTCGACC
GAGACGTGCTACTTCCATTTGTC
TGAAATGGTAGCCAGTGACCCGTT
AATGGTGCAATCTCAGCTCACTGC

The above table indicates the primers utilized for sequencing of pmiR-Report constructs
RNA isolation and cDNA synthesis
RNA was extracted from cells treated with antagomirs for 72 hrs in liquid culture
using Sigma TRI Reagent (Sigma Aldrich, St. Louis, Cat# T9424) according to
manufacturer’s instructions. Briefly, cell pellets were collected in a 1.5 mL
microcentrifuge tube and spun down at 3000 rpm. Cells were resuspended in .5 mL - 1
mL of TRI reagent under a fume hood (according to cell number) Once mixture was
homogenous, cells were frozen and stored at -80˚ C for later use.
RNA collection was performed under RNAse free conditions using filter tips. All
workspaces and pipettes were cleaned with RNAse Zap (Life Technologies, Carlsbad,
Cat# AM9782) prior to use. RNA samples were thawed and processed according to TRI
reagent standard protocol. Briefly, 200 µL of chloroform was added per mL of TRI
reagent used. Mixture was inverted vigorously 15 times to mix samples. Samples were
separated by centrifugation at 13000 rpm at 4˚C in a microcentrifuge. The aqueous layer
was removed and added to a microcentrifuge tube containing 560 µL Isopropanol/mL
TRI reagent used. After a 15 minute incubation, RNA was precipitated by centrifugation.
Pellet was washed once in 70% ethanol and air dried. Pellets were resuspended in
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nuclease free H20 and dissolved at 65˚C for 1 hour. Resulting RNA mix was
subsequently handled on ice in an RNAse free environment.
cDNA synthesis was performed using 10 ng of total RNA using Applied
Biosystems miRNA Reverse Transcription kit (Life Technologies, Carlsbad Cat#
4366596) according to manufacturer’s protocol. RNA was quantified and quality was
assessed using a Nanodrop 2000. RNA was normalized to a concentration of 100 ng/µL
and subsequently diluted to a working concentration. 10 ng of RNA was used per reverse
transcription (RT) reaction. For each sample, separate RT reactions were performed for
each RNA or control to be quantified. To control for potential discrepancies in RNA
level/quality between tubes, a master mix was made for each sample with all components
except the RT primers. The appropriate master mix was then added to the RT tube with
the appropriate RT primer. Reverse transcription reactions were performed in a Thermo
Hybaid PCR Express Cycler using the following cycling parameters: 16° C for 30 mins,
42° C for 30 mins, 85° C for 5 mins, 4° C hold.
Quantitative real-time polymerase chain reaction
To determine relative miRNA levels, quantitative real-time PCR was performed
on an Applied Biosystems 7300 cycler using Applied Biosystems Taqman assays for hsamiR-17-5p, hsa-miR-19a, hsa-miR-196b, or RNU6.
Quantitative real-time PCR was performed in technical triplicates. Master mixes
were prepared for each reaction in excess of 3 fold the amount required for complete
reaction. TaqMan small RNA assay kits were utilized for hsa-miR-17, hsa-miR-19a, hsamiR-196b, and RNU6. Each reaction consisted of 1 µL TaqMan Small RNA Assay
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(20X), 10 µL TaqMan Universal PCR Master Mix II, 7.67 µL RNAse free H20, and 1.33
µL of cDNA product. PCR reactions were prepared in the dark. Plates were spun down
for 2 mins at 1000 rpm to collect sample at bottom of plate.
Cycling parameters for qPCR were defined by the kit manufacturer. Briefly,
cycling condition were as follows: 50˚C for 2 minutes, 95˚C for 10 mins, and 40 cycles
of 95˚C for 15 seconds, 60˚C for 1 minute. “No template” controls were run to verify
that contamination was not present. Data was analyzed using the Delta Delta Ct (2-∆∆Ct)
method with RNU6 serving as a control [245].
Human methylcellulose colony assays
Methylcellulose colony assays for human cell lines were performed using H4100
Methocult methylcellulose (Stemcell, Vancouver, Cat# 04100) supplemented with a final
serum concentration of 10% FBS. Methylcellulose colony assays were performed in 12well plates.
To ensure consistent results, human cell lines were maintained at >90% viability
for at least 3 days prior to use in any methylcellulose assay. Immediately prior to
treatment, cells were counted and resuspended at a concentration of 1X105 cells/mL.
Because each cell line has a different clonogenic potential, each cell line was plated in
methylcellulose at different concentrations (numbers given for treatment in 12-well
plate): MOLM-13 (100 cells/well), MV4-11 (1000 cells/well), RS4;11 (250 cells/well),
HL-60 (250 cells/well), U937 (250 cells/well). Antagomir treatment concentrations were
empirically determined for the MLL fusion-containing cell lines and were set to 1-2 µM).
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Non-MLL cell lines were treated at 2 µM to be equivalent to highest treatment
concentrations.
Appropriate cell numbers were then added to a 1.5 mL microcentrifuge tube
containing antagomirs (1.65 µL for 1 µM treatment, and 3.3 µL for 2 µM treatment).,
10X PBS to compensate for antagomiR volumes, and media +10% FBS to a final volume
of 550 µL . The resulting solution was then gently pipetted into a FACS tube containing
(1.1 mL) methylcellulose and mixed by briefly by vortexing. 550 µL of the final
cell/antagomir/methylcellulose mixture was added to each well in a 12-well plate in
duplicates. Individual colonies were counted on Leica DMIL inverted microscope and
photographed using a Cannon PowerShot SD1000, at 7.1 MP after 7-8 days in culture for
MV4-11, MOLM-13, RS4;11 and K562. THP1 colonies were cultured for 14-15 days.
Combinatorial treatments were counted on a Leica DMIL inverted microscope and
photographed using a Nikon camera.
To collect cells, 1 mL of PBS was added to each well to diluted methylcellulose.
Methylcellulose was gently rinsed from the plate and subsequently washed 2 times with
PBS. Each duplicate experiment was resuspended in a total of 12 mL PBS. Cells were
spun down and resuspended in PBS (.1-2mL) for counting, collecting for slides,
collecting for FACS, etc. Colonies were viewed under a Nikon microscope and imaged
with Olympus DP21 imaging system at 100X.
Cell proliferation Assay
To asses cell proliferation I used the Cell-Titer-Glo assay (Promega, Madison,
Cat# G7570). This assay measures cell number indirectly by measuring the ATP content

74

in a luminescent assay. Because ATP content remains constant across live cells,
quantification of ATP may be used to indirectly quantify the total number of live cells.
Cells were counted and resuspended at 100k cells/mL in culture medium under sterile
culture conditions. Cells were added to a mixture of antagomirs, 10X PBS, and culture
media to yield a final concentration of 50k cells/mL, 1-2 µM antagomirs (specified in
figure legends), and 10X PBS to compensate for antagomir volumes. Cells were plated in
96-well plates in triplicate with 100 µL of cell/antagomiR mixture per well in 3
independent experiments. Cell viability was assessed after 4 days of antagomir treatment
using Promega Cell-Titer-Glo kit (Promega, Madison, Cat# G7570) according to
manufacturer’s instructions. Briefly, cells in 96 well plates were gently resuspended by
pipetting up and down. 15 µL of cells were subsequently added to 85 µL of media in a
white opaque plate, 100 µL of Cell Titer Glo reagent was thawed at room temperature in
the dark and subsequently added to the cell –media mixture.
Luminescence was measured on a Glomax 96 microplate luminometer using the
default program setting. Integration time was set at 0.5 seconds/well for all samples.
Averages of 3 triplicates were averaged for each sample tested. Remaining cells were
collected for cell cycle analysis.
Murine MLL-AF9 transformed bone marrow cells were examined for cell viability
in culture after infection with either MIGR1, MSCV-Meis1-pgk-EGFP, or MSCV-pKOF2Prep1-GFP. Similarly to human cell lines, viability was assessed using Cell-Titer-Glo
assay (Promega, Madison, G7570). GFP+ cells were plated at 50k cells/mL in 100 µL in
96 well plates. At given time points, 15 µL of cells were removed from media and

75

subsequently added to 85 µL of media in a white opaque plate, 100 µL of Cell Titer Glo
reagent was thawed at room temperature in the dark and added to cell–media mixture.
Luminescence was measured on Glomax 96 microplate luminometer using the protocol
utilized for human cell lines.
Cell cycle analysis
To determine cell cycle distribution, cells were fixed and stained with propidium
iodide (PI) and analyzed via FACS. Propidium iodide (PI) is a fluorescent DNA
intercalating agent that readily enters fixed cells and can subsequently be used to quantify
the amount of DNA in a particular cell. Because DNA is synthesized during replication,
the quantity of DNA can be used to indicate whether a cell is actively cycling.
To determine cell cycle distribution upon antagomir treatment, all three replicates
from each sample of the previous cell viability were collected and pooled in a 5 mL
FACS tube. Cells were washed once with 3 mLs of PBS+5%FBS and fixed in ice-cold
70% Ethanol. Cell suspension was stored at -20˚C overnight for fixation. Cells were
then washed in PBS + 5% FBS and resuspended in 250 µL PBS solution containing
RNAse A (10 µg/mL) to eliminate free RNA that would potentially confound results.
250 µL PBS with propidium iodide (100 µg/mL) was then added to the mixture to yield a
final concentration of 5 µg/mL RNAse A and 50 µg/mL propidium iodide. Cells were
incubated on ice for 1 hour prior to FACS analysis. Samples were analyzed on a FACSCANTO II and data was processed analyzed using Flowjo Software Package (Version
9.03). Cell cycle distribution was determined using the Watson Pragmatic function within
FlowJo. Total live cell number was counted and percentages were calculated with MS

76

Excel.
Luciferase reporter assays
Luciferase reporter assays were performed in HEK293T cells using the pmiRReport system. pmiR-Report constructs possess a luciferase gene driven by a CMV
promoter. A multiple cloning site downstream of the luciferase cassette allows cloning of
a valid 3-UTR into the plasmid. Co-transfection with wither miRNA expressing
plasmids, synthetic miRNAs, or miRNA inhibitors, provide a platform with which to test
miRNA:mRNA relationships. HEK293T cells were plated at 6.0x105 cells/well in 24
well plates. After 24 hours, cells were co-transfected with a reporter construct containing
either the 120 ng of pmiR-Report reporter construct (wild-type or mutant 3’UTR for
PKNOX1, 10 ng of a control Renilla luciferase construct, and 600 ng of either MSCV-PIG
or MSCV-PIG-miR-17-19b. Cells were cultured for 48 hrs and collected for luciferase
analysis with the Promega Dual-Luciferase Reporter Assay System (Promega, Madison,
#E1910) according to manufacturer’s instructions. Due to the relatively loose attachment
of HEK293T cells to a plate, chilled washing PBS was added directly to the well. Plates
were swirled and PBS was used to rinse cells loose from plate. Cells were collected into
1.5 mL microcentrifuge tubes and centrifuged at 3000 rpm to pellet cells. PBS was
removed by aspiration and cells were resuspended in 1X Passive Lysis buffer and kept at
-20° C for future analysis. For experimental analysis, lysate was diluted 1:20 fold to
bring luciferase concentration into the linear range of the luminometer immediately prior
to luminometer measurements.
Luciferase activity was measured on a Femto manual luminometer using default
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machine settings. 10 µL of each sample was added to the bottom of a 1.5 mL
microcentrifuge tube. 50 µL of LARII buffer was added to each tube and gently pipette
up and down to mix solution. Sample was immediately read in the machine to obtain
level of Firefly luciferase activity. 50 µL of freshly prepared Stop and Glo reagent was
added to each tube and briefly vortexed. Samples were immediately read to obtain
Renilla Luciferase activity level. To ensure fidelity of experimental reads, dilution levels
of samples was kept low enough to ensure that sample reading were below 10 million and
remained steady during the course of the integration time. Experiments were performed
in triplicate and measured in duplicates.
Protein isolation and western blotting
To collect proteins, cells were collected into a 1.5 mL microcentrifuge tube and
washed once in chilled PBS. Cell pellets were snap frozen on dry ice and stored at -80˚C
for future use. Cell pellets were handled in a manner determined by cell line. Pellets from
human leukemia cell lines were thawed on ice in 1X SDS loading buffer. Cells from
HEK293T cells were resuspended in IPH buffer (50 mM Tris-HCl, 150 mM NaCl, 5mM
EDTA, .5% NP-40) supplemented with 1:100 freshly added Protease inhibitor cocktail
(Sigma Aldrich, St. Louis, Cat# P8340). Cells were resuspended in IPH at a
concentration of 1x107 cells/mL. If cells were not used for a co-IP experiment, they were
sonicated for 4 pulses at 20% power.
Cell pellets were thawed on ice in IPH buffer. Appropriate quantities were
mixed with 5X SDS loading buffer (250 mM Tris pH6.8, 500 mM DTT, 10% SDS, 0.5%
Bromophenol Blue, 50% Glycerol). Lysate solution was boiled for 5 minutes and
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subsequently centrifuged at 13000 rpm for 5 mins at 4° C to clear lysate of any cellular
debris.
Lysates were separated by Sodium Dodecyl Sulfate –Poly Acrylamide Gel
Electrophooresis (SDS-PAGE). Gels were cast using the BioRad Mini-PROTEAN
system. Gels were comprised of a 10% resolving gel (40% Acrylamide 2.5 mL, 1.5M
Tris pH8.8 = 2.5 mL, 10% SDS = 100 ul, 10% APS = 50 ul, TEMED = 10 ul), and a 4%
stacking gel (40% Bis-Acrylamide .5 mL, 1M Tris pH=6.8 = .625 mL, 10%SDS 50ul,
10% Ammonium Persulfate = 25 ul, TEMED = 5 ul, ddH2O 3.8 mL, TOTAL 5mL).
Samples were loaded into the gel and run in parallel with 5 µL of Kaleidescope
ladder (BioRad, Hercules, Ca, Cat# 1610324). Gels were run in 1X Tris-Running buffer
(15.1g Tris pH8.8, 94g Glycine, 5g SDS, H20 1L) at 50V for 15mins to condense protein
into stacking gel, and 150V until dye front reached the bottom of the gel. Protein was
transferred to Nitrocellulose membranes (BioRad, Hercules, Ca, Cat# 170-4158, 1704159) using Trans BlotTurbo transfer system (BioRad, Hercules, Ca, Cat# 170-4155).
BioRad, Hercules, Ca 1.5 mm gel program was used (2.5A, 25V, 10 mins). Transfer was
verified by staining membrane briefly in .5% (w/v) Ponceau S solution (Sigma Aldrich,
St. Louis, Cat # P7170), and subsequently washing in PBS-T until Ponceau stain was
fully removed. Membranes were blocked overnight at 4˚C in blocking solution (PBS, .5%
Tween, 5% dry milk).
Membranes were probed with anti-PKNOX1 (N15) (Santa Cruz Biotechnology,
Santa Cruz, Cat# SC-6245) at 1:1000 in blocking buffer, anti-PBX1/2/3 (C-20) (Santa
Cruz Biotechnology, Santa Cruz, Cat# SC-888) at 1:1000 in blocking buffer, anti-MEIS1
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(Milipore, Billerica, MA, Cat# 05-779) ) at 1:1000 in blocking buffer, anti-HOXA9
(Milipore, Billerica, MA, Cat#07-178) at 1:1000 in blocking buffer, or anti-Actin (Sigma
Aldrich, St. Louis, A5441) at 1:8000 in blocking buffer. Secondary antibody probing was
performed with TrueBlot anti-rabbit (eBioscience, San Diego, Cat# 18-8816-31) at
1:1000 in blocking buffer, anti-mouse-HRP (GE Life Sciences, Piscataway, NJ, Cat#
NA931VS) at 1:8000 in blocking buffer, or anti-Rabbit-HRP (GE Life Sciences,
Piscataway, NJ, Cat# NA934VS) at 1:8000 in blocking buffer. Western blots were
imaged using a Fuji LAS-3000 lightbox system. Images processed using MultiGauge
v3.0.
Co-immunoprecipitation assays
Cells for co-immunoprecipitation were collected and washed once in PBS. Cell
pellet was resuspended in IPH buffer (50 mM Tris-HCl, 150 mM NaCl, 5mM EDTA,
.5% NP-40) with 1:100 freshly added Protease inhibitor cocktail (Sigma Aldrich, St.
Louis, Cat# P8340). Co-Immunoprecipitation was performed in IPH buffer using
Agarose A beads (Santa Cruz Biotechnology, Santa Cruz, Cat# SC-2001) incubated
overnight at 4° C with 1.5X106 cells. Equilibration and washes were performed with IPH
buffer with 1:1000 freshly added Protease inhibitor cocktail (Sigma Aldrich, St. Louis,
Cat# P8340).
20 µL of beads were used per reaction. Beads were equilibrated to IPH buffer by
washing beads IPH buffer with 1:1000 Protease inhibitor cocktail (Sigma Aldrich, St.
Louis, Cat# P8340) 3 times. For each wash, beads were pooled into a 1.5 mL
microcentrifuge tube and 500 µL of buffer was added. Mixture was vortexed briefly and
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spun down at 6000 rpm for 30 seconds. Supernatant was removed, careful not to disrupt
bead pellet. For the final round of equilibration, bead/buffer mixture was aliquoted to
separate microcentrifuge tubes to the equivalent of 20 µL of beads per tube. After final
round of equilibration, cell lysates from 150k cells was added to each tube in a volume of
150 ul. 5 µL of PBX1/2/3 antibody (Santa Cruz Biotechnology, Santa Cruz, Cat# SC888) was added to each tube and gently mixed by flicking the tube several times. The
lysate solution was incubated with beads and antibody at 4° C overnight on a rocker to
allow complex-bead interactions to form. After incubation, beads were washed 3 times
with 500 µL of IPH buffer (plus 1:1000 protease inhibitor cocktail), and resuspended in
30 µL of 2X SDS lysis buffer and boiled for 10 mins at 95° C. Lysate was cleared of
Protein A beads by 10 mins of centrifugation at 13000 rpm at 4° C. 30 µL of each
mixture was used for each well.
Colony assays for cells infected with Pknox1 expressing retrovirus
For the examination of Pknox1 contribution to MLL-AF9 transformed murine
bone marrow subject to additional infections with either MIGR1, MSCV-Meis1-pgkEGFP, or MSCV-pKOF2-Prep1-GFP were generated and checked for quality as
described. After passing cells through methylcellulose for 4 weeks, cells were acclimated
to liquid culture for 1 week and treated with additional spinoculations. I selected for
successfully infected cells by FACS sorting for GFP positivity 48 hours after infection.
Colony assays were performed over the course of 1 week, and were imaged.
FACS analysis of surface markers
Cell surface marker staining was performed on live cells to examine the
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differentiation of cells after antagomir treatment. After 6 days of antagomir treatments,
cells from methylcellulose colony assays were isolated. 100k cells were suspended in a
chilled PBS + 2%PBS. Antibody panels were mixed into a master mix and added to
samples at a final dilution of antibodies. Cells were incubated in the dark, on ice for 20
minutes and washed with 500 µL of PBS+2%PBS. Cells were resuspended in 250 µL
PBS+2%FBS
Cell surface marker staining was performed as previously described [23] using
fluorophore conjugated antibodies against CD117-APC (eBioscience, San Diego, Cat#
17-1171-82), CD11B-PE (eBioscience, San Diego, Cat# 12-0112-85), GR-1-PE-Cy5
(eBioscience, San Diego, Cat# 15-5931-81). FACS analysis was performed with initial
gating on live cells. Secondary gating was for GFP + cells. Subsequent gates were
drawn by excluding cells in a negative control. Data was processed using FlowJo
Software Package.

CHAPTER 4
RESULTS
Antagomir uptake occurs in a dose dependent manner
Previous studies by our lab and others have utilized ‘antagomirs’ to examine the
role of miRNA in MLL leukemia in a mouse model [11, 234, 235]. Characterization of
the ‘antagomir’ pattern of modifications was initially performed in vivo, studying the
knockdown of miR-122 in the liver [232, 233]. To characterize uptake in vitro, cells
were treated with a fluorescently labeled antagomir, and examined by FACS analysis,
with antagomir uptake being detectable as an increase in fluorescence (Figure 9). As a
negative control, cells were treated with anti-Ce-miR-67, while uptake was observed in
treatments with anti-Ce-miR-67-DY547, an antagomir with a fluorescent label conjugated
to the 5' end. Both anti-Ce-miR-67 and anti-Ce-miR-67-DY547 are designed to target a C.
elegans miRNA that has no mammalian homolog. If antagomirs are taken up by the
cells, then fluorescence would increase, indicated by a rightward shift in the FACS plot.
Uptake was examined in THP1 cells (described in Methods) and MLL-AF9 transduced
murine bone marrow utilizing three different treatment regimens: 1) a superficial addition
of antagomirs to the media at the final treatment concentration without any additional
steps, 2) superficial addition with pre-incubation at 10X the final treatment concentration
(as described in Materials and Methods), or 3) transfection by Lipofectamine 2000
(Figure 9). For THP1 cells, pre-incubation did not alter the uptake of fluorescently
82
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labeled antagomir compared to superficial addition of antagomir to the media without
pre-incubation (Figure 9). For both superficial antagomir treatment and superficial
treatment with pre-incubation, anti-Ce-miR-67-DY547-treated THP1cells fluoresced at a
narrow peak centered to the right of the negative control, indicating that antagomir uptake
was both robust and very uniform. Lipofectamine treatment resulted in two populations
of cells with a very broad distribution of fluorescence indicating a lack of uniformity in
cellular uptake of antagomirs when introduced by Lipofectamine. The majority of cells
were positive for antagomir uptake, and the most brightly fluorescent cells were much
brighter than those treated with either the superficial addition or superficial addition with
pre-incubation. However, approximately 11% remained negative for fluorescence.
Antagomir uptake for MLL-AF9-transduced bone marrow was similar to that observed
for THP1 cells. However, antagomir uptake after treatment with the superficial addition
with pre-incubation protocol resulted in a slightly broader peak with an increase in the
most fluorescent cells, indicating an improved uptake for at least a small subset of cells.
As with THP1 cells, Lipofectamine treated MLL-AF9 transformed bone marrow cells
were distributed into two populations with a very broad distribution of antagomir uptake.
Lipofectamine antagomir treatment resulted in a very high level of uptake compared to
either superficial addition or superficial with pre-incubation. However, approximately
45% of MLL-AF9 cells remained negative.
To determine treatment concentrations for antagomirs, I treated multiple cell lines
with antagomir directed against either anti-Ce-miR-67 or a fluorescent labeled anti-CemiR-67-DY547 at concentrations of 20 nM, 200 nM, 500 nM, 1000 nM, and 2000 nM for
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Figure 9. Antagomir uptake upon treatment with different methodologies

Antagomir treatments via different mechanisms of delivery. Antagomir uptake
determined by FACS analysis for treatment with Grimes protocol (top), superficial
addition (middle), and lipofectamine (bottom). Treatments were compared between a
fluorescent labeled antagomir (anti-Ce-miR-67-DY547) and a non-fluorescent control
(anti-Ce-miR-67). A) THP1 cells were examined with all three treatment regimens as a
representative of human cell lines. B) MLL-AF9 transformed bone marrow cells were
examined with all three treatment regimens.
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72 hrs and examined fluorescence by FACS analysis (Figure 10). As expected, treatment
with increasing concentrations of anti-Ce-miR-67 without a fluorophore did not result in
fluorescence for any treatment. Treatment with anti-Ce-miR-67-DY547 resulted in a
concomitant increase in fluorescence for MOLM-13, MV4-11, RS4;11, and MLL-AF9
transformed bone marrow. All treatments resulted in narrow peaks of fluorescence,
indicating uniform uptake at all treatment concentrations. The ratio of detected
fluorescence to treatment concentration remained linear even at the highest concentration,
indicating that 2 µM antagomirs treatment did not saturate the capacity for cells to take
up antagomirs. Antagomir uptake for each human leukemia cell line had roughly similar
patterns of uptake. MLL-AF9 transduced bone marrow took up antagomir at a lower rate
than human leukemia cell lines. Further experiments for murine MLL-AF9 utilized the
superficial with pre-incubation protocol, while treatment of human cell lines relied upon
superficial addition of antagomir to the media.
To determine the efficacy of antagomir treatment, I examined the capability of
antagomir treatment to reduce the levels of targeted miRNA. Experiments examining
uptake do not indicate subcellular localization or function of the antagomirs, necessitating
further examination of antagomir function. To assess antagomir function, I treated
MOLM-13, RS4;11 and MV4-11 with antagomirs directed against miR-17-5p, 19a, or
196b at concentrations of 1-2 µM (indicated in figure legend) and quantified target
miRNA levels relative to a control treatment (Figure 11). Both vehicle and anti-Ce-miR67 were used as controls to ensure that antagomir treatment did not result in a broad or
non-specific effect on untargeted antagomirs. Anti-Ce-miR-67 is an antisense oligo
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Figure 10. Antagomir uptake in human MLL leukemia cell lines

Antagomir uptake was determined by FACS analysis using a fluorescently labeled
antagomir utilizing superficial antagomir treatment (20 nM – 2000 nM). A) Antagomir
uptake quantified relative to treatment concentration. B) Treatments were compared
between a fluorescent labeled antagomir (anti-Ce-miR-67-DY547) and a non-fluorescent
control (anti-Ce-miR-67). Example plots of uptake for MOLM-13, RS4;11, and MV4-11
at 20 nM, 200 nM, 500 nM, 1000 nM, 2000 nM.
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designed to hybridize with a miRNA from C. elegans with no homologous miRNA found
in mammals. In antagomir treated cells, target miRNA levels decreased in response to
antagomir treatments. Anti-miR-17 treatment in MOLM-13, RS4;11, and MV4-11
resulted in a decrease to 16%, 5%, and 31%, respectively, when compared to anti-CemiR-67. When compared to vehicle, anti-miR-17 treatment resulted in decreases to 2.5%,
7.8%, and 31% of miR-17 miRNA levels of control treated cells. For MOLM-13, a nonspecific decrease in miR-17 and miR-19a levels was observed after treatment with antiCe-miR-67 (data not shown). MLL-AF9 transduced bone marrow cells were also tested
for miRNA knockdown. Upon antagomir treatment with anti-miR-196b, relative levels of
miR-196b decreased to 11% of levels observed in cells treated with anti-Ce-miR-67.
Treatment concentration for all human cell line antagomir experiments was determined
based on these standardization experiments.
Effect of individual antagomir treatment on colony forming ability of human
leukemia cell lines
To examine MLL leukemia in a human model, I performed colony assays using
human MLL leukemia cell lines (Figures 12-19). MOLM-13 was used to represent MLLAF9 gene fusion expressing leukemias, while MV4-11 and RS4;11 were used to
represent MLL-AF4 gene fusion expression leukemias. Colony assays were performed
over the course of approximately 1 week and were not subjected to serial replating.
While murine colony assays examined the role of miRNAs in the initiation of leukemia,
human colony assays examine the role of miRNAs in cells that have previously been
transformed. Similar to murine colony assays, I examined colony number, cell number,

88

Figure 11. Antagomir treatment results in a knockdown of target miRNAs.

Antagomir mediated knockdown of target miRNAs was examined for anti-miR-17, antimiR-19a, and anti-miR-196b in human. A) Antagomir treatment effects were examined
for anti-miR-17. miRNA levels compared to cells treated with anti-Ce-miR-67 (left) or
vehicle (right). B) Antagomir treatment effects were examined for anti-miR-19a. miRNA
levels compared to cells treated with anti-Ce-miR-67 (left) or vehicle (right). C)
Antagomir treatment effects were examined for anti-miR-196b. miRNA levels compared
to cells treated with anti-Ce-miR-67 in human cell lines (left) or in MLL-AF9 transformed
bone marrow (right).
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colony morphology (Figures 12-19). I hypothesized that increased expression of
individual miRNAs were essential for maintaining MLL leukemia cell proliferation and
clonogenic capacity. MLL leukemia cell lines were treated with antagomirs directed
against a subset of miRNAs overexpressed in MLL leukemia.
Colony assays were examined at 7-8 days after initial plating. Colony morphology
was dramatically different from the standard murine colonies. While murine MLL-AF9
transformed colonies are typically compact and consist of closer cell-cell contacts, human
cell line colonies are widely diffuse and do not contain close cell-cell contacts. Number
of cells plated per colony assay varied based on cell line as each cell line possesses a
different baseline capability to form colonies. Colony assays were set up with a target of
70 colonies/plate. MOLM-13 cells were the most clonogenic with an approximate
colony forming frequency of 1 colony per/2.04 cells (49.0%). RS4;11 formed colonies at
a frequency of 1 colony per/3.34 cells (29.86%), and MV4-11 formed colonies at a
frequency of 1 colony per/13.42 cells (7.45%).
Cells were treated with individual antagomirs using treatment methodology and
concentrations determined in uptake and knockdown experiments (Figures 12-16).
Antagomir treatments were directed against the individual miRNAs of the miR-17-92
cluster (anti-miR-17-5p, anti-miR-18a, anti-miR-19a, anti-miR-20a, anti-miR-19b, and
anti-miR-92). Additional, treatments were directed against additional miRNAs
upregulated in MLL leukemia miR-10a, miR-196b, miR-191 and miR-93*. MOLM-13
and MV4-11 were treated at 2 µM concentrations, while RS4;11 was treated at 1 µM
concentrations. Non-MLL cell lines were always treated at 2 µM concentrations to
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control for both miRNA knockdown and potential non-specific toxic effects of
antagomirs. Antagomir treatment at 2 µM concentrations resulted in the formation of a
precipitate for several different treatments. Antagomir precipitation occurred upon 2 µM
treatments of anti-miR-67, anti-miR-18a, anti-miR-92, anti-miR-93*, and anti-miR-191 in
both liquid culture and methylcellulose. Notably, antagomir treatment with anti-miR-18a
and anti-miR-191 resulted in a very faint precipitate formation. This precipitation appears
to be sequence specific and has been linked to the presence of the cholesterol tag at the
3’end of the oligo (technical support, Thermo). The mechanism of the effects of
precipitate formation on cell growth and colony forming ability are currently unclear.
Moreover, while aggregation was visible at 2 µM for the indicated antagomir, it is
possible that sub-microscopic aggregations occur for other antagomirs and at lower
concentrations. Though the exact mechanism by which anti-Ce-miR-67 produced a toxic
effect is unknown, it is likely that the toxicity is related to the precipitate which formed as
a result of antagomir aggregation. Previous studies of antagomirs in vivo have indicated
that antagomirs bind to lipoproteins as wells serum albumin, providing evidence for
antagomir-protein interactions [224]. Thus, it is possible that the antagomir and its
precipitates bind to the cell membrane and cellular proteins, impeding normal function.
Several antagomir treatments showed minimal effects upon treatment. Anti-miR10a, anti-miR-191, and anti-miR-93* all had minimal effect on colony forming ability
(Figures 12, 13, 16). Treatment with anti-miR-10a or anti-miR-191 showed lesser effects
than treatment with the control antagomir anti-Ce-miR-67 in several cell lines (Figures
12,16). The minor effects of these treatments (anti-miR-10a and anti-miR-191) suggests
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that the miRNAs examined were either unnecessary to the function of MLL leukemia or
that their functions were redundant with other miRNAs in colony forming ability. As
these treatments did not decrease any outcomes in cell lines under consideration, and
either did not produce a precipitate in culture or produced a very faint precipitate, I have
utilized anti-miR-10a and anti-miR-191 as a treatment controls in subsequent experiments
(indicated in figure legends). Antagomir treatment against members of the miR-17
family showed a decrease in colony number and total cell number in human MLL
leukemia cell lines. Anti-miR-17 and anti-miR-20a both showed a decrease in colony
numbers relative to both the vehicle and the control antagomir-treatment (anti-miR-10a)
(Figure 14). The effect was most pronounced in MOLM-13 and MV4-11. Antagomir
treatment in MV4-11 resulted in a complete loss of colony forming ability (Figure 14).
Only anti-miR-20a treatment was significant in colony forming assays for RS4;11
(Figure 14). Cell numbers decreased similarly to colony numbers, but with a greater
decrease in percentage relative to vehicle. The decrease of cell number relative to colony
number is apparent in the changes in colony morphology. For both antagomir treatments,
colonies appeared smaller in radius and had an abnormal distribution of cells within the
colony.
Treatment against miR-19a or miR-19b resulted in a very limited decrease in
colony forming ability. Colony number decreased relative to vehicle, but was
insignificant in comparison to control antagomir. The only significant decrease observed
was the decrease of anti-miR-19b in MV4-11 (Figure 15). Cell number was decreased
slightly for anti-miR-19b in both MOLM-13 and MV4-11 (Figure 15). Colony
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Figure 12. Antagomir treatment against miR-10a and miR-196b in human MLL
leukemia cell lines

Individual antagomir treatments against miR-10a and miR-196b. A) Antagomir
treatments were performed against individual miRNAs at a total concentration of 2 µM
for MOLM-13 and MV4-11 and 1 µM for RS4;11. MOLM-13 and MV4-11 were tested
in three independent experiments. MV4-11 was tested in two independent experiments.
Significance was tested against a control antagomir using Student’s t-test (α = .05).
Significance against vehicle indicated in red. Significance against anti-Ce-miR-67
indicated in green. Significance against anti-miR-10a indicated in black. B) Colony
morphology from antagomir treated colony assays.
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Figure 13. Antagomir treatment against miR-18a and miR-92 in human MLL
leukemia cell lines

Individual antagomir treatments against miR-18a and miR-92. A) Antagomir treatments
were performed against individual miRNAs at a total concentration of 2 µM for MOLM13 and MV4-11 and 1 µM for RS4;11. MOLM-13 and MV4-11 were tested in three
independent experiments. MV4-11 was tested in two independent experiments.
Significance was tested against a control antagomir using Student’s t-test (α = .05). AntiCe-miR-67 was used as a control for RS4;11, and anti-miR-10a was used as a control for
MOLM-13 and MV4-11. B) Colony morphology from antagomir treated colony assays.
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Figure 14 . Antagomir treatment against miR-17 and miR-20a in human MLL
leukemia cell lines

Individual antagomir treatments against miR-17-5p and miR-20a. A) Antagomir
treatments were performed against individual miRNAs at a total concentration of 2 µM
for MOLM-13 and MV4-11 and 1 µM for RS4;11. MOLM-13 and MV4-11 were tested
in three independent experiments. MV4-11 was tested in two independent experiments.
Significance was tested against a control antagomir using Student’s t-test (α = .05). AntiCe-miR-67 was used as a control for RS4;11, and anti-miR-10a was used as a control for
MOLM-13 and MV4-11. B) Colony morphology from antagomir treated colony assays.
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Figure 15. Antagomir treatment against miR-19a and miR-19b in human MLL
leukemia cell lines

Individual antagomir treatments against miR-19a and miR-19b. A) Antagomir treatments
were performed against individual miRNAs at a total concentration of 2 µM for MOLM13 and MV4-11 and 1 µM for RS4;11. MOLM-13 and MV4-11 were tested in three
independent experiments. MV4-11 was tested in two independent experiments.
Significance was tested against a control antagomir using Student’s t-test (α = .05). AntiCe-miR-67 was used as a control for RS4;11, and anti-miR-10a was used as a control for
MOLM-13 and MV4-11. B) Colony morphology from antagomir treated colony assays.
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Figure 16. Antagomir treatment against miR-93* and miR-191 in human MLL
leukemia cell lines

Individual antagomir treatments against miR-93* and miR-191. A) Antagomir treatments
were performed against individual miRNAs at a total concentration of 2 µM for MOLM13 and MV4-11 and 1 µM for RS4;11. MOLM-13 and MV4-11 were tested in three
independent experiments. MV4-11 was tested in two independent experiments.
Significance was tested against a control antagomir using Student’s t-test (α = .05). AntiCe-miR-67 was used as a control for RS4;11, and anti-miR-10a was used as a control for
MOLM-13 and MV4-11. B) Colony morphology from antagomir treated colony assays.
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morphology did not change in response to antagomir treatment for anti-miR-19a or antimiR-19b (Figure 15).
I additionally examined potential antagomir treatments against miR-18a, miR-92,
and miR-196b (Figures 12, 13). For these antagomir treatments, no treatment effect were
observed relative to control treatment for MOLM-13 or RS4;11. Anti-miR-18a and antimiR-92 resulted in a minor decrease in colony forming ability for MV4-11. Treatments
against either anti-miR-18a or anti-miR-92 showed minor, but significant decreases in
cell number (Figure 13). Colony morphology reflected these treatment effects with
minor decreases in colony size and sparseness.
Combined inhibition of miR-17, 20a or miR-17, 19a reduces colony formation and
increases differentiation of MLL leukemia cells
Of the miRNAs overexpressed in MLL leukemia, several are classified into the
same miRNA family based on miRNA seed sequence. I examined the effects of
combinatorial antagomir treatments on human cell lines to determine whether
simultaneously targeting multiple miRNAs with the same seed sequence or targeting
multiple miRNAs with different seed sequences would potentiate the effects on colony
forming capacity or proliferation. Combinatorial treatment resulted in a greater decrease
in colony forming ability than treatment with either anti-miR-17 or anti-miR-20a alone
(Figure 17). Simultaneous inhibition of both miR-19a and 19b resulted in decreased
colony formation of RS4;11 and MV4-11 cell lines (Figure 17). Intriguingly, treatment
with anti-miR-17 and anti-miR-19a produced a dramatic effect beyond that observed for
either antagomir individually. Further, this combination produced an effect beyond an
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additive effect on colony and cell numbers. Morphologically, cells appear more
differentiated with a greater cytoplasmic:nuclear ratio and increased vacuolarity (Figure
18). For all cell lines, combinatorial treatment with antagomirs directed against miR-17,
and miR-19a resulted in a change in cell morphology (Figure 18).
miRNA contributions to MLL leukemia were further examined in combinatorial
treatments against multiple miRNAs simultaneously. To avoid the potential for nonspecific toxicity, combinatorial treatments were examined at a total concentration equal
to that of individual treatments. I hypothesized that miRNA contributions were
cooperative and that simultaneous inhibition of multiple miRNAs would produce a
greater effect than individual treatments. In examining this hypothesis, I have tested
against antagomirs directed against miRNAs of the same family and miRNAs of different
families. While miRNAs from the same family possess the same seed region and would
likely regulate similar targets, miRNAs of different families do not possess the sequence
homology to target the same binding sites within the 3’UTR.
Combinatorial treatments against miR-17 and miR-20a resulted in a dramatic
decrease in colony forming ability and cell number (Figure 17). Effects for combinatorial
treatment were more dramatic than for either single treatment suggesting that inhibition
of miRNAs from the same family provides a superior model of therapeutic intervention.
Treatment with anti-miR-17 or anti-miR-20a produced the greatest decrease in colony
forming ability in MOLM13, RS4;11, and MV4-11 cell lines(Figure 14, 17). Anti-miR20a had more pronounced activity than anti-miR-17 (Figures 14, 17)
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Figure 17. Combinatorial antagomir treatment decreases colony forming ability and
total cell number in colony assays.

Combinatorial antagomir treatments result in a decrease in colony forming ability and
total cell number. Antagomir treatments were performed against either individual
miRNAs (anti-miR-17, anti-miR-20a, anti-miR-19a, or anti-miR-19b) or combinations of
miRNAs (anti-miR-17, 20a; anti-miR19ab; or anti-miR-17,19a) at a total concentration
of 2 µM for MOLM-13, MV4-11, HL-60, and U937 and 1 µM for RS4;11. MOLM-13,
MV4-11, HL-60, and U937 were tested in three independent experiments. MV4-11 was
tested in two independent experiments. Significance was tested against a control
antagomir using Student’s t-test (α = .05). Anti-Ce-miR-67 was used as a control for
RS4;11, and anti-miR-10a was used as a control for MOLM-13 and MV4-11.
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Figure 18. Combinatorial antagomir treatment results in decreased colony density
and a change in cell morphology.

Colony and cell morphology from combinatorial antagomir treatments in colony assays at
1 week. Treatment with combinations of miRNAs (anti-miR-17, 20a; anti-miR19ab; or
anti-miR-17,19a) relative to a vehicle control were examined. MOLM-13, MV4-11, HL60, and U937 were treated at a total concentration of 2 µM. RS4;11 was treated at a total
concentration of 1 µM. Scale bars represent 200 µm. Collected cells were stained with
Wright-Giemsa (inset).
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Therapeutic intervention against miR-19a and miR-19b resulted in a greater defect
in colony forming ability than intervention against either miRNA alone. Single
treatments did not result in significant changes for MOLM-13 or RS4;11. However,
combinatorial treatments resulted in a 50% decrease in colony forming ability of RS4;11.
Treatment against miR-19a caused no significant decrease relative to treatments with a
control antagomir (Figure 15, 17). Anti-miR-19b treatment caused a decrease relative to
both vehicle and control antagomir treatments in MV4-11 cells (Figures 15,17).
Colonies were smaller and contained fewer cells after treatment with either antimiR-17,20a, anti-miR-19a,19b, or anti-miR-17,19a (Figure 17). Further, I observed a
decrease in cell number that was greater than the decrease in colony number in our
combinatorial treatments, suggesting that in addition to inhibition of colony forming
ability, antagomir treatments either inhibited proliferation, or increased cell death and/or
differentiation.
Both colony number and total cell number decreased in multiple antagomir
treatment regimens. To determine whether any decrease in cell number was independent
of decrease in colony number, I charted the relative decrease in cell number against the
relative decrease in colony number (Figure 19). If a proliferative defect is present,
independent of a colony defect, then cell number should decrease at a greater rate than
colonies relatively to wild type control. For MV4-11 and RS4;11, cell and colony
number decreased proportionately. MOLM-13 however had dramatic decreases in cell
number without any accompanying decrease in colony number. This suggests that
antagomir treatments affect proliferation in addition to colony forming ability.
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Figure 19. Cell number varies similarly to colony number in antagomir treated
colony assays.

Values for cell number
relative to vehicle compared
to colony number relative to
vehicle for human leukemia
cell lines after antagomir
treatment (2 µM). Plotted
values indicate average of 3
independent experiments for
MOLM-13, MV4-11, HL60, and U937 and 2
independent experiments for
MV4-11.
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miRNA inhibition results in a modest decrease in cell number and accumulation of
cells at G0/G1
To dissociate the possible proliferative effects of antagomir treatments from
colony forming ability, antagomir treatments were performed in liquid culture (Figures
21-23). Decreased colony size suggests a potential deficiency in proliferation, decreases
in cell number could potentially be attributed to a decrease in colony numbers. Further,
colony assays require smaller initial cell numbers and effective treatment against specific
miRNAs results in a final cell number insufficient to examine subtle changes in cell
cycle. To examine the proliferation of cells upon antagomir treatment, cells were
cultured according to standard culture conditions with antagomirs. After 4 days, cells
were analyzed using Cell-Titer-Glo to determine the total cell number, and fixed for
FACS analysis of cell cycle.
As with colony assay experiments, cells were subjected to both individual and
combinatorial treatments. Individual antagomir treatments were performed at a
concentration of 1 µM total concentration. Only anti-miR-20a and anti-miR-92 resulted
in significant decreases in cell number at 4 days (Figure 21). These effects were
observed in RS4;11 and Molm13. No individual treatment resulted in significant
decreases in MV4-11.
Combinatorial antagomir treatments were performed at both 1 µM total
concentration (Figure 22) and 1 µM each antagomir (Figure 23). Treatments at higher
concentrations included controls specific to each cell line to control for non-specific
toxicity resulting from increased oligo concentrations. For each cell line, I selected
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Figure 20. Linear relationship between cell number and CTG reading

Standard curve was a established
for MOLM-13 (blue circles),
RS4;11 (red square), and MV4-11
(green triangle) cell lines using
Promega Cell Titer Glo. Best fit
line and equations were
determined using PRISM.
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potential controls from the antagomir treatments which produced either no treatment
effect in colony assays or very limited effects relative to vehicle (herein referred to as the
least responding antagomir). For experiments with a total treatment concentration of 2
µM or 3 µM, I used the least responding antagomir at 2 µM or 3 µM, respectively, as a
control. As an alternative, a combinatorial control treatment was performed using the
least responding antagomir treatment in combination with the second least responding
treatment at 1 µM each. For a 3 µM alternative control, the 3 least responsive antagomirs
for each cell line were added at 1 µM each. Combinatorial treatments examined the
treatment effect of antagomirs directed against miRNAs from the same family as well as
treatments against miR-17, 19a, and 196b. Cross family antagomir treatments were
further divided into all 2 antagomir permutations of the miR-17, 19a, 196b combination.
Combinatorial antagomir treatment effects were observed for anti-miR-17,20a in
Molm13 and RS4;11 at both concentrations (Figure 22-23). Cell cycle analysis indicated
an accumulation of cells at G0/G1. No combinatorial antagomir treatments resulted in a
significant decrease for MV4-11. All combinatorial treatments resulted in a significant
decrease in RS4;11 at 1 µM. Due to a slight increase in toxicity, significance was less
apparent at increased treatment concentrations RS4;11.
To examine the effects of antagomir treatment on proliferation, I treated human
cell lines with antagomirs in liquid culture (Figure 21-23). Doing so allowed me to
separate any proliferative defects from colony forming ability. I simultaneously tested
both individual treatments and combinatorial treatments in human MLL cell lines. In
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Figure 21. Single antagomir treated human MLL leukemia cell lines in liquid
culture

Individual antagomir treatments in liquid culture. A) Antagomir treatments were
performed against individual miRNAs at a total concentration of 1 µM for MOLM-13,
MV4-11, and RS4;11 for 4 days and cell number was determined using the Cell-TiterGlo cell viability assay. All cell lines were tested in three independent experiments.
Significance was tested against a control antagomir using Student’s t-test (α = .05). AntiCe-miR-67 was used as a control for RS4;11, and anti-miR-10a was used as a control for
MOLM-13 and MV4-11. B) Cell Cycle distribution was analyzed in parallel with cell
viability assays on day 4.
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Figure 22. Combinatorial antagomir treated human MLL leukemia cell lines at 1
µM total concentration

Individual antagomir treatments in liquid culture. A) Antagomir treatments were
performed against individual miRNAs at a total concentration of 1 µM for MOLM-13,
MV4-11, and RS4;11 for 4 days and cell number was determined using the Cell-TiterGlo cell viability assay. All cell lines were tested in three independent experiments.
Significance was tested against a control antagomir using Student’s t-test (α = .05). AntiCe-miR-67 was used as a control for RS4;11, and anti-miR-10a was used as a control for
MOLM-13 and MV4-11. B) Cell Cycle distribution was analyzed in parallel with cell
viability assays on day 4.
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Figure 23. Combinatorial antagomir treated human MLL leukemia cell lines at 1
µM each antagomir.

Combinatorial antagomir treatments in liquid culture. A) Antagomir treatments were
performed against individual miRNAs at a total concentration of 1 µM for MOLM-13,
MV4-11, and RS4;11 for 4 days and cell number was determined using the Cell-TiterGlo cell viability assay. All cell lines were tested in three independent experiments.
Significance was tested against a control antagomir using Student’s t-test (α = .05). AntimiR-191 was used as a control for RS4;11, and anti-miR-10a was used as a control for
MOLM-13. Anti-miR-93* was used a control for MV4-11. B) Cell cycle distribution was
analyzed in parallel with cell viability assays on day 4.
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individual treatments, I observed decreases that largely mirrored our colony assay data.
Treatment with anti-miR-17 or anti-miR-20a resulted in a decrease in total cell number at
4 days, while treatment with anti-miR-19a or anti-miR-19b were individually unaffected
(Figure 22, 23). Combinatorial treatment against miR-17,20a resulted in a decrease in
total cell number for RS4;11, while anti-miR-17,20a and anti-miR-17,19a were both
significant in MOLM-13 (Figure 22, 23). I did not detect any decrease relative to control
in MV4-11. Antagomir-treatment produced a less dramatic effect in liquid culture than in
colony assays.
To further examine proliferation, I examined cell cycle by propidium iodide
staining (Figures 21-23). Decreased cell numbers were accompanied by accumulation of
cells at G1/G0 for those antagomir. For example anti-miR-17,20a treatment in MOLM13 resulted in a modest decrease in cell number accompanied by an increase in cells at
G0/G1 (Figure 22). Collectively, these data indicate that decrease in colony forming
ability was accompanied by a mild proliferative defect.
Effect of antagomir treatment on colony forming ability of MLL-AF9 transformed
murine bone marrow
To examine the contribution of miRNAs to MLL leukemia, I screened for
individual antaogmiR treatment effects in MLL-AF9 transduced bone marrow (Figures
24, 25). Bone marrow was isolated, selected for c-Kit+ cells, spinoculated with MLLAF9 expressing retrovirus, and treated with antagomirs with superficial addition and preincubation.
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Figure 24. Anatagomir treatment against miR-19a and miR-196b result in a decrease
in colony formation of MLL-AF9 transformed bone marrow

Antagomir treatments against MLL-AF9 bone marrow cells that were serially treated with
antagomir at 100 nM (n=3). A) Colony formation, B) Cell growth in colony forming
assays, C) Example colonies observed in colony assays.
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Previous studies by our lab, performed in collaboration with the Grimes lab, have
shown that miR-196b is essential to the transformation process in MLL-AF9 transformed
bone marrow [11]. Treatment with anti-miR-196b resulted in a decrease in colony
forming ability consistent with that observed these studies (Figure 24). Colony formation
declined at 3 and 4 weeks of serial plating. Week 4 colonies assays indicated a complete
collapse of colony forming ability. Cell number decreased along with colony number
over the same time frame. Additionally, colony morphology was distinctly different
between anti-miR-196b and control antagomir treatment. While anti-Ce-miR-67 treated
colonies were predominantly type 1 tight colonies, anti-miR-196b treated colonies were
primarily type 3 by weeks 3 and 4. This change in colony morphology is indicative of
more differentiated cell types and implies that the decrease in colony numbers is a result
of differentiation over the course of 4 weeks.
Anti-miR-19a treatment resulted in a decrease in colony forming ability over the
course of 4 weeks (Figure 24). Concurrently, cell number decreased with colony number.
The decrease in colony number and cell number for anti-miR-19a was the most dramatic
observed in these experiments and represented a complete loss of colony forming ability.
In addition to the observed decrease in colony number, I observed a dramatic change in
colony morphology. Similar to anti-miR-196b treatment, anti-miR-19a treatment results
in a change in colony morphology from type I colonies to type III colonies (Figure 24).
Treatment of MLL-AF9 transduced bone marrow with anti-miR-17-5p resulted in
no significant difference in colony forming ability or colony morphology relative to
control treated cells. However, total cell number was significantly decreased at 3 weeks.
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Figure 25. Antagomir treatments in MLL-AF9 transformed bone marrow
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Antagomir treatments performed against MLL-AF9 transformed bone marrow. Colony
assays performed with 200 nM antagomiR treatments All antagomir treatments arranged
similarly. Left panel indicates colony numbers, middle panel indicated cell number, and
right panel indicates colony morphology. A) anti-miR-18a, B) anti-miR-19b, C) antimiR-20a, D) anti-miR-92, E) anti-miR-93*, F) anti-miR-191, G) anti-miR-10a.
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The reason for the recovery of cell number at week 4 is not immediately clear, but
could be due to selection for cells that have increased expression of compensatory factors
that make miRNA involvement dispensable to leukemia development. Strikingly, the
decrease in cell number did not correlate to any decrease in colony number or change in
colony morphology, suggesting the decrease in cell number is not due to differentiation.
In addition to treatment against miR-196b and miR-19a, minor treatment effects
were observed for anti-miR-10a treated cells (Figure 25). Anti-miR-10a treatment
showed a minor but significant decrease in colony forming ability at 4 weeks. At weeks
1 and 2, a small proportion of colonies displayed an abnormal morphology of abnormally
large and disperse colonies (Figure 25). No treatment effects were observed for
additional colony assays performed with anti-miR-18a, anti-miR-92, anti-miR-191, antimiR-20a, or anti-miR-93* relative to either a control antagomir or vehicle (Figure 25).
Similarly, neither colony morphology nor total cell number changed in response to
treatment with these antagomirs (Figure 25).
PKNOX1 is a valid target of the miR-17-92 cluster
I next sought to identify potential mRNA targets, focusing on mRNA transcripts
predicted to be targeted by multiple miRNAs upregulated in MLL leukemia. Further, I
focused on genes with functions potentially related to colony forming ability. Search
results using multiple target prediction algorithms (miRanda, TargetScan, Diana-mT)
identified the MEINOX family gene PKNOX1 as an intriguing possibility. Previous
studies in mouse models have indicated that complexes including Hoxa9-Pknox1
functions distinctly from Hoxa9-Meis1 [111-113].
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Figure 26. The PKNOX1 3'UTR possesses multiple putative target sites for
regulation by the miR-17-92 cluster

Positioning and
sequences of putative
microRNA response
elements in the
PKNOX1 3'UTR. A)
Schematic of putative
MRE location with
identification of miRNA
family predicted to
target that site. B)
Alignment of miRNAs
with PKNOX1 3'UTR
for wild type and
mutated constructs.
Seed region:mRNA
interation indicated with
dotted lines. MRE
indicated in blue.
Mutations indicated in
green SNP observed in
the putative MRE of
miR-18a is indicated in
red
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Figure 27. PKNOX1 is a valid target of the miR-17-92 cluster.

Luciferase assays were performed in HEK293T cells in 4 independent experiments. A)
Schematic of luciferase construct with miRNA binding to PKNOX1 3'UTR. Putative
miRNA binding sites are indicated with gray miRNAs above 3' UTR. Mutation of
miRNA binding sites are indicated with red X's above 3'UTR. B) Readouts of Luciferase
assays. Experiments were normalized to control (wild type PKNOX13'UTR, treated with
MSCV-PIG-miR-17-19b) in each experiment. Statistical significance was tested using
student’s t-test against wild-type PKNOX1 3’UTR treated with MSCV-PIG-miR-17-19b.
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PKNOX1 is predicted to be targeted by all miRNAs in the miR-17-92 cluster. In
total, the 3’UTR of PKNOX1 possesses 7 putative binding sites for miR-17-92 miRNAs
(also known as miRNA Response Element or MREs) that are conserved between mouse
and human (Figure 26). The miR-17 family putatively targets the PKNOX1 3’UTR at 2
distinct sites, while miR-19ab putatively targets the PKNOX1 3’ UTR at a single site.
The Pknox1 3’UTR is putatively targeted by miR-18a at a single site and miR-92 at 2
sites. Interestingly, I observed a single nucleotide polymorphism in the miR-18a binding
site in the PKNOX1 3’UTR (Figure 26). The polymorphism consists of a G to C
mutation outside of the seed region, and should not affect mRNA recognition.
I hypothesized that PKNOX1 was a valid target of regulation by the miR-17-92
cluster. To examine the miRNA:mRNA relationship between the miR-17-92 cluster and
PKNOX1, I performed a luciferase reporter assay against the PKNOX1 3’UTR (Figure
27). I generated a construct fusing the PKNOX1 3’UTR to a luciferase reporter construct,
as well as additional constructs with mutations in individual MREs as well as a
compound mutant with mutations for all predicted MREs. If the relationship is valid, then
mutations in the MREs will result in an increase in luciferase activity. Transfection with
MSCV-PIG-miR-17-19b resulted in decreased levels of luminescence relative to control
for the wild type plasmid (Figure 27). However, due to outliers, statistical significance
was not apparent with 4 samples. Mutation of miR-17, 20a MREs in luciferase construct
resulted in an increase in luminescence consistent with the hypothesis that miR-17, or
miR-20a regulate PKNOX1 at the mRNA level. Luminescence increased by 15% for the
miR-17 mutant, which encompassed mutations in 2 miRNA response elements (Figure
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Figure 28. Steady-state levels of PKNOX1 in human cell lines

Steady state levels of PKNOX1were
examined in several different human cell
lines, including HEK293T (non-MLL
adherent cell line), K562 (non-MLL AML
cell line), MV4-11 (MLL-AF4), MOM-13
(MLL-AF9), and RS4;11 (MLL-AF4).
Extraneous lanes cropped from blot.
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27). Mutation of the single miR-19ab MRE resulted in an increase of approximately 15%
(Figure 27). Compound mutation of all miR-17-92 related MREs also resulted in a
statistically significant increase (Figure 27). The compound mutant had an
approximately 25% increase in luminescence. Though the increase is greater than that
observed for individual miRNAs, no statistical significance was a reached when testing
the compound mutation against either miR-17 or miR-19 mutants.
To further examine the relationship between the miR-17-92 cluster, I examined
the changes in Pknox1 at the protein level in HEK293T cells transfected with increasing
concentrations of MSCV-miR-17-19b (Figure 29). HEK293T cells express relatively high
endogenous levels of PKNOX1 (Figure 28,29). If PKNOX1 is a valid target of the
miRNAs, protein level should decrease with increased concentrations of transfected
MSCV-PIG-miR-17-19b in a dose dependent manner. Consistent with the hypothesis,
PKNOX1 levels decreased in response to increased concentrations of miR-17-92
transfection (Figure 29).
I examined the endogenous levels of PKNOX1 and PBX1/2/3 at the protein level
between adherent cell lines and MLL fusion containing leukemia cell lines (Figure 28).
It was important to determine the basal levels of PKNOX1 in MLL leukemia cell lines in
order to ensure the potential validity of my model. If PKNOX1 is highly expressed in
MLL-AF9 leukemia cell lines, then PKNOX1 modulation by miRNA is not likely to be
physiologically important to leukemia. Simultaneously, PBX levels are an important
potential limiting factor for the integrity of the model. I hypothesized that PKNOX1 and
PBX levels were lower in MLL fusion containing cell lines. As expected, I observed low
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Figure 29. PKNOX1 decreases in response to exogenous miR-17-19b expression

HEK293T cells expressing with
increasing concentrations of
exogenous miR-17-19b. Blot
representative of 3 independent
experiments. Numbers represent
PKNOX1/ACTIN ratios for the
depicted blot.
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levels of PKNOX1 in all three cell lines (Figure 28) relative to HEK293T and K562 cells
(representing an adherent cell line and non-MLL leukemia cell line). MOLM-13 cells
expressed the least amount of PKNOX1 followed by MV4-11 and RS4;11. Further, I
observed low levels of PBX1/2/3 in all three MLL leukemia cell lines relative to
HEK293T and K562 cell lines (Figure 28). Use of a an anti-PBX1/2/3 antibody made it
impossible to discern the relative levels of each PBX homolog, but allows to determine
the overall combined levels of PBX1/2/3 containing complexes.
While experiments testing the miRNA:mRNA relationship utilized HEK293T
cells as a model system, these experiments do not establish that the miRNA:mRNA
relationship is relevant in MLL leukemia cells or that the protein levels change in
response to miRNA disregulation. To examine antagomir-mediated regulation of
PKNOX1, I examined the change in PKNOX1 protein levels in response to combinatorial
antagomir treatments (Figure 30). If PKNOX1 is regulated by the miR-17-92 cluster in
MLL leukemia cell lines, inhibition of miRNAs that target the PKNOX1 mRNA will
result in a de-repression of the mRNA transcript and subsequent increase in protein level.
I hypothesized that PKNOX1 level would increase upon antagomir treatment relative to
levels observed for cells treated with a control antagomir. Cells were cultured in liquid
culture for 3 days at 2 µM treatment concentration for MOLM-13 and 1 µM total
concentration for RS4;11. Consistent with my hypothesis, PKNOX1 protein levels
increased in response to the treatment with antagomir combinations, indicating that
antagomir treatment results in increased PKNOX1 (Figure 30).
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Figure 30. PKNOX1 levels increase in response to combinatorial antagomir
treatments

Antagomir treatment results in increased PKNOX1 protein levels relative to treatment
with a control antagomir (anti-miR-10a). Human leukemia cell lines were treated with
antagomirs (2 μM for 72 hrs) and analyzed for PKNOX1 levels by western blot.
Numbers below bots indicate relative values of PKNOX1 after normalization to Actin for
blot depicted.
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PKNOX1 and MEIS1 compete for participation in PBX-containing complexes
Physiologically, PKNOX1 upregulation has several potential outcomes. PKNOX1
and MEIS1 share high homology in their PBX interacting domains and homeodomains
and have both been documented to form ternary complexes with PBX and HOX proteins,
suggesting that these proteins compete for inclusion into ternary complexes. However,
ChIP-seq analysis of co-occupancies indicate that Meis1-Hox and Pknox1-Pbx
complexes are abundant during murine embryonic development [111]. Thus disregulation
of MEIS1 or PKNOX1 in leukemia could alternatively drive the formation of binary
complexes without affecting the balance of MEIS1 or PKNOX1 inclusion in ternary
complexes. I hypothesized that increased PKNOX1 expression would result in a decrease
in MEIS1 inclusion into these complexes.
To test for MEINOX competition within ternary PBX-containing complexes, I
examined the composition of PBX-containing complexes for the relative levels of
MEIS1/2/3 and PKNOX1 upon transfection with increasing concentrations of Meis1 (0
ug, .5 ug, 1 ug, 2 ug, 4 ug) and co-immunoprecipitation of PBX-containing complexes
using an anti-PBX1/2/3 antibody (Figure 31). Immunoprecipitation was performed with
an antibody targeting PBX1/2/3 to pull down all PBX containing complexes in a nonbiased fashion. HEK293T cells express reasonably high levels of PKNOX1 and
PBX1/2/3 proteins and barely detectable levels of MEIS1/2/3 (Figure 31). If a
competitive mechanism is not present, then total complex participation would not change
in response to modulation of either MEINOX component. However, if PKNOX1
competes for utilization of the same partner components, then exogenous expression of
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Figure 31. PKNOX1 is a direct competitor of MEIS1 in PBX-containing complexes

HEK293T cells were transfected with Meis1 expressing plasmid and subjected to coimmunoprecipitation for PBX1/2/3. 20% input (left) was subject to western blotting for
PKNOX1 and MEIS1. Co-immunoprecipitation was performed using antibody against
PBX1/2/3
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MEIS1 should result in a decrease of PKNOX1 when immunoprecipitating PBXcontaining complexes. Upon treatment with increasing levels of Meis1, I observed a
decrease in PKNOX1 participation in these complexes, indicating that MEIS1 and
PKNOX1 compete for inclusion into the same complexes (Figure 31). Intriguingly, at
very high concentrations of Meis1, I observed a decrease in the total levels of
immunoprecipitated complex as indicated by blotting for PBX1/2/3 (Figure 31).
Pknox1 overexpression decreases the colony formation, promotes differentiation,
and results in a decrease in cell number in MLL-AF9 transformed bone marrow
Pknox1 has previously been examined in the cooperation with Hoxa9 for
transformation in mouse models [94]. These studies indicate that Pknox1 lacks the
oncogenic capability of Meis1 in a Hoxa9-dependent transformation model. Further,
developmental studies indicate that Pknox1-containing complexes and Meis1-containing
complexes often operate in opposition to each other [111]. Previous studies have relied
upon co-infection of HoxA9 and Pbx1 with Meis1 or Pknox1. In these studies, Pknox1Meis1 complex partners are highly expressed under viral promoters and do not need to
compete for inclusion into potentially limited complexes.
The role of Pknox1 within an MLL-AF9 context remains to be tested. I
hypothesized that over-expression of Pknox1 would have an inhibitory role in an MLLAF9 leukemia models. To examine this question, I infected MLL-AF9 transformed bone
marrow with MIGR1, MSCV-Meis1-PGK-GFP, or MSCV-pKOF2-Prep1-PGK-GFP
(Figure 32). These viruses serve as an empty vector control (MIGR1), a Meis1expressing virus (MSCV-Meis1-PGK-GFP), and a Pknox1 expressing virus (MSCV-
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Figure 32. Pknox1 overexpression reduces colony forming ability in MLL-AF9
transformed bone marrow

MLL-AF9 transformed bone marrow was infected with MIGR1, Meis1 expressing virus,
or Pknox1 expressing virus. Colony assays were performed in 4 independent
experiments. Statistical analysis was performed using Student’s t-test. A) Total colony
count/10000 cells plated (left) and Colony type (right). B) Total cell number. C)
Representative colony pictures displayed for each treatment. Top panels in bright field
microscopy, with lower panels utilizing fluorescent microscopy. GFP fluorescence
indicates successful infection with retrovirus.
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Figure 33. Pknox1 overexpression in MLL-AF9 transformed bone marrow results in
an increase in differentiation-associated surface markers

Cells from colony assays were analyzed for surface markers was performed for 3
independent experiments. A) Representative plots showing CD117, MAC-1 and GR-1
staining. B) Mean fluorescence intensity shown from 4 independent experiments.
Statistical significance was tested using Student's t-test. Pknox1 infected cells showed
statistically significant increases in mean fluorescence intensity for both Mac-1 (p<.0001)
and GR-1 (p<.001), relative to levels in either MIGR1, or Meis1 infected cells.
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pKOF2-Prep1-PGK-GFP). MLL-AF9 transformed bone marrow readily forms colonies
at a high rate. If Pknox1 has an inhibitory role in MLL leukemia, then enforced
overexpression of Pknox1 will result in a decrease in colony forming ability. To prevent
unsuccessfully infected cells from confounding experimental readouts, all infections were
sorted for GFP positivity 48 hrs post infection, prior to plating in methylcellulose (not
shown). Additionally, colonies were verified for GFP expression at counting.
Intriguingly, Pknox1 infection resulted in a larger GFP negative population at 48 hrs,
suggesting a selective pressure against Pknox1 expressing cells (data not shown).
Infection with Pknox1 expressing virus resulted in a decrease in colony number
relative to both control MIGR1 treated cells and Meis1 infected cells (Figure 32). When I
examined the composition of colonies by subtype, I observed that the decrease in colony
number came primarily from a decrease in Type I colonies. No significant differences
were observed in type 2 colonies or type 3 colonies. Total cell number isolated from each
colony assay also decreased upon Pknox1 overexpression. Meis1 overexpression resulted
in a modest but statistically insignificant decrease in cell number.
As type I colonies represent the least differentiated cells, I hypothesized that
Pknox1 overexpression caused a loss of stemness (Figure 33). To examine this
possibility, I isolated cells from colony assays at one week and stained with fluorophore
conjugated antibodies against CD117, Sca-1, CD11B, and GR-1 for FACS analysis
(Figure 33). CD117 (a.k.a. C-kit) and Sca-1 are markers for stemness within
hematopoiesis. Conversely, MAC-1 and GR-1 are markers for differentiation.
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Figure 34. Pknox1 overexpression reduces total cell number in MLL-AF9
transformed bone marrow

A) Standard curve for calculating cell number of MLL-AF9 transformed bone marrow B)
Proliferation curve for MLL-AF9 bone marrow infected with MIGR1, Meis1, or Pknox1
expressing virus in 3 independent experiments.
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Figure 35. Pknox1 overexpression results in an accumulation of cells at G0/G1 in
MLL-AF9 transformed bone marrow

Cell cycle distribution was documented after 7 days in liquid culture by FACS analysis
for 4 independent experiments. A) Representative FACS plots with gating. B)
distribution of live cells measured for MLL-AF9 transformed bone marrow infected with
MIGR1, Meis1, or Pknox1.
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Exogenous overexpression of Pknox1 resulted in both a decrease in c-kit expression and
in increase in differentiation markers GR-1 and Mac-1 (Figure 32).
As with human colony assays, examination of the proliferation and cell cycle in
colony assays remains confounded by the decrease in colony forming ability and the
limited number of cells. To distinguish the effects of Pknox1 on proliferation from the
decrease in total cell number in colony assays, I infected MLL-AF9 transformed bone
marrow cells and plated cells in liquid culture. I examined the proliferation curve of cells
over the course of several days, measuring the cell number at days 3, 5, and 7 (Figure
34). As with human cell lines, total cell number was calculated based on comparing CellTiter-Glo assay readouts to a previously established standard curve. Enforced expression
of Pknox1 resulted in a decrease in proliferation over the course of 7 days (Figure 34).
Surprisingly, enforced overexpression of Meis1 also resulted in a small, though
insignificant, decrease relative to MIGR1 infected cells (Figure 34).
The remaining cells were analyzed by FACS for cell cycle (Figure 35). As with
my human cell line experiments, I observed a modest accumulation of cells at G0/G1
(Figure 35). This observation is consistent with our model of differentiation and
proliferative arrest observed in human cell lines. Collectively, this data suggests that
decrease in Pknox1 infected MLL-AF9 transformed cells is the result of either a cell cycle
arrest at G1, senescence, or differentiation. The lack of a significant increase in a
<G0/G1 populations suggests that apoptosis in not likely the cause of Pknox1 mediated
decrease in cell number.

CHAPTER 5
DISCUSSION
This dissertation examines the contribution of miRNAs to MLL leukemia through
knockdown of miRNAs that have increased expression in MLL AMLs relative to nonMLL AMLs. I have identified miRNAs critical to colony forming ability in MLL
translocated human cell lines, through individual and combinatorial knockdown of
miRNAs. Additionally, I have validated PKNOX1 as a target of the miR-17 and miR-19
families of the miR-17-92 cluster through luciferase reporter studies and examination of
protein levels upon miRNA level manipulation. Finally, this dissertation demonstrates
the competitive relationship between PKNOX1 and MEIS1 in PBX complex formation
and the inhibitory role of PKNOX1 in an MLL specific context (Figure 36).
I have determined the requirement of specific miRNAs in the miR-17-92 cluster to
maintain the transformed phenotype of MLL leukemia by antagonizing miRNAs overexpressed in this subtype of leukemia. Treatment with antagomirs against miR-17 or
miR-20a individually caused a decrease in MLL leukemia colony forming ability (Figure
14). For antagomir treatments against either miR-17 or miR-20a alone, colony forming
ability decreased by >40% in MOLM-13, >30% in RS4;11, and >99% in MV4-11. These
treatment effects underscore the importance of the miR-17 family in MLL leukemia and
suggest that inhibiting even a single family member is sufficient to disrupt the delicate
regulatory balance they enforce. Combinations of multiple antagomirs for treatment
132
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caused a further decrease in colony forming ability (Figure 15). In particular,
antagonizing both miR-17 and miR-20a, or both miR-17 and miR-19a resulted in a
dramatic decreases in colony forming ability in methylcellulose colony assays (Figure
15). In this study, I approached combinatorial antagomir treatments by targeting either
related miRNAs of the same miRNA family (e.g. miR-17, 20a) or targeting unrelated
miRNAs (e.g. miR-17,19a). Antagonizing related miRNAs of the same family would
potentially block redundant functions caused by multiple miRNA family members’
ability to target the same mRNA transcript. Antagonizing unrelated miRNAs would
potentially expose areas of miRNA coordination in regulating a phenotype. Strikingly,
antagonism of non-family miRNAs, miR-17 and miR-19a showed a more dramatic effect
beyond that observed for targeting only the constituent individual miRNA family
members, indicating that the miRNAs from different families function are coordinated
(Figure 17). This could be due to regulation of different target gene mRNAs or because
multiple miRNAs simultaneously and more efficiently target the same critical mRNA.
I observed that several single antagomir treatments have no effects relative to the
control antagomir treatment (Figures 12, 16). miR-10a is located in the HOX clusters and
has been documented as being upregulated in MLL leukemias relative to non-MLL
AMLs [148]. miR-191 is a negative prognostic indicator for AML, suggesting the
possibility of a functional role in disease development [155]. However, neither inhibition
of miR-10a nor of miR-191 resulted in a decrease in colony forming ability. It is possible
that these miRNAs share redundant functions with other miRNAs, and inhibition of a
single miRNA is unable to relieve the repression of a target mRNA. Alternatively, these
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miRNAs may be upregulated but have no functional importance in leukemia.
The antagomir treatment effects varied in scale between the different cell lines
examined (Figure 12-17). These studies utilized human cell lines with either t(4;11) or
t(9;11) translocations, resulting in MLL-AF4 or MLL-AF9 fusions, respectively. Despite
their genetic similarities, the human cell lines examined in my experiments had
somewhat different results in colony assays. MV4-11 showed the most dramatic effects
upon antagomir treatment with massive decreases in colony forming ability and total cell
number, while MOLM-13 and RS4;11 showed smaller, but still significant effects. For
example, anti-miR-20a treatment results in a significant decrease in colony forming
ability of MOLM-13 and RS4;11 with decreases of 62% and 42% relative to the control
antagomir treatment. However, in MV4-11, colony forming ability was completely lost
(Figure 14). It is possible that the differences in colony forming potential are caused by
differences in genetic factors not related to the MLL fusion protein, including:
cooperating mutations incurred throughout several decades of cell culture, or differences
in gene expression for critical factors in colony formation. For example, the cell lines I
examined showed differential basal levels of PBX1/2/3 (Figure 28). It is also possible
that there is variance in the basal levels of miRNAs necessary for MLL leukemia. In this
case, a decrease in colony forming ability may be more easily obtainable upon antagomir
treatment, as decreasing the miRNA levels below the minimal required amount for
colony formation may be more easily achieved. Alternatively, another potential cause
could be the different clonogenic potentials of the cell lines utilized. Loss of colony
forming ability was most severe in MV4-11, which possesses the lowest baseline
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clonogenicity. The decreased clonogenicity could result in a greater sensitivity to
antagomir treatments. It is not immediately clear what factors govern the differences in
clonogenicity between cell lines.
After observing decreased colony size and a decrease in cell number in
methylcellulose, I hypothesized that loss of colony forming ability was accompanied by a
decrease in proliferation. I only observed a modest difference in the number of
antagomir treated cells in liquid culture relative to control treatments that corresponded to
the colony assays (Figure 22-23). Nor did I observe a sizable change in cell cycle
distribution (Figure 22-23). This could indicate that the decrease in cell number observed
in colony assays is dependent on the colony forming ability. However, because colony
assays reflect the capabilities of only a small subset of cells, it is possible that the
proliferative defect is only apparent in these cells, and any subsequent decrease on cell
number is the result of an absence of colonies. Alternatively, expression of target gene
mRNAs may vary based on the difference in culture conditions between methylcellulose
and liquid culture. However, the molecular aspects of cells in methylcellulose are of
greater interest because methylcellulose colony forming ability has been utilized as a
surrogate for Leukemia Stem Cell (LSC) activity in MLL and the ability to block colony
forming ability in methylcellulose may be used to identify factors essential to MLL
leukemia.
In addition to examining miRNA inhibition in human cell lines, I have
additionally utilized antagomirs for miRNA inhibition of MLL-AF9 transformed murine
bone marrow progenitor cells in colony formation assays (Figures 24-25). Antagomir
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treatments have previously been utilized by our lab in this type of murine system. The
decrease in colony forming ability in anti-miR-196b treated cells was expected as it
confirmed the role established for miR-196b by a previous member of our lab Dr. Relja
Popovic [11]. Relja's work, in collaboration with the Grimes lab (Cincinnati Children’s
Hospital), show that inhibition of miR-196b results in a loss of colony forming ability
[11]. Decrease in colony number and change in colony morphology was observed and
suggest a loss of stemness. However, no treatment effect is observed for MLL-AF9
transformed bone marrow treated with anti-miR-19b, despite the high homology between
miR-19a and miR-19b (Figure 24-25). It is possible that the non-seed region nucleotides
involved in stabilization of the miRNA:mRNA interaction provide the critical balance in
whether or not a functionally important target mRNA is successfully targeted.
Numerous potential causes could explain the differences in results between the
human and murine systems. Primarily, the human cell lines used contain a myriad of
additional mutations accumulated over decades in culture. To address this possibility,
further work may utilize primary patient derived samples. Additionally, there may be a
difference in gene regulation, as each system may present different target mRNAs or may
express common target mRNAs at different levels. Finally, the human and mouse model
systems utilize cells at different disease stages.
In addition to the miRNAs examined in this work, recent advancements have
identified several miRNAs possessing critical functions in MLL leukemia. miR-9 has
been shown to be upregulated in MLL leukemia relative to both non-MLL AML and
normal cells [246]. Inhibition of miR-9 through a miRNA-binding sponge results in a
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decrease of MLL-AF9 transformation ability in vitro and in vivo, while over expression of
miR-9 in conjunction with MLL-AF9 transformation increases the transformation ability
of MLL-AF9 in colony forming assays and in vivo experiments [246] Studies performed
by our collaborator, Dr. Grimes (Cincinnati Children's Hospital), identify miR-21 and
miR-196b as a having synergistic roles in AML development [234, 247]. Both miR-196b
and miR-21 are negatively regulated by the transcriptional repressor GFI1, which
functions in opposition to HOXA9 mediated transcriptional activation [247]. In HOXdependant transcriptional programs, including MLL-AF9 mediated transformation,
antagomir inhibition of miR-196b, miR-21, or both, reduced colony forming ability and in
vivo leukemogenesis through targeting leukemia initiating cells (LIC) activity [234].
Collectively, these studies implicate an additional miRNA, miR-21, in the development of
MLL leukemia, and further illustrate the importance of miR-196b in MLL leukemia.
While this study focused on several miRNAs upregulated in MLL leukemia, it does not
address the roles of miRNAs that are downregulated or lost in MLL leukemia, which
contribute to transformation. Several miRNAs, including miR-495, the miR-181 family
(miR-181a/b/c/d), and miR-150 have been identified as tumor suppressors and have been
shown to be down regulated in MLL leukemias [86, 148, 248, 249]. Several
downregulated miRNAs function through regulation of the Hox complex components
essential to MLL leukemogenesis. MLL leukemias show downregulation of, the miR-181
family (miR-181a/b/c/d), relative to non-MLL AMLs [152]. Examination of miR-181
among cytogenetically abnormal AMLs, identify loss of miR-181 as a negative
prognostic indicator [86]. Further, a signature of 4 miR-181 targets, HOXA7, HOXA9,
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HOXA11, and PBX3 are upregulated, and have been functionally evaluated in vitro and in
vivo [86]. Overexpression of miR-495 is downregulated in MLL leukemias relative to
non-MLL AMLs. Overexpression of miR-495 has been shown to reduce colony forming
ability in vitro and leukemogenesis in vivo by targeting both PBX3 and MEIS1 [248].
MiR-150 has been implicated as a tumor suppressor miRNA down regulated in most
AMLs relative to normal controls [249]. The MLL-fusion/Myc/LIN28 axis represses
miR-150 maturation [249]. MiR-150 regulates Myb and Flt3 resulting in a decrease in the
Myb regulatory targets Hoxa9 and Meis1 [249]. Ectopic overexpression of miR-150 in
MLL-AF9 transformed bone marrow reduced colony formation in vitro and in
leukemogenesis in vivo [249, 250]. Critically, these miRNAs and their contributions to
MLL leukemia are linked to regulation of components of the HOX-PBX-MEINOX
complexes required for MLL leukemia. However, my work differs from these critical
studies, in that I examine the contribution of miRNAs in MLL leukemia through
regulation of a MEIS1 competitor.
My data demonstrates that PKNOX1 is a valid downstream target of the miR-1792 cluster (Figure 27). Multiple different miRNAs from this cluster simultaneously
regulate PKNOX1 mRNA through binding to 3 separate miRNA response elements
(Figure 27). Four of the 6 miRNAs of the miR-17-92 cluster (miR-17, 20a, 19a, and 19b)
regulate PKNOX1. This redundancy of miRNAs targeting the same mRNA suggest that
the relationship of miR-17-92 and PKNOX1 functions as an important regulatory switch
which may respond to various cellular signals. To determine the interactions between
miRNAs and the PKNOX1 3' UTR, I performed a luciferase reporter experiment with a
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luciferase construct modified to encode the PKNOX1 3'UTR downstream of the
luciferase coding sequence. Mutation of PKNOX1 3'UTR at the miRNA response
elements to which the miRNAs bind for either the miR-17 family or the miR-19 family
show an increase in luciferase activity relative to a wild type PKNOX1 3' UTR (Figure
27). Simultaneous targeting of a single 3’UTR by multiple miRNAs has been reported to
regulate mRNA levels in a cooperative manner utilizing AGO1, AGO3, and AGO4containing RISC complexes [251]. Efficient miRNA cooperativity requires relatively
close proximity of MREs within the target 3'UTR, approximately 13-35 nts between the
start of the seed region binding [252]. A transcriptome-wide examination of miRNA
binding sites (utilizing HITS-CLIP and PAR-CLIP) found an enrichment of miRNAbinding sites located 15-26 nts apart [253]. Within the PKNOX1 mRNA, the initial miR17 family binding site (MRE1) and the sole miR-19 family binding site are located at
nucleotide positions 20 and 52 of the 3'UTR, respectively. This 32 nt difference in
position, is close enough to suggest that miR-17 and miR-19 family miRNAs negatively
regulate PKNOX1 through cooperative targeting of the same mRNA. It is possible that
combinatorial miRNA effects may additionally occur through non-cooperative targeting
on separate mRNA transcripts where the overall ratio of miRNAs to mRNAs controls the
final level of mRNA available for translation, through productive single miRNA
mediated silencing of mRNA transcripts.
I observed a polymorphism within the predicted miR-18 binding site of the
PKNOX1 3'UTR (Figure 26). This polymorphism, encoding a G to A mutation at
position 2811 of the PKNOX1 3' UTR, is located outside of the sequence targeted by the
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seed region and should not affect the core targeting of the PKNOX1 3' UTR by miR-18,
but may affect the binding stability of the miR-18 miRNA:RISC complex to the PKNOX1
3'UTR. Previous studies have identified MRE single nucleotide polymorphisms as
having functional roles in miRNA:mRNA interactions and as serving as prognostic
indicators for cancers [254-256]. This polymorphism I observed is predicted to be
involved in stabilization of binding with the miR-18 containing miRNA:RISC complex
through interaction with the uracil located at position 15 of miR-18a. In the previously
documented mRNA transcript, the guanine base interacts with the uracil through a
wobble base pairing. The polymorphism, encoding an adenine in place of the guanine,
would result in an improved binding stability between the PKNOX1 3'UTR and the miR18 containing RISC complex.
The miR-17-92 cluster is one of the best studied miRNA clusters to date, with
targets involved in processes including cell death, cell cycle, development, and a number
of different cancers, including lymphoma, and breast cancer (reviewed in [173-175]). In
addition to PKNOX1, miR-17 and miR-19a also target other mRNA transcripts that are
important to MLL leukemia. PTEN has been validated as a target for both miR-17 and
miR-19a [190, 257] PTEN mRNA levels have been reported to inversely vary with
miRNA overexpression for both miR-17 and miR-19b in transformed bone marrow [12].
MiR-17 has additionally been shown to be important in regulating the G1 checkpoint by
regulating both CDKN1A (p21) and E2F1 [177, 183]. While shRNA knockdown of
CDKN1A (p21) in an MLL leukemia model phenocopies overexpression of the miR-1719b [183], it is not currently known to be targeted by miR-19a. My data indicate only a
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minor G0/G1 arrest, suggesting that the miR-17-92 cluster functions through other
mechanisms (Figure 22-23). A lack of visible G0/G1 arrest in cell cycle assays may be
attributable to a decrease in cell cycle progression through both G1 and G2 checkpoints.
Previous work performed by our lab has identified the G2/M checkpoint regulator WEE1
as a bona fide target of the miR-17-92 cluster [258]. My antagomir treatment data
indicate a more severe phenotype upon combinatorial treatment with anti-miR-17 and
anti-miR-19a (Figure 17). As a result, I focused on a target that is regulated by both miR17 and miR-19a. While binding affinity to PKNOX1 transcript is predicted to be
thermodynamically stable, it is likely that other mRNAs are targeted simultaneously
dependent on availability of targets.
The nature of miRNA function suggests that a great deal of binding promiscuity is
possible. MiRNAs bind to target mRNAs based on Watson-Crick base pairing between
the seed region and a target mRNA. While this study has characterized a single transcript
that is regulated by miRNAs in MLL leukemia, PKNOX1 is not the sole target of the
miR-17-92 cluster. A previous study by our collaborator, Dr. Jianjun Chen, observed that
overexpression of the miR-17-92 cluster in murine bone marrow results in
downregulation of 363 potential target genes predicted to be regulated by the miR-17-92
cluster by at least one miRNA target prediction algorithm, suggesting that disregulation
of the miR-17-92 cluster has broad implications in target mRNA regulation [12].
Currently, miRNA target prediction algorithms focus on predicting the actions of
individual miRNAs. MiRNA target prediction algorithms have predicted a number of
target mRNAs that are shared between numerous miRNAs. 2 PBX family members,
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PBX1 and PBX3, are predicted to be common targets of miR-196b and the miR-17-92
cluster. PBX1 is predicted to be targeted by the miR-19 family and miR-196b, while
PBX3 is predicted to be targeted by the miR-17 family and miR-196b. While PBX3 is a
known oncogene with a critical role in the formation of MLL leukemia, the role of PBX1
is less clearly defined, and may lack the ability to promote oncogenesis. If PBX1 lacks
the oncogenic capabilities of PBX3, miRNA regulation of the PBX1 transcript could
potentially contribute to MLL leukemia through elimination of PBX1 competition with
PBX3 for inclusion in HOXA9-MEIS1 complexes, similar to the effect I observed for
miRNA regulation of PKNOX1.
Studies to determine the role of the miR-17-92 cluster in MLL leukemia are
complicated by presence of its 2 homologous clusters, miR-106a-363 and miR-106b-25.
While direct regulation of the miR-17-92 cluster by MLL fusion proteins has been
verified, the regulation of miR-106a-363 and miR-106b-25 in MLL leukemia has not yet
been explored.
The potential implications of upregulation of the miR-106 clusters is further
complicated by the composition of each cluster. The miR-17-92 cluster is composed of 2
members of the miR-17 family, 2 members of the miR-19 family, a member of the miR18 family, and member of the miR-92 family (see Figure 7). However, miR106a-363 and
miR-106b-25 clusters are composed of different proportions of constituent miRNAs
(Figure 7). If these miRNA clusters are simultaneously upregulated in MLL leukemia,
then we must further consider the potential cooperative pathways between the miR-92
and miR-18 families, as their representation among miRNA:RISC complexes would be
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increased.
In addition to the regulation by the miR-17-92 cluster, additional miRNAs have
been documented as regulators of PKNOX1. A study performed by Zhuang, et al
examined the mRNA targets of miR-223 in macrophages in adipose tissue inflammation
[259]. They identified PKNOX1 as a valid targeted of miR-223 and determined that it
regulates macrophage polarization, driving macrophage activation towards a classical M1
pro-inflammatory Macrophage activation [259]. Additional studies have identified miR223 as a critical factor in granulopoiesis, with miR-223 deficient mice showing defects in
differentiation [260, 261]. One study has identified miR-223 as being regulated by
CEBPA binding and downregulated in AML [262]. However, no studies have identified
miR-223 as being upregulated in leukemia.
Future studies to expand on miRNA function may reveal additional mechanisms
of action, and subsequently expand our understanding of miRNA contribution to
diseases. Though miRNA were originally identified through complementary binding to
the 3' UTR of target mRNAs, there is evidence that miRNAs can also target the 5'UTRs
to downregulate target genes [143]. Further, miRNAs such as miR-10a possess novel
regulatory mechanisms [144]. For example, miR-10a has been shown to bind to the TOP
motifs within 5' UTR of target genes and results in an increase in transcription [144].
Further, recent experiments utilizing HITS-CLIP sequencing, an unbiased
immunoprecipitation for RISC bound mRNAs, have indicated that miRNAs bind to a
more diverse collection of mRNA targets than had previously been thought [146]. As
future studies continue to unveil new miRNA functions, our understanding of the role
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miRNAs in diseases will evolve to include new classes of targets.
Western blotting indicated an additional band present in PKNOX1 western blots
running slightly above the expected molecular weight (Figure 30). This data suggests
PKNOX1 may be regulated through post-transcriptional modifications (e.g.
phosphorylation). While there have been no documented post-translational modification
to PKNOX1 in the literature, such a mechanism could potentially add to the complexity
of control of PKNOX1 levels.
I have examined the effects of exogenous overexpression of Pknox1 in MLL-AF9
transformed murine bone marrow to determine the role of Pknox1 in MLL leukemia.
(Figures 32, 33, 35). PKNOX1 and MEIS1 are homologous in their PBX-interacting
domains and homeodomains [72, 73]. However, Meis1 oncogenic activity is dependent
on its C-terminal domain, which is not shared with Pknox1 [94]. The C-terminal domain
of Meis1 is known to have multiple protein-protein interactions. It is currently unclear
whether the Pknox1 C-terminal domain has any protein-protein interactions of its own.
Functional examination of the Pknox1 C-terminal domain is required to determine the
mechanism of Pknox1 regulation of target genes. Previous studies found that infection
with Pknox1-expressing virus fails to accelerate leukemia similarly to Meis1 when coexpressed with Hoxa9 [94]. This dissertation demonstrates that altering the balance of
PKNOX1 to MEIS1 levels affects MLL leukemia cell proliferation and colony-forming
ability. Pknox1 overexpression in a murine MLL leukemia model decreased colony
forming ability, primarily from a loss of less differentiated colonies. Antagomir treatment
of human MLL leukemia cells had a similar outcome on colony forming ability, which
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could possibly be due to increasing the PKNOX1:MEIS1 ratio within these cells. Colony
forming capability has been used as a measure of leukemia stem cell activity in the MLL
leukemia model system. Thus, loss of colony forming ability in response to antagomir
treatments suggests that MLL leukemia stem cell activity may be predominantly targeted
by these miRNAs. Future work could determine whether specific cell contact-mediated
pathways are particularly influenced by miR-17-92 cluster miRNAs in MLL leukemia.
I observed a greater decrease in proliferation upon Pknox1 overexpression than
upon antagomir treatment. This difference may be attributed to multiple factors, such as
dosage of Pknox1, effectiveness of antagomir delivery, or inherent differences between
mouse and human cell lines. Exogenous overexpression of Pknox1 from a viral promoter
would result in a much higher amount of Pknox1 relative to Meis1. While removing the
inhibition of the miRNAs through use of antagomirs allows Pknox1 levels to increase,
exogenous overexpression drives Pknox1 levels very high. Cell cycle analysis of Meis1
transduced cells indicates no significant change in the cell cycle distribution relative to
control vector-transduced cells. The minor decrease in Meis1 transduced cells is thus not
likely to be of similar origin as the decrease observed with Pknox1.
Pknox1 has additionally been characterized as a tumor suppressor in an Eµ-Myc
lymphoma model with Pknox1 hypomorph mutants and Pknox1 heterozygotes resulting
in increased tumor size and accelerated onset of lymphoma [109]. The Eµ-Myc
lymphoma model is driven by the constituent activity of the c-Myc proto-oncogene
behind an immunoglobulin promoter, designed to simulate a B-cell lymphoma [263].
Loss of Pknox1 expression within this context leads to a shift in the B-cell population;
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with Eµ-Myc; Pknox1(+/-) mice having more immature phenotypes, consisting of Proand Pre-B-cells, and Eµ-Myc; Pknox (+/+) mice having more mature phenotypes [264].
It is possible that Pknox1 competition with Meis1 may regulate the development of BCells, such that loss of Pknox1 may result in decreased B-Cell differentiation.
These findings indicate that the canonical HOXA9-MEIS1 pathway is regulated
through the coordinated action of multiple miRNAs. miRNAs including miR-495, miR181a/b, and miR-150, which would negatively regulate the expression of the HOXA9PBX3-MEIS1 complexes, are down regulated, relieving the repression of HOXA9MEIS1 transcriptional regulation. Opposing these effects, previous work has indicated
that miR-196b down regulates both Hoxa9 and Meis1, resulting in an initial delay in
leukemia onset in a murine leukemia model, but ultimately with development of a more
aggressive leukemia [163]. miR-196b functions as both a tumor suppressor and oncogene
through repression of HOXA and MEIS1 and FAS, respectively [163]. Because HOXA9
and MEIS1 are essential for MLL leukemia, and miR-196b is upregulated in MLL
leukemias, this relationship presents a unique puzzle. If HOXA9 and MEIS1 are
downregulated, additional factors must either restore HOXA9 and MEIS1 levels or
otherwise ameliorate the effect. Both miR-196b and miR-17-92 are directly regulated by
MLL, and are upregulated in MLL leukemias [12, 64, 152]. I propose that the miR-17-92
cluster acts as a counterbalance to the tumor suppressor properties of miR-196b. As
miRNA regulation of HOXA9 and MEIS1 is held in a delicate balance, regulation of the
MEIS1 competitor PKNOX1 provides a critical mechanism for regulation of HOXA9MEIS1 activity. During leukemogenesis, miR-17-92 expression results in a decrease in
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PKNOX1 expression, alleviating competition with MEIS1 for PBX-HOX complex
inclusion. Additional work has indicated that 5' Hox transcription factors, acting in
conjunction with a Cdx2 partner, positively regulate the expression of miR-196b in neural
tube development [265]. As a result, a negative feedback loop would be present, limiting
the overall expression of Meis1.
Meis1 overexpression in MLL-AF9 transformed bone marrow resulted in an
intermediate phenotype with cell surface markers and Meis1 overexpression resulted in a
decrease in cellular proliferation (Figure 33, 35). Exogenous overexpression of Meis1, in
addition to MLL-AF9 transformation mediated overexpression of Meis1, appears to have
its own toxicity. Exogenous Meis1 overexpression is potentially toxic to the cells and
may result in a decrease in exogenous Meis1 expression. The mechanism of toxicity is
not yet apparent, but may be caused by a variety of factors, including mitotic catastrophe
or apoptosis, among other possibilities. Overall levels of Meis1 may need to be
maintained below a certain level. Though Meis1 overexpression was originally utilized
as a negative control for Pknox1 overexpression, Meis1 activity may present its own
complications attributable to the regulation of target genes.
Complex regulatory circuits involving miRNAs are starting to be defined in MLL
leukemia. This includes those regulating the HOX-PBX-MEIS trimeric protein complex.
Both HOXA9 and MEIS1 are directly regulated by MLL and are necessary for MLL
leukemia development [6, 24, 91, 113]. HOXA9 and MEIS1 are negatively regulated by
miR-196b, one of the miRNAs overexpressed in MLL leukemia, thus limiting the
amounts of these proteins available for incorporation into HOX-PBX-MEIS complexes.
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Although this causes an initial delay in the onset of leukemia, increased miR-196b
expression ultimately contributes to a more aggressive leukemia [163]. HOX-PBX3
protein-protein interaction is also essential for MLL leukemia development and inhibition
of this interaction with a small peptide selectively kills cells dependent on HOXA and
PBX3 overexpression [87]. MiRNAs in the miR-17-92 cluster are also overexpressed in
MLL leukemia. I show here that miR-17-92 cluster miRNAs, including miR-17 and miR19a, target PKNOX1 and that antagonizing these miRNAs causes increased PKNOX1
expression. I also show that MEIS1 and PKNOX1 can compete for binding in HOXPBX-containing complexes and that manipulation of relative MEIS1/PKNOX1 levels has
a dramatic effect on MLL leukemia. More HOX-PBX-MEIS1 complexes as compared to
HOX-PBX-PKNOX1 complexes potentiate MLL leukemia colony forming activity.
Together, this suggests that HOX-MEIS-PBX complexes may be a limiting factor in
MLL leukemia which may be amenable to functional disruption via antagonizing critical
regulatory miRNAs.
Recently, the Blasi group published data which support and complement my
findings [112, 113]. They found that Prep1 (Pknox1) competes with Meis1 for binding to
Pbx1, and Prep1 depletion enabled Meis1 to transform MEFs [112]. The authors
transfected Prep1 hypomorphic MEFs with Meis1 and Prep1, and observed that Meis1
transfected MEFs form colonies in soft agar colony assays. Co-transfection with Prep1
results in a decrease in Meis1 stability and colony capability. Further, Meis1 colony
formation in MEFs as well as Pknox1 mediated inhibition of Meis1 requires Pbx1. The
authors further examined the complex formation, and identified the Ddx3 and Ddx5 as
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critical complex components which are required for colony formation. These findings
support my hypothesis that PKNOX1 competes with MEIS1 for inclusion into PBXcontaining complexes. My studies utilize HEK293T cell with increasing expression of
exogenously introduced MEIS1 to examine the competitive role between MEIS1 and
PKNOX1, which my data supports. It is unclear whether Ddx3, and Ddx5 are
functionally important for Meis1 activity in MLL leukemia. A subsequent study by the
same group identified that deficiency of Pknox1 accelerated the onset of Meis1-Hoxa9mediated leukemogenesis in a murine model of serial transplantation [113]. Critically, the
Blasi group examined the effects of a lack of Pknox1 as a factor involved in the
acceleration of leukemogenesis. I am interested in the opposite effects - in potentially
increasing Pknox1 levels as a mechanism to block Meis1-Hoxa9 mediated transformation
in hematopoietic cells. Further, while the Blasi group utilized exogenous overexpression
of Meis1 and Hoxa9, my studies assessed the relationship between MEIS1 and PKNOX1
within an MLL-AF9 context. They hypothesized that increasing PKNOX1 levels may be
an important area for future therapeutic development [112]. My work agrees with this
suggestion.
To examine the target genes regulated by Meis1 and Pknox1, the Sauvegeau lab
examined the gene expression profiles of cells infected bone marrow progenitor cells
with viruses expressing either: Hoxa9 + Pknox1, Hoxa9 + Meis , or Hoxa9 + Pknox1-MC
(a chimeric Pknox1 possessing the oncogenic Meis1 CTD appended to the C-terminus).
Critically, cells with exogenously overexpressed Hoxa9 + Pknox1 or Hoxa9 + Meis1,
resulted in very different gene expression profiles [94]. Hoxa9 + Meis1 infection results
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in the upregulation of 1202 genes with a significant upregulation of genes related to
chromosomal organization, cell cycle, DNA damage response. However, Hoxa9 +
Pknox1 infection resulted in upregulation of 885 genes, with no significant enrichment in
genes related to any cellular process. Numerous target genes were of particular interest
to the development and function of leukemia. For example, mRNA levels of the Meis1
target Flt3 was differentially regulated between Meis1+ Hoxa9 and Pknox1+ Hoxa9
[94]. Moreover, transformation with either Hoxa9 + Meis1or Hoxa9 + Pknox1-MC
results in the upregulation of Meis1, suggesting the possibility of a positive feedback
mechanism whereby Hoxa9 and Meis1 contribute to the elevation of Meis1 levels [94].
My studies examine PKNOX1 as a competitor with MEIS1 for inclusion into
HOX-PBX-MEINOX complexes. However, changes in the binary complex composition
may also vary in response to Pknox1 upregulation. Examination of Pknox1, Meis1, Hox
and Pbx during murine embryonic development by Penkov and colleagues identify
commonly occurring binary complexes that form in addition to Meinox-Pbx-Hox ternary
complexes [111]. Pknox1 forms binary complexes with Pbx that bind throughout the
coding sequences and have an inhibitory role in gene regulation [111]. Meis1,
meanwhile, was observed in binary complexes with Hox associated with promoter
regions and contributing to gene expression [111]. The interaction of Meis-Hox binary
complexes occurs through the binding between Hox proteins and the Meis1 C-terminal
domain [84]. PBX participation within a ternary complex is essential to HOXA9-MEIS1
activity as disruption of the HOX-PBX interaction through a peptide, HRX9, blocks
leukemia formation [87]. The peptide used was designed to mimic the conserved motif
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found within HOX proteins which interacts with PBX binding partners [266]. Though
initially utilized to block HOX-PBX dimers in melanoma [266], multiple myeloma [267],
and ovarian cancer [266]; within MLL leukemia, this peptide implicates the ternary
complexes as the active HOXA9-MEIS1 effectors in leukemia because disruption of the
HOX-PBX interaction would only alter levels of HOXA9-PBX-MEIS1 ternary
complexes and not HOXA9-MEIS1 complexes. However, if the MEIS1-HOXA9 binary
complexes are similarly capable of upregulating target genes, this may provide an avenue
of escape for leukemia cells treated with antagomirs. Further, HOX protein availability
would still be limited due to HOX incorporation into HOX-PBX-PKNOX1 complexes.
The possibility of PKNOX1-PBX1 binary complex formation could potentially raise
issues with this explanation. However, the extent of binary PKNOX1-PBX complex
formation is unclear.
It is additionally possible that complex formation varies between the different
PBX components. My Co-IP experiments utilize an anti-PBX1/2/3 antibody, and thus do
not distinguish between any of the PBX homologs. This was a deliberate choice in
experimental design to avoid any bias towards any PBX homolog and to account for
MEINOX inclusion into any PBX containing complexes. However, additional
experiments may be required to discern which PBX family members are bound by
PKNOX1 in MLL leukemia. Inclusion of different PBX components may alter binding
specificity to DNA sequences. Many of the initial studies to characterize the binding and
function of PBX proteins were performed using overexpressed PBX1 – the founding
member of the PBX family. However, the biochemical differences between the different
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PBX family members is an area of potential further study.
Further studies may strengthen these finding by examining antagomir treatment
effects in conjunction with PKNOX1 knockdown. My studies have shown that antagomir
treatment results in a decrease in colony formation and a change in colony and cellular
morphology (Figure 12-18), and PKNOX1 protein levels (Figure 30). To ensure that the
antagomir treatment effect is attributable to changes in PKNOX1 protein levels, further
studies may seek to rescue colony formation ability by knocking down PKNOX1 via
siRNA or shRNA in conjunction with antagomir treatments. If antagomir mediated
decreases in colony forming ability is mediated by an increase in PKNOX1, then
PKNOX1 knockdown will result in an increase in colony numbers.
It would be of further interest to examine the effects of antagomir treatment in
vivo. This dissertation focuses on antagomir mediated treatment effects in vitro, utilizing
colony forming ability as a surrogate for leukemogenesis. Further studies utilizing in
vivo antagomir treatments against MLL-AF9 transformed bone marrow would provide a
more complete picture of the potential of antagomirs as a therapeutic option. However,
in vivo studies are potentially complicated by the delivery of antagomirs to a therapeutic
level in leukemic cells. Though antagomirs were originally developed for in vivo use,
their delivery may be enhanced through the use of various nanoparticles currently under
development, including dendrimers. It is not clear whether in vivo therapeutic targeting
of a limited number of miRNAs would have significant toxicity issues; however, it would
be worthwhile to explore as an additional therapeutic approach for MLL leukemia. My
data indicates that the antagomir treatments were particularly effective in human cell

153

lines and that exogenously added Pknox1 effectively reduced colony forming ability in a
mouse model. To bridge the gap between the two sets of data, future rescue experiments
should be performed using both model systems.
Additional studies are needed to further clarify the functional difference
associated with PKNOX1 and MEIS1. Publicly available datasets from the Gene
Expression commons [268] indicate that Pknox1 RNA levels increase throughout
hematopoiesis differentiation while Meis1 RNA levels decrease (Figure 4). This inverse
level of expression suggests that Pknox1 may be an important factor in guiding
differentiation. As such, indirect upregulation of Pknox1 mediated by downregulation of
Pknox1-regulating miRNAs could guide cells along a particular differentiation pathway.
This is consistent with my results in the human cell antagomir treatments, where
combinatorial antagomir treatment resulted in changes to cellular morphology that
include increased vacuolarity and a decrease in nuclear to cytoplasmic ratio, possibly
indicating monocytic differentiation (Figure 18). Further, transfection of MLL-AF9
transformed bone marrow with a Pknox1 expressing retrovirus resulted in a change in
surface markers consistent with differentiation relative to cells infected with a MIGR1
control virus (Figure 33). To understand the mechanism of PKNOX1 in MLL leukemia,
ChIP experiments could be performed in human leukemia cell lines upon antagomir
treatment. I would predict that PKNOX1 would associate with HOXA9 and PBX1 at
selected target genes. Treatment with antagomirs would result in an increase of PKNOX1
association at target genes known to be regulated by MEIS1-HOXA9 complexes and a
decrease of MEIS1 association, as MEIS1 would be excluded from PBX containing
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complexes and degraded. To date, many MLL leukemia studies have operated on a sense
of equivalency of different components of the same protein families. Functional studies
are needed to determine the different roles of PBX components and how these relate to
pairing with either MEIS1 of PKNOX1.
My findings contribute to an increasing body of evidence illustrating the potential
for miRNA inhibition by anti-miRNA oligo nucleotides (AMOs) as a therapeutic tool. At
the dosages utilized in these studies, I observed some cellular toxicity upon antagomir
treatment (Figures 12-17), including a modest decrease in colony forming ability.
However, these modest treatment effects may be overcome by altering the dosages
slightly, or by employing a modified delivery system that would improve efficacy at a
lower dosage.
Collectively, this dissertation implicates the miR-17-92 cluster as an essential
component of MLL leukemia through the role of miR-17 and miR-19a in their repression
of the MEIS1 competitor, PKNOX1 (Figure 36). MLL fusion proteins aberrantly maintain
the expression of a variety of target genes including HOX genes, MEIS1, and several
miRNAs, including miR-196b, miR-10a, and the miR-17-92 cluster. Previous studies
have shown HOXA9 and MEIS1 genes are essential for MLL leukemia. HOXA9 and
MEIS1 form ternary complexes with a PBX family member to regulate numerous
downstream targets. This study examined the necessity of specific miRNAs to MLL
leukemia through the inhibition of miRNAs using highly specific anti-miRNA
oligonucleotides. Here, I establish that miR-17 and miR-19a are essential to MLL
leukemia and cooperate in their contribution to MLL leukemia. This effect is mediated
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through miR-17 and miR-19a regulation of PKNOX1, which competes for inclusion into
PBX containing complexes. Blocking of miR-17 and miR-19a results in upregulation of
PKNOX1 and an altered balance of HOX/PBX gene regulatory complexes, resulting in a
skewing away from MEIS1-containing HOX/PBX complexes and a loss of leukemogenic
ability. In summary, I conclude that expression of several miRNAs of the miR-17-92
cluster are critical for the continued survival of MLL leukemia . Further examination of
the role of miRNAs and PKNOX1 would serve to both deepen our understanding of
complex regulatory mechanisms that guide the development of leukemia, and also to aid
in the development of targeted therapeutics which may someday provide a valuable
clinical tool in leukemia treatment.
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Figure 36. Model for miRNA involvement in MLL leukemia.

Model of miRNA involvement in MLL leukemia. MLL fusion containing complexes
maintain the expression of the components of oncogenic HOX-PBX-MEIS complexes as
well as miRNAs including the miR-17-92 cluster. MiRNAs regulate the complex
composition through downregulation of the non-oncogenic component PKNOX1, which
serves as a competitor to MEIS1 for complex inclusion and whose overexpression has an
inhibitory effect on MLL leukemia function.
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